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P a r t  I
Introduction
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AbsTRACT
Inhibition of angiogenesis with humanized monoclonal antibodies to vascular endo-
thelial growth factor (VEGF) or with tyrosine kinase inhibitors targeting VEGF receptors 
has become an established treatment for various tumor types. Contrary to expectations, 
angiogenesis inhibition by blocking VEGF-mediated signaling is associated with seri-
ous side effects including hypertension and renal and cardiac toxicity in a substantial 
proportion of patients. Fortunately, most of these side effects as discussed in this paper 
seem to be manageable, but likely become more problematic when survival increases. 
Although several hypotheses regarding the etiology of angiogenesis inhibition-related 
cardiovascular and renal side effects have been postulated, many of the underlying 
pathophysiological mechanisms remain to be elucidated. This may lead to the develop-
ment of more specific angiogenesis inhibitors, better management of their side effects 
and may potentially provide new insights into the pathogenesis of cardiovascular 
disease in general.
Introduction 13
InTRoDuCTIon
Angiogenesis, the formation of new capillaries from an existing vasculature, is critical to 
tumor growth as well as metastasis. This process is regulated by several growth factors 
and their receptors among which vascular endothelial growth factor (VEGF) and its cor-
responding receptors play a key role. Angiogenesis inhibition as a therapeutic strategy 
against malignancies was first proposed by Folkman in 1971.1 Meanwhile a variety of 
drugs, that target VEGF or its receptors, have been developed for the treatment of differ-
ent tumor types and the expectation is that a number of new agents will be introduced 
within coming years. VEGF receptors (VEGFRs) are mainly expressed on endothelial 
cells. As over 99% of endothelial cells is quiescent under physiological conditions, it 
was expected that angiogenesis inhibition would have minimal side effects.2 However, 
clinical experience has revealed that inhibition of VEGF induces several side effects in-
cluding hypertension and renal and cardiac toxicity. Insight into the pathophysiological 
mechanisms of these side effects likely contributes to improved management of the 
toxicities associated with VEGF inhibition. Furthermore, the cardiovascular side effects 
observed with angiogenesis inhibition may provide new insights into the pathogenesis 
of cardiovascular disease in general. In this review we focus on the physiology of VEGF, 
its receptors and the signal transduction involved after VEGFR stimulation, the various 
forms of VEGF inhibition currently available, the vascular, renal and cardiac side effects 
of VEGF inhibition and potential pathophysiological mechanisms and proposals for the 
management of side effects, in particular angiogenesis inhibition-associated hyperten-
sion.
VeGF AnD ITs ReCePToRs
VEGF, a 45 kDA glycoprotein, is an angiogenic growth factor normally produced by en-
dothelial cells, podocytes, macrophages, fibroblasts and in malignancies by tumor cells 
or adjacent stroma.3 Alternative splicing of the VEGF gene results in six different isoforms 
constituting of respectively 121, 145, 165, 183, 189 and 206 amino acids.4,5 All isoforms 
express identical biological activity, but different binding to heparin and extracellular 
matrix. Loss of the heparin-binding domain of VEGF results in a reduction of its angio-
genic activity. VEGF165 (VEGF-A) is the predominant, most biologically active isoform and 
will be referred to as VEGF in the review. As depicted in Figure 1, the expression of VEGF 
is stimulated and regulated by multiple factors. Among these factors, hypoxia is the 
main stimulator of VEGF transcription mediated through the hypoxia inducible factor 
1 (HIF-1).3,4 Transcription of the VEGF gene is inhibited by tumor necrosis factor alpha 
(TNF-α). VEGF upregulates the expression of endothelial nitric oxide synthase (eNOS) 
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and increases nitric oxide production. Nitric oxide on the contrary may down-regulate 
VEGF expression via a negative feedback mechanism.6 Tumor suppressor genes and 
oncogenes have also been found to play an important role in regulating VEGF gene 
expression. Loss or inactivation of tumor suppressor genes, such as von Hippel-Lindau 
(VHL), p53, p73, Phosphatase and Tensin homolog (PTEN) and p16, as well as activated 
forms of oncogenes, such as Ras, Src, human epidermal growth factor receptor 2 (HER2/
neu) and Breakpoint cluster region/Abelson (Bcr/Abl), increase VEGF gene expression.7
VEGF binds two tyrosine kinase receptors, VEGF receptor 1 [VEGFR-1 or fms-like tyrosine 
kinase (Flt-1) murine homologue] and VEGF receptor 2 [VEGFR-2 or kinase domain re-
gion (KDR) human homologue or Flk-1 murine homologue]. Both receptors contain an 
extracellular region consisting of seven immunoglobulin-like domains, a hydrophobic 
transmembrane domain and a cytoplasmatic bipartite tyrosine kinase domain. VEGFR-1 
and VEFGR-2 are expressed on endothelial cells of most blood vessels, including those 
of preglomerular, glomerular and peritubular vessels. Furthermore, these receptors are 
present on hematopoietic stem cells, circulating endothelial progenitor cells, dendritic 
cells, trophoblasts, monocytes, retinal progenitor cells and certain types of tumor cells.3,8 
Most of the biologically relevant VEGF signaling in endothelial cells is mediated by 
HypoxiaGrowth 
C t ki(HIF-1)factors y o nes
ROS
A i t i IIng o ens n 
↑ VEGF
Prostaglandins
NO
Mechanical 
stress
TNF-α
AGE’s
Oncogenes
Hyperglycemia
PKC
pH
Figure 1. Regulation of VEGF expression. AGE’s, advanced glycation endproducts; HIF-1, hypoxia inducible 
factor 1; NO, nitric oxide; PKC, protein kinase C; ROS, reactive oxygen species; TNF-α, tumour necrosis 
factor α, VEGF, vascular endothelial growth factor.
Introduction 15
VEGFR-2, activated by ligand-stimulated receptor dimerization and trans- (auto-) phos-
phorylation of the tyrosine residues in the cytoplasmatic domain.9
The extracellular domain of Flt-1 is also present as a soluble protein (sFlt-1) that inhibits 
angiogenesis by forming an inactive complex with circulating VEGF. Soluble Flt-1 can 
act as a physiological VEGF inhibitor by binding and inactivating membrane-bound 
VEGFR-1 and VEGFR-2 via receptor homodimerization or heterodimerization.8 VEGFR-1 
has a 10-fold higher affinity for binding VEGF than VEGFR-2 but autophosphorylation of 
the tyrosine residues of the VEGFR-1 in response to VEGF binding is weak.8 VEGFR-1, like 
sFlt-1, may rather perform a decoy function by sequestering VEGF and leaving less VEGF 
available for VEGFR-2, than mediating a mitogenic response. VEGFR-1 also binds pla-
cental growth factor (PlGF), which might be of importance for the reported synergism 
between VEGF and PlGF in vivo. In contrast to sFlt-1, PlGF potentiates the action of VEGF 
by displacing VEGF from VEGFR-1, thereby directing VEGF towards the VEGFR-2.3
VEGFR-3 (fms-like-tyrosine kinase (Flt)-4) is also a member of the receptor tyrosine ki-
nases, but only responds to VEGF-C or VEGF-D and not to VEGF-A. This receptor is mainly 
found on lymphatic endothelium and is important for lymphangiogenesis. VEGF also 
interacts with neuropilin-1 and -2 receptors. The interaction of neuropilin-1 and VEGFRs 
facilitates VEGF binding to the VEGFR.3,7
VAsCulAR enDoTHelIAl GRoWTH FACToR sIGnAl TRAnsDuCTIon AnD 
bIoloGICAl eFFeCTs
General aspects
VEGF exerts a variety of biological activities. Its original name, vascular permeability 
factor, indicates that it enhances permeability. Furthermore, VEGF plays a key role in 
the mobilization of endothelial progenitor cells from the bone marrow, endothelial cell 
proliferation, migration, survival and tube formation. It is a potent stimulator of angio-
genesis during embryogenesis, menstrual cycle, wound healing and tumor growth. 
In addition, it inhibits antigen-presenting dendritic cells and stimulates monocyte 
chemotaxis and the expression of adhesion molecules. Finally, it induces vasodilation 
through activation of the nitric oxide pathway.3 The mentioned activities of VEGF are 
effectuated via several pathways including activation of the PI3K/Akt (protein kinase B)/
mTOR pathway, partly mediating VEGF-induced nitric oxide production via eNOS phos-
phorylation (Fig. 2). Other actions include the activation of phospholipase C-γ (PLC-γ), 
protein kinase C (PKC), Raf-1, extracellular-signal-regulated protein kinase (ERK1/2), 
fatal adhesion kinase (Fak) and mitogen-activated protein kinase (MEK1/2) pathways. 
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Like the PI3K/Akt/mTOR pathway, the PLC-γ pathway also plays a crucial role in the 
production of nitric oxide and prostacyclin (PGI2) by endothelial cells.
9-11 Calcium mo-
bilization is essential for VEGF-induced PGI2 production. In addition, calcium signalling 
also mediates short-term nitric oxide production through activation of the constitutive 
eNOS isoform. Calcium-independent nitric oxide production mediated via the PI3K/Akt/
mTOR pathway may also involve VEGF-induced up-regulation of eNOS mRNA, whereas 
long-term prostanoid production is mediated through VEGF-induced expression of the 
inducible cyclo-oxygenase (COX)-2 isoform (Fig. 2).9 In human umbilical vein endothelial 
cells, VEGF stimulates a biphasic, dose-dependent and time-dependent release of nitric 
oxide: an initial acute phase (1 h) regulated by calcium-spiking and a secondary chronic 
phase (> 24 h) caused by an increase in eNOS mRNA transcription. The VEGF-induced 
upregulation of eNOS mRNA and protein levels is dose-dependent.6
Part of the VEGF signaling occurs in a paracrine way, which is essential for the prolifera-
tion, survival, permeability responses and endothelial differentiation of the angiogenic 
cascade. An autocrine signaling loop (cell-autonomous) for VEGF is also required for 
VEGF
VEGFR
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Figure 2. NO and PGI2 synthesis through VEGF-mediated signaling. Akt/PKB, anti-apoptotic kinase / 
protein kinase B; Ca2+, calcium; COX2, cyclo-oxygenase 2; cPLA2, cytosolic phospholipase A2; cPLA2-P, 
phosphorylated cPLA2; eNOS, endothelial nitric oxide synthase; e-NOS-P, phosphorylated eNOS; ERK1/2, 
extracellular-signal-regulated protein kinase; IP3, 1,4,5-triphosphate; MEK1/2, mitogen-activated protein 
kinase; NO, nitric oxide; PGI2, prostacyclin; PKC, proteinkinase C; PIK3, phosphoinositide 3-kinase; PLC-γ, 
phospholipase C; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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survival of blood vessels. Both paracrine and autocrine activation are mediated by 
VEGFR-2.12
Vascular effects induced by vascular endothelial growth factor
VEGF has shown to induce endothelium-dependent vasorelaxation in arteries of dif-
ferent sizes of various species including human vessels.13-17 This vasodilatation appears 
to be mainly mediated via nitric oxide, as it is attenuated in the presence of N-nitro-L-
arginine (L-NNA), an eNOS inhibitor.13-15 In the presence of both L-NNA and HbO, a nitric 
oxide scavenger, the VEGF-induced vasodilatation is further decreased and it is almost 
completely abolished after removal of the endothelium, indicating a crucial role of the 
endothelium in the VEGF-mediated vasorelaxation.16-18 This endothelium-dependent 
vasodilation is mainly due to VEGFR-2 stimulation.17 In internal mammary arteries ob-
tained from patients with severe coronary artery atherosclerosis, both PGI2 and nitric 
oxide appeared to contribute to the VEGF-mediated vasorelaxation.15 VEGF-induced 
vasorelaxation is impaired in spontaneously hypertensive rats (SHR) compared with 
normotensive Wistar Kyoto (WKY) rats, possibly related to endothelial dysfunction in 
these rodents.13 In porcine vessels VEGF dilates the small-sized arterioles and venules 
and has no vasorelaxing effect on medium-sized arteries and veins.14
In addition to the observed vasorelaxation in vitro, in vivo experiments showed that 
intravenous injection of VEGF in conscious male Sprague-Dawley rats resulted in a 
dose-dependent decrease in mean arterial pressure and an increase in heart rate 
almost immediately after VEGF injection.17 An intravenous bolus injection of VEGF in 
anesthesized rats caused an acute reduction in diastolic blood pressure of more than 
20 mmHg, whereas a second injection of VEGF 40 min later had no effect, indicating 
that VEGF-related vasodilatation is subject to tachyphylaxis.19 In the VEGF in Ischemia 
for Vascular Angiogenesis (VIVA) trial performed in patients with coronary artery disease 
both intracoronary and intravenous infusions of recombinant human VEGF produced 
dose-related falls in systolic blood pressure of up to 22% with the highest dose and 
facial flushing.20 In summary, VEGF induces hypotension through vasorelaxation, which 
appears to be endothelium-dependent and in part mediated by nitric oxide.
VAsCulAR enDoTHelIAl GRoWTH FACToR InHIbITIon 
(AnTI‑AnGIoGenesIs)
As diseases relying on angiogenesis such as cancer are often partially driven by VEGF, 
inhibition of angiogenesis as a therapeutic strategy against malignancies was proposed 
by Folkman already in 1971.1 Meanwhile a variety of drugs, which target VEGF or its 
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receptors, have been developed for the treatment of cancer including monoclonal 
antibodies to VEGF, small receptor tyrosine kinase inhibitors (RTKIs) and circulating 
VEGF receptors to trap VEGF (‘VEGF-Trap’). Bevacizumab (Avastin; Genentech, South San 
Francisco, California, USA) is a humanized monoclonal antibody that selectively binds 
VEGF and was the first FDA-approved VEGF inhibitor for systemic use in various forms 
of cancer including colorectal, breast, renal and nonsquamous, non-small cell lung 
cancer.21-24 Bevacizumab has to be administered intravenously in contrast to the RTKIs 
such as sunitinib (SU011248, Sutent; Pfizer, New York, New York, USA) and sorafenib 
(Bay 43-9006, Nexavar; Bayer Pharmaceuticals, West Haven, Connecticut, USA and Onyx 
Pharmaceuticals, Richmond, California, USA), which are suitable for oral administration. 
These agents are not selective, as they target a number of tyrosine kinases. For instance, 
sunitinib inhibits VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor (PDGFR)-α 
and PDGFR-β, c-KIT, fms-like tyrosine kinase-3 (Flt3), colony stimulating factor receptor 
type 1 and the glial cell line-derived neutrophic factor receptor RET (rearranged during 
transfection). Sunitinib is approved for the treatment of imatinib-resistant metastatic 
gastrointestinal stromal tumors (GIST) and first-line treatment of metastatic renal cell 
carcinoma.24,25 Sorafenib is approved for the treatment of advanced renal cell carcinoma 
after failure of interleukin-2 or interferon-α treatment.24,26 The RTKIs are administered in 
cycles according to a 4 weeks “ON” and 2 weeks “OFF” (wash-out period) scheme. VEGF-
Trap (Regeneraon Pharmaceuticals, Tarrytown, New York, USA) is a protein consisting of 
portions of the extracellular domains of VEGFR-1 and VEGFR-2, fused to the Fc-portion of 
human immunoglobulin γ1. It binds and thereby inactivates VEGF in the circulation and 
tissues. The clinical effectiveness of this drug has still to be determined.26
Anti-angiogenic therapy rarely produces complete tumor regression and resistance to 
treatment develops after a median of 6-12 months of therapy. Mechanisms responsible 
for tumor cell resistance may include incomplete inactivation of the VEGF pathway, 
activation of other hypoxia-inducible factor-driven genes or selection of tumor cell 
populations able to survive in the presence of VEGFR-2 blockade for example through 
activation of VEGF-independent pathways such as fibroblast growth factor and interleu-
kin-8.27
sIDe eFFeCTs oF VAsCulAR enDoTHelIAl GRoWTH FACToR InHIbITIon
As over 99% of endothelial cells is quiescent under physiological conditions, side ef-
fects during angiogenesis inhibition were expected to be minimal.2 Meanwhile, it has 
been well established that inhibition of VEGF is associated with the development of 
several untoward effects (table 1).24,28,29 In particular RTKIs, which also inhibit numerous 
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receptors other than the VEGFR, are characterized by a broad spectrum of toxicities. 
Of these, hypertension and renal toxicity are also observed when using monoclonal 
antibodies directed towards VEGF. As these antibodies specifically inhibit VEGF and do 
not directly affect other factors, hypertension and renal toxicity can be considered truly 
VEGF-inhibition-dependent side effects. Given the relationship of hypertension and re-
nal toxicity with cardiac events, the latter will be addressed as well. Cardiac toxicity has 
been reported less frequently with the use of bevacizumab than with RTKIs, suggesting 
that this side effect is in part independent of VEGF inhibition per se. However, this side 
effect was not routinely monitored for and could therefore have been underreported.
Hypertension
Hypertension has been reported in up to 36% of patients during treatment with the 
humanized VEGF antibody bevacizumab with blood pressure normalization after 
treatment cessation.21,30,31 Initial reported incidences of sunitinib-induced hyperten-
sion varied from 16-23%, but more recent studies reported an incidence of up to 47% 
(Table2).32-41 This difference in reported incidence of hypertension might be related to 
greater awareness of the development of this side effect and to the fact patients with 
poorly controlled hypertension were excluded from participation in the initial trials. 
Moreover, according to the Common Toxicity Criteria for Adverse Events, hypertension 
in earlier studies was diagnosed when blood pressure was more than 150/100 mmHg or 
diastolic blood pressure had increased by more than 20 mmHg.42 These threshold values 
are considerably higher than those recommended by the ESH/ISH. With more complete 
Table 1. Clinical adverse effects of VEGF-signaling inhibitors
Constitutional Fatigue, fever
Gastrointestinal Diarrhea, nausea, mucositis / stomatitis, vomiting, constipation, 
abdominal pain, gastrointestinal perforation
Cardiovascular Hypertension, left ventricular dysfunction, cardiac failure, cardiac 
ischemia or infarction
Renal Proteinuria, glomerulonephritis, thrombotic micorangiopathy
Haemorrhage and thrombosis Epistaxis, bleeding at all sites, venous and arterial thrombosis
Endocrine dysfunction Thyroid dysfunction (hypo- and hyperthyroidism)
Haematology Leucopenia, neutropenia, anemia, thrombopenia, lymphopenia
Dermatology Hand-foot syndrome, skin discoloration, rash
Metabolism / nutrition Anorexia, asthenia
Respiratory Dyspnea, cough
Neurology Altered taste, headache
Musculoskeletal Arthalgia, back pain, myalgia
Impaired wound healing
Table based on information from [24,28,29].
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angiogenesis inhibition the incidence of hypertension appears to increase further. For 
instance the incidence of hypertension was 67% with the combined treatment of beva-
cizumab and sorafenib and 92% with the combination of bevacizumab and sunitinib in 
patients with advanced solid tumors or renal cell carcinoma respectively.43,44
The rise in blood pressure after initiation of angiogenesis inhibition is relatively fast and 
shows an “ON”/“OFF” effect similar to the treatment scheme as demonstrated by a study 
using home blood pressure monitoring.34 After 4 weeks of treatment with sunitinib, 
blood pressure in patients who were normotensive at baseline had increased by 22 ± 
6 mmHg systolic and 17 ± 6 mmHg diastolic and returned to baseline values during 
the 2 weeks off-treatment period.34 Likewise, during treatment with the RTKI pazopanib 
(GW786034) hypertension developed during the first 4 weeks of treatment in almost all 
patients.45 The reported severity of hypertension is variable, with in rare cases develop-
ment of malignant hypertension complicated by the reversible posterior leukoencepha-
lopathy syndrome or hemorrhagic stroke.46-49
The clinical finding of hypertension due to VEGF inhibition has been verified in ex-
perimental studies. Single oral doses of the RTKI cediranib (AZD2171, Recentin, Astra-
Table 2. Incidence of hypertension in patients treated with sunitinib
Reference Disease Sunitinib dose 
(mg/day)
Treatment 
duration
No. of patients Hypertension 
(%)
Azizi et al.34 mRCC 50 12 weeks
(2 cycles)
7a 100a
Zhu et al.35 
(unpublished data)
NA NA NA NA 22.5
Chu et al.33 GISTb 50 24 weeks 75 47
Rixe et al.36 mRCC 50 12 weeks
(2 cycles)
40 22.5
Motzer et al.37 mRCC 50 6 months 375 24
Motzer et al.38 mRCC 50 7 months 106 16
Faivre et al.39 Solid
malignancyc
50-150 3-4 weeks 28 18
Motzer et al.40 mRCC 25-75d 9 months 63 5
Demetri et al.41 GISTb 50 12 weeks
(2 cycles)
207 11
Maki et al.32 GISTb 50 1 year 97 16
GIST, gastro-intestinal stromal tumor; mRCC, metastatic renal cell carcinoma; NA, not available. a Home 
blood pressure monitoring in 7 normotensive patients treated with sunitinib; after 4 weeks of treatment 
all 7 patients had become hypertensive. b imatinib-resistant metastatic GIST. c advanced solid malignancy 
for which no other therapy was possible. d intra-patient dose escalation up to 75 mg/day was permitted in 
the absence of treatment-related toxicity, dose reduction was allowed to 25 mg/day.
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Zeneca) administered to Wistar-Kyoto rats was associated with a 15 mmHg rise in blood 
pressure, whereas daily administration of higher doses for 4 days was associated with a 
rise in blood pressure of 35-50 mmHg.19
Mechanism of hypertension
Although the mechanism underlying the development of hypertension induced by 
angiogenesis inhibition still remains to be elucidated, decreased nitric oxide bioavail-
ability is thought to be a critical factor (Fig. 3). Because eNOS is upregulated by VEGF, 
inhibition of VEGF by neutralizing antibodies or a VEGFR blocker will lead to a decrease 
in nitric oxide production by endothelial cells that may account for the development of 
hypertension.24 Clinical evidence for the presence of endothelial dysfunction induced by 
VEGF inhibition is still very limited. Hovens et al. measured flow-mediated and nitroglyc-
erin-mediated dilatation of the brachial artery as respective measures of endothelial-
dependent and independent vasodilatation in patients treated with the experimental 
RTKI telatinib (Bay 57-9352).50 After 5 weeks of treatment systolic and diastolic blood 
pressure were increased by respectively 6.6 and 4.7 mmHg. This rise in blood pressure 
was associated with a small decrease in flow-mediated dilatation of 2.1% and a decrease 
in nitroglycerin-mediated dilatation of 5.1%. Although reduced nitric oxide availability 
might have caused the decrease in flow-mediated dilatation in this study, it cannot be 
ruled out that the development of hypertension itself had caused this reduction.50 Of 
note, impaired nitric oxide production may not only cause a generalized vasoconstrictor 
response but may also affect renal sodium handling, contributing to the maintenance of 
hypertension in the longer run.51
Possible mechanisms involved in hypertension due to VEGF inhibition
↓ NO
Rarefaction
↑ Vascular stiffness
VEGF inhibition
Thyroid dysfunction
 
Eff t VSMCec  on 
Stimulation of neurohumoral   
pathways?
Figure 3. Possible mechanisms involved in hypertension due to vascular endothelial growth factor 
inhibition. NO, nitric oxide; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell.
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Due to the anti-angiogenic properties, another potential mechanism involved in the 
development of hypertension during angiogenesis inhibition is functional (a decrease 
in perfused microvessels) or structural (a reduction in capillary density) rarefaction.52,53 
Using intravital video-microscopy to measure dermal capillary densities in the dorsum 
of the fingers a significant decrease in functional and structural capillary densities 
after 6 months of treatment with bevacizumab compared with baseline was observed 
in patients, whereas blood pressure had increased by 16mmHg systolic and 8 mmHg 
diastolic.54 In addition, a reduction of capillaries in the mucosa of the mouth in patients 
enrolled in a phase 1 study with telatinib has been reported.53 Despite these observa-
tions, rarefaction as a cause of hypertension, at least in the initial phase of angiogenesis 
inhibition seems not very likely, considering the short interval at which hypertension 
can develop after initiation and the almost immediate reversibility after cessation of 
anti-angiogenic therapy. The observed rarefaction in the studies mentioned might be 
a consequence rather than a cause of hypertension. The same reasoning, that is, con-
sequence rather than cause, might be true for the rise in large artery stiffness reported 
during angiogenesis inhibition.50,55
To further explore potential mechanisms involved in the development of hypertension 
during angiogenesis inhibition, Veronese et al. have measured plasma levels of catechol-
amines, renin, aldosterone, urotensin II and endothelin-1 (ET-1) in patients treated with 
sorafenib.55 After a 3-week treatment period systolic blood pressure had increased by 
20 mmHg in 60% of patients. This rise in blood pressure was initially accompanied by 
a decrease in heart rate. More interestingly, there was an inverse correlation between 
change in heart rate and change in systolic blood pressure after 3 weeks of treatment. 
Despite the rise in blood pressure, plasma concentrations of the previous mentioned 
parameters remained unchanged, suggesting that neither the renin-angiotensin system 
nor the sympathetic nervous system is involved in the development of hypertension.55 In 
contrast to the study reported by Veronese et al, we found a marked decrease in plasma 
renin activity after a 4-week treatment period with sunitinib, whereas blood pressure at 
that time had increased by 15 mmHg systolic and 14 mmHg diastolic (n = 12) [unpub-
lished data]. With respect to ET-1, blockade of VEGF signaling may disturb the balance 
between nitric oxide and ET-1, favoring vasoconstriction.2 In a recently published study 
in telemetry-instrumented rats, the rise in blood pressure caused by an experimental TKI 
could be prevented by an ETA receptor blocker.
56 As administration of this ETA receptor 
blocker to untreated rats also lowered blood pressure, definite conclusions about the 
role of the endothelin system in the rise in blood pressure during angiogenesis inhibi-
tion cannot be drawn at this moment.
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Thyroid dysfunction might be another factor that contributes to the development of 
hypertension during RTKI administration. Hypothyroidism or transient elevation of 
TSH levels have been reported in up to 46-85% of patients treated with sunitinib and 
hyperthyroidism in up to 24% of patients.57-59 Since both hyperthyroidism and hypo-
thyroidism have been reported to be associated with hypertension, such a mechanism 
might sometimes be involved in angiogenesis-inhibition associated hypertension. The 
mean time to develop hypothyroidism during treatment with sunitinib generally is 50 
weeks, although it has been reported to occur as soon as after 12 weeks (cycle 2) of the 
treatment course. Therefore, hypothyroidism as a cause of hypertension, at least in the 
initial phase of angiogenesis inhibition, seems unlikely.57,58
Patients with renal cell carcinoma may be more susceptible to develop hypertension 
due to previous nephrectomy and renal dysfunction. In a meta-analysis of Wu et al. on 
the incidence and risk of hypertension associated with the use of sorafenib, no signifi-
cant difference was detected between patients with or without a renal cell carcinoma.60 
It should be remarked that in this meta-analysis the incidence of hypertension was 
compared in relation to the presence of one or two kidneys rather than in relation to the 
actual renal function.
Renal toxicity
Another frequently observed side effect of angiogenesis inhibition is renal toxicity, pre-
dominantly reflected by proteinuria. According to the Common Terminology Criteria for 
Adverse Events version 3.0 proteinuria is classified in four different grades: grade 1 (0.15-
1.0 g/24hrs corresponding with dipstick 1+), grade 2 (>1.0-3.5 g/24hrs corresponding 
with dipstick 2+ to 3+), grade 3 (>3.5 g/24hrs corresponding with dipstick 4+) and grade 
4, nephrotic syndrome range proteinuria.42 Table 3 provides an overview of the inci-
dence of proteinuria in response to various angiogenesis inhibiting treatments.30,31,61-66 
Proteinuria related to treatment with bevacizumab is clearly a dose-dependent side 
effect and has been reported in up to 41-63% of patients.35 Although patients with renal 
cell carcinoma may especially be prone to develop proteinuria because of the prior 
nephrectomy causing impaired renal function or because of the presence of the primary 
tumor in situ, the risk of proteinuria and hypertension related to bevacizumab treatment 
did not alter after exclusion of patients with renal cell cancer in a meta-analysis.35
Although bevacizumab-associated proteinuria is usually not severe, proteinuria more 
than 3.5 g/day has been reported in up to 6.5% of patients.30 The incidence of protein-
uria associated with RTKIs is not well known, because screening for this condition was 
not routinely performed in the initial studies. In a phase 1 trial of the investigational 
RTKI KRN951, 14 of 15 patients developed hypertension and three (20%) dose-limiting 
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proteinuria.67 In contrast, in a report of Patel et al. only 2.3% of 298 patients treated with 
sunitinib or sorafenib developed substantial proteinuria (average level of 3.8 g/day) with 
a peak occurring after a median treatment period of 24 weeks.66 The relationship be-
tween antiangiogenic treatment and proteinuria seems to be causal, since proteinuria 
diminished or disappeared after reduction or discontinuation of this treatment.66,68
The proteinuric effect of VEGF inhibition is reported to be increased in patients using 
non-steroidal anti-inflammatory drugs and bisphosphonates.31 An apparent association 
between hypertension and proteinuria has been noted in patients with metastatic 
breast cancer treated with the combination of bevacizumab plus the cytotoxic drug 
capecitabine.31 Patients who did develop proteinuria were more likely to have hyperten-
sion (47.1%) than those who did not (16.9%).
Renal biopsy specimens of patients treated with VEGF inhibitors who developed protein-
uria have revealed various pathological abnormalities such as endotheliolysis, mesan-
giolysis, endothelial swelling, red cell fragments and thrombi.68 Glomerular thrombotic 
microangiopathy is a commonly reported finding that reverses when the antiangiogenic 
drug is withdrawn.68 The type and course of these renal lesions resemble those observed 
Table 3. Incidence of proteinuria during VEGF inhibition
Reference Disease Regimen No. of patients Proteinuria (%)
Kabbinavar et al.61 mCRC bevacizumab 67 25.3
Kabbinavar et al.62 mCRC bevacizumab 244 13.1
Hurwitz et al.21 mCRC bevacizumab 402 26.5
Yang et al.30 mRCC bevacizumab
low-dosea
high-dosea
76
40.5
64.1
Miller et al.31 mBC bevacizumab 232 22
Johnson et al.63 NSCLC bevacizumab 66 31.8
Nguyen et al.64 ARMD VEGF-Trap 19 31.6
Rugo et al.65 Various cancers AG013736b 36 8
Patel et al.66 GISTc sunitinib / sorafenib 298 2.3d
ARMD, age-related macula degeneration; GIST, gastro intestinal stromal tumor; mBC, metastatic breast 
cancer; mCRC, metastatic colorectal cancer; mRCC, metastatic renal cell carcinoma; NSCLC, non-small cell 
lung carcinoma; VEGF, vascular endothelial growth factor. a low-dose bevacizumab: 3mg/kg body weight 
i.v. every two weeks, high-dose bevacizumab: 10mg/kg body weight i.v. every two weeks. b AG013736 
(Axitinib, Pfizer Inc, New York, NY), an oral tyrosine kinase inhibitor of all VEGFRs, PDGFR-β and c-KIT. c 
case series of 7 patients with proteinuria were selected from the total population of patients treated with 
sunitinib or sorafenib, 5 patients with GIST, 1 patient with epitheloid hemangioendothelioma, 1 patient 
with teratocarcinosarcoma. dThe true prevalence of sunitinib- or sorafenib-associated proteinuria is 
probably higher because patients were not routinely and systematically screened for the development of 
proteinuria.
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during preeclampsia in which increased levels of s-Flt-1, produced by the placenta, bind 
and inactivate VEGF and PlGF. After delivery of the placenta, preeclampsia, including 
the renal lesions, resolves.68 Other reported renal pathologies include cryoglobulinemic, 
collapsing, membranoproliferative, and ischemic glomerulopathies as well as interstitial 
nephritis.69
Mechanism of renal toxicity
In the human kidney, VEGF-expression is most prominent in glomerular podocytes and 
tubular epithelial cells, whereas VEGFR-1 and VEGFR-2 are mainly found on preglomeru-
lar, glomerular and peritubular endothelial cells.5 Eremina et al. showed, by conditional 
gene targeting (deleting a single VEGF allele from renal podocytes), that local reduction 
of VEGF within the kidney of adult mice resulted in profound thrombotic glomerular 
injury.68 This injury preceded the development of hypertension making hypertension as 
the cause of proteinuria unlikely. In this context it is interesting to note that disrupted 
glomerular VEGF signalling has also been implicated in the pathogenesis of preeclamp-
sia.70,71
In a rodent model of crescentic glomerulonephritis, administration of the soluble 
VEGF receptor accelerated proteinuria with the development of massive ascites. Renal 
morphology revealed glomerulosclerosis and interstitial fibrosis associated with the 
loss of nephrin and endothelium.72 Single intravenous infusions of anti-VEGF antibod-
ies or s-Flt-1 into normal healthy mice resulted in excessive proteinuria via glomerular 
endothelial cell detachment and a decrease in the expression of nephrin.73 Nephrin is 
a protein exclusively expressed by glomerular podocytes and is critical for the main-
tenance of the glomerular filtration barrier by preventing podocyte apoptosis.72 It has 
been suggested that VEGF maintains podocyte function and survival by regulation of 
nephrin expression.72 Given these findings, inhibition of glomerular VEGF signalling ap-
pears to be a plausible mechanism that underlies the renal toxic effects of angiogenesis 
inhibition. Remarkably, not only underexpression, but also VEGF overexpression may 
induce renal toxicity. VEGF overexpression by podocytes in mice led to development of 
a collapsing glomerulopathy.74 In contrast, injection of VEGF in normal rats had no effect 
on kidney function and glomerular morphology, did not induce proteinuria and did not 
affect glomerular cell proliferation and the number of endothelial fenestrations.5
Cardiac toxicity
In addition to hypertension and renal toxicity, angiogenesis inhibition might also lead 
to cardiac toxicity. An overview of the incidence of cardiac toxicity in patients treated 
with sunitinib is provided in Table 4.33,37,40,41,75 In a retrospective study impaired cardiac 
function has been observed in up to 28% of patients treated with sunitinib, indicated by 
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a decrease in left ventricular ejection fraction (LVEF) of 10-15% or more.33 The median 
time to onset of congestive heart failure was 33 weeks (range 5 to 74 weeks). Multivari-
ate analysis in sunitinib-treated patients revealed that coronary artery disease was the 
only independent predictor of congestive heart failure. A reduction in left ventricular 
ejection fraction (LVEF) was present in most of the patients treated with sunitinib and 
was related with the duration of treatment. Six percent (2/36) of the patients had LVEF 
reductions of at least 20% and 19% (7/36) of at least 25%, whereas 8% (3/36) of patients 
developed New York Heart Association class III–IV heart failure. A decrease in LVEF has 
also been reported in patients treated with sorafenib (19%) or bevacizumab (5-11%).76,77 
The cardiac toxicity seems to be non-reversible, although it should be noted that long-
term follow-up after discontinuation of the angiogenesis inhibitors is lacking.75 Apart 
from a reduction in LVEF, other abnormalities, varying from an increase in biomarkers 
(e.g. creatine kinase, creatine kinase MB, cardiac troponin T, brain natriuretic peptide) 
and ECG changes only to mild or life-threatening clinical symptoms (e.g. angina, dys-
pnea, treatment in ICU) have also been reported.76
Mechanism of cardiac toxicity
Several hypotheses concerning the mechanism of cardiac toxicity due to angiogenesis 
inhibition can be postulated. Endomyocardial biopsy samples obtained from patients 
developing impaired cardiac function following treatment with sunitinib revealed 
cardiomyocyte hypertrophy on light microscopy. Electron microscopy showed myocyte 
hypertrophy and changes in mitochondrial structure without inflammatory or fibrotic 
changes.33 It should be noted that all of the patients in this study had previously been 
treated with imatinib and some also with anthracyclines, agents known to induce car-
diotoxicity. Hence, the possibility that this pre-treatment had contributed to the cardiac 
dysfunction observed during sunitinib treatment cannot be excluded.33 In accordance 
Table 4. Incidence of cardiac toxicity in patients treated with sunitinib
Reference Disease Sunitinib dose 
(mg/day)
Treatment 
durationa
No. of 
patients
Decrease in LVEF
(% of patients)
Motzer et al.37 mRCC 50 6 months 375 10
Motzer et al.40 mRCC 50 9 months 63 11
Demetri et al.41 mGISTb 50 8 weeks 207 0
Chu et al.33 mGISTb 50 24 weeks 75 28
Khakoo et al.75 Various 
cancers
25-50 4 – 44 days 224 2.7
Schmidinger et al.76 mRCC 50c 8 weeks 74 12
LVEF, left ventricular ejection fraction; mGIST, metastatic gastrointestinal stromal tumor; mRCC, metastatic 
renal cell carcinoma. a Treatment duration after which a decrease in LVEF was reported. b Imatinib-resistent 
GIST. c Patients received either sunitinib 50 mg/day (schedule:‘4 weeks ON / 2 weeks OFF’) or sorafenib 
800mg/day (continuously).
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with the histopathological changes in cardiomyocytes observed in human individuals, 
mitochondrial swelling and degenerative changes of cardiomyocytes after 12 days of 
sunitinib administration were also found in mice.33 The contractile ventricular dysfunc-
tion observed with RTKIs could therefore be due to impaired adenosinetriphosphate 
(ATP) generation secondary to mitochondrial dysfunction. However, only sorafenib has 
been shown to impair mitochondrial function at clinically relevant concentrations in iso-
lated rat heart mitochondria, whereas concentrations above clinical values were needed 
for sunitinib, imatinib and dasatinib.78 In cultured rat myocytes, sunitinib has shown to 
induce cytochrome C release into the cytosol and activation of caspase 9, leading to 
activation of mitochondrial apoptotic pathways.33 In contrast, no apoptosis or fibrosis 
was observed in hearts of mice treated with sunitinib for 12 days, unless the mice were 
also exposed to phenylephrine, the latter to induce hypertension.33 Another possible 
explanation for the cardiotoxic effect of sunitinib might be found in the inhibition of KIT, 
the receptor for stem cell factor, expressed on hemangioblasts.79 Hemangioblasts are 
the precursors of hematopoietic stem cells and endothelial progenitor cells and inhibi-
tion of KIT on these cells may prevent the beneficial homing of progenitor endothelial 
cells to areas of injury in the heart.79
Inhibition of VEGF-VEGFR signaling in the heart might be of particular concern in situ-
ations of poorly controlled hypertension. In mice, disruption of VEGF-VEGFR signaling 
by means of adenoviral delivery of a decoy VEGFR was associated with a reduction in 
myocardial capillary density, contractile dysfunction, fibrosis and heart failure during 
imposition of pressure load, whereas in the absence of a pressure load angiogenesis 
inhibition was without adverse cardiac effects.79-81 The preservation of myocardial capil-
lary density during angiogenesis inhibition in absence of pressure load is supported by 
the findings of Kamba et al.81 These authors found that capillaries of pancreatic islets, 
thyroid, adrenal cortex and pituitary do depend on VEGF for survival, but in the heart 
only a few of these capillaries are present.
In addition to inhibiting several growth factor receptors, sorafenib also inhibits Raf1, 
which may affect cardiac function.79 Deletion of Raf1 in the heart of mice led to a dilated, 
hypocontractile heart with enhanced cardiomyocyte apoptosis and fibrosis.79 Raf1 ki-
nase activity does not seem to be important in the absence of pressure load, whereas 
it provides protection in the pressure-loaded heart.79 As sorafenib inhibits Raf1 and 
induces hypertension, it can be expected that sorafenib, like sunitinib, induces cardiac 
dysfunction.
Patients treated with angiogenesis inhibitors will be predominantly older individuals 
(e.g. renal cell carcinoma occurs predominantly in patients over the age of 50), some-
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times with a history of coronary artery disease and the presence of various cardiac risk 
factors. Due to these unfavorable characteristics they are likely more prone to develop 
left ventricular dysfunction and congestive heart failure. Finally, RTKI-induced hypothy-
roidism can exacerbate or even cause left ventricular dysfunction.
Thromboembolic complications
Angiogenesis inhibition, like chemotherapy, is associated with an increased risk of 
venous and arterial thrombosis.82,83 In a recently published meta-analysis, combina-
tion therapy with a chemotherapeutic agent and bevacizumab was associated with a 
33% increased risk to develop venous thromboembolic events (VTE) compared with 
chemotherapy alone. This risk appeared to be dose-independent. It should be noted 
that the progression-free survival times in the combination groups were longer than 
in the control groups. Related to this increased survival, exposure to the combination 
therapy was also longer, which in turn might have contributed to the increased risk. As 
some smaller studies evaluating the role of bevacizumab as monotherapy did not report 
significantly higher incidences of VTE, the increased risk of VTE might be a consequence 
of bevacizumab-combination therapy rather than of bevacizumab itself.83 Combination 
therapy of the RTKI samaxibin (SU5416) and chemotherapy also resulted in a marked 
increase in VTE rate with evidence of endothelial injury as reflected by increased plasma 
levels of E-selectin, von Willebrand factor and tissue factor.84 The incidence of thrombo-
embolic complications associated with sunitinib and sorafenib appears to be low, but 
sporadic cases of arterial thromboembolism, particularly myocardial infarction have 
been reported.82
Mechanism of thromboembolic complications
A variety of factors may account for the increased thromboembolic risk associated with 
angiogenesis inhibition. First of all, VEGF is necessary for the regeneration of endothelial 
cells. During VEGF inhibition this regeneration may be impaired, leading to an increased 
exposure of platelets and coagulation factors to subendothelial-located procoagulant 
phospholipids. Second, VEGF is involved in the production of PGI2 and nitric oxide by the 
endothelium. PGI2 and nitric oxide have both antiplatelet activity, and a decrease in their 
production may promote thrombosis. Third, due to increased production of erythropoi-
etin, VEGF inhibition can increase hematocrit and blood viscosity, which may contribute 
to a prothrombotic state. Fourth, anti-angiogenic therapy may lead to an increased re-
lease of procoagulant factors from the tumor and may also induce increased production 
of proinflammatory cytokines, thereby increasing the risk of thrombosis. On the other 
hand, the reported increased incidence of thrombotic events may also result from the 
prolonged survival time associated with the use of angiogenesis inhibitors. Finally, the 
etiology of a thromboembolic event in most instances is multifactorial because factors 
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as age, mobility, functional status, concurrent chemotherapy, stage and histology of the 
malignant tumor can all contribute to its development.83
At this moment it remains difficult to determine whether patients who are treated with 
anti-angiogenic agents should be treated preventively with anticoagulant or antiplate-
let drugs. This decision is complicated by the knowledge that anti-angiogenic treatment 
is associated with a higher risk of bleeding, although to date no increased prevalence 
of hemorrhage has been reported in bevacizumab-treated patients who were already 
using antiplatelet drugs or warfarin for thrombotic events.82
Angiogenesis inhibition in retinal disorders
VEGF has been demonstrated in the vitreous fluid of many ocular neovascularizing 
syndromes such as age-related macular degeneration, proliferative diabetic retinopathy 
and diabetic macular edema and is thought to play an important role in the abnormal 
vessel proliferation that is prominent in these disorders.85 Anti-VEGF agents such as beva-
cizumab have shown to be beneficial in the treatment of proliferative ocular diseases. As 
systemic administration of bevacizumab was commonly associated with hypertension, 
intravitreal administration of bevacizumab as an alternative to minimize systemic effects 
was proposed by Rosenfeld et al.86,87 The safety of intravitreal administration of either 1.25 
mg or 2.5 mg of bevacizumab in patients with a variety of retinal disorders was retro-
spectively investigated in the uncontrolled PACORES (Pan-American Collaborative Retina 
Study Group) study. In the 1173 treated patients (on average 3.3 injections per eye) with 
1 year of follow-up, the most common systemic side effect was a transient elevation in 
blood pressure (0.6%). The blood pressure rise was generally mild and occurred from 7 h 
to 2 weeks following injection. The most common ocular complication was subconjunc-
tival hemorrhage, which was seen in 838 patients. Routine cardiac examination was not 
performed and therefore the rate of cardiac adverse events might have been underesti-
mated. On the basis of PACORES’ findings, intravitreal injection of bevacizumab appeared 
to be safe and well tolerated, at least during the first year after injection.85
Management of hypertension induced by vascular endothelial growth factor 
inhibition
The recognition that anti-angiogenic therapy is associated with the development of 
de novo hypertension, worsening of pre-existent hypertension, proteinuria, and renal 
and cardiac function impairment implies that patients subjected to such a treatment 
should be closely monitored for the occurrence of these side effects. For optimal man-
agement of angiogenesis inhibition-induced side effects close collaboration between 
oncologists, cardiologists, hypertensive specialists and nephrologists is mandatory. As 
hypertension can occur at any moment after initiation of angiogenesis inhibition, blood 
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pressure should be measured at least during every standard visit in the outpatient clinic, 
and even weekly monitoring during the first 6-8 weeks after initiation of angiogenesis 
inhibition has been advocated.88 Home blood pressure measurements and telemonitor-
ing may be advantageous by making it possible to timely initiate and, when necessary, 
to discontinue antihypertensive therapy. Especially when antihypertensive treatment 
has been initiated, blood pressure can drop with the risk of hypotension during the 2 
week ‘OFF’-period. As cancer usually occurs at advanced age, a substantial proportion 
of patients eligible for anti-angiogenic therapy may already have hypertension. In these 
patients care should be taken that their blood pressure is controlled before the anti-
angiogenic therapy is initiated.
Because of the lack of controlled studies favoring another approach, management of 
patients with angiogenesis-inhibitor induced hypertension should be in accordance 
to standard clinical practice. According to the ESH/ESC guidelines of 2007 blood pres-
sure should be reduced to at least below140/90 mmHg in all hypertensive patients 
and to at least below 130/80 mmHg in high-risk patients with clinical conditions such 
as renal dysfunction, proteinuria, a history of cardiovascular disease or diabetes mel-
litus.89 Whether these strict targets should also apply for patients with non-curable 
cancer and a decreased life expectancy is questionable. Nevertheless, timely starting 
of antihypertensive treatment is recommended in order to prevent the development 
of serious complications such as hypertensive encephalopathy, hemorrhagic strokes 
and heart failure, conditions that all have been reported to associate with the use of 
antiangiogenic treatment.33,46-48 As is true for the management of hypertensive patients 
in general, comorbid conditions are an important guide for the selection of the most 
appropriate antihypertensive therapy in an individual patient.89
In various studies all major classes of antihypertensive agents have been successfully 
used to treat anti-angiogenesis-induced hypertension.88 On the basis of pathophysiologi-
cal insights, drugs acting to increase nitric oxide, such as nitrates or phosphodiesterase 
inhibitors, are likely to be effective, but as these agents are not registered for the treat-
ment of hypertension they are not recommended as first-line agents. There is limited 
evidence that long-acting oral nitrates can restore blood pressure to baseline values in 
patients with hypertension refractory to combination treatment with an ACE-inhibitor 
and calcium channel blocker (CCB).90 The CCB nifedipine effectively reduced high blood 
pressure induced by the RTKI cediranib in rats.19 As nifedipine has shown to induce VEGF 
secretion thereby possibly promoting angiogenesis, other CCBs might be preferred.60 
Most of the clinically approved RTKIs are metabolized in the liver by the CYP3A4 system. 
As the non-dihydropyridine CCBs verapamil and diltiazem inhibit this system they can 
increase the plasma concentration of RTKIs and therefore are contraindicated.60,88
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Angiotensin-converting-enzyme inhibitors (ACE-inhibitors) and angiotensin recep-
tor blockers (ARBs) also seem appropriate in the treatment of hypertension induced 
by angiogenesis inhibition considering their renal protective effect and absence of 
pharmacokinetic interaction with RTKIs. ACE-inhibition has shown to restore podocyte 
nephrin expression in diabetic nephropathy.91,92 As nephrin underexpression is one of 
the potential mechanisms of proteinuria induced by anti-angiogenic therapy, treatment 
with ACE-inhibitors seems a logical choice, especially in the presence of both hyperten-
sion and proteinuria.69 It should be remarked that in a clinical study performed at our 
medical center a marked decrease in plasma renin activity was observed during treat-
ment with sunitinib [unpublished data]. This renin-suppression may impair the blood 
pressure lowering effect of ACE-inhibitors or ARBs. Both ACE-inhibitors and ARBs might 
exert antineoplastic effects due to a reduction of angiotensin II synthesis or blockade of 
its effects. Angiotensin II exerts mitogenic activities and promotes VEGF-induced tube 
formation in vitro.93 Furthermore, angiotensin II regulates apoptotic pathways and both 
ACE-inhibitors and ARBs can inhibit myocardial angiogenesis induced by VEGF.60,88 On 
the other hand, bradykinin, which increases during ACE-inhibition, might stimulate 
angiogenesis via activation of the B2 receptor, inducing nitric oxide and prostacyclin 
synthesis.10 Finally, it has been reported that hypertension induced by angiogenesis 
inhibitors can successfully be treated with diuretics and β-blockers. As non-vasodilating 
β-blockers can further increase peripheral vascular resistance and may disturb car-
diac conduction or modify QT- intervals they should in our view not be considered as 
first-choice agents for the treatment of anti-angiogenesis-associated hypertension.76 
Nebivolol might theoretically be a good choice as this agent exerts a vasodilating ef-
fect mediated by the L-arginine nitric oxide pathway and lowers peripheral resistance.88 
Diuretics should be used with caution, especially in the presence of bone metastasis and 
hypercalcemia, because of the risk of inducing or aggravating hypercalcemia.
Prophylactic antihypertensive treatment instead of starting antihypertensive treatment 
after hypertension has developed might be an alternative strategy to minimize dose 
reductions or dose interruptions of anti-angiogenic therapy. This has been explored in a 
recent study with the investigational RTKI cediranib.94 Patients (n = 126) were randomized 
for antihypertensive prophylaxis with a low dose of a CCB 3-7 days before initiation of 
treatment with the angiogenesis inhibitor cediranib or no antihypertensive prophylaxis. 
Although antihypertensive prophylaxis markedly reduced the development of severe 
hypertension, it did not result in less dose reductions or dose interruptions of cediranib 
as compared with the non-prophylaxis group. Hence, prophylactic antihypertensive 
treatment does not seem to provide much advantage.94
In summary, we propose the following recommendations considering the treatment 
of hypertension induced by angiogenesis inhibition:
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1. Blood pressure should be measured before the initiation of an angiogenesis in-
hibitor and thereafter on a regularly basis, at least during every standard visit in the 
outpatient clinic. Home blood pressure measurements and telemonitoring may be 
especially advantageous.
2. In patients with hypertension, blood pressure should be controlled before anti-
angiogenic therapy is initiated.
3. Prophylactic treatment with antihypertensive drugs in patients without hyperten-
sion is not recommended as such a strategy appears to have no effect on the number 
of dose interruptions or dose reductions of the angiogenesis inhibitor.
4. Antihypertensive treatment should be started in accordance with standard clinical 
practice. To prevent acute hypertensive complications a target blood pressure of less 
than 140/90 mmHg is advised for all patients treated with anti-angiogenesis inhibi-
tors.
5. Preferential antihypertensive drugs include CCBs, ACE-inhibitors or ARBs chosen 
on an individual basis (e.g. in patients with proteinuria ACE-inhibitors or ARBs are 
preferred). Non-dihydropyridine CCBs should be avoided during treatment with TKIs 
because of pharmacokinetic interaction.
6. In case of uncontrolled hypertension despite adequate antihypertensive treatment, 
discontinuation of the angiogenesis inhibitor, either temporarily or permanently, 
should be considered.
Conclusion
Angiogenesis is a critical factor in primary tumor growth and metastasis. Decades 
ago, angiogenesis inhibition has been proposed as a therapeutic strategy for cancer 
therapy, which in the mean time has proven to be highly effective. Unfortunately, VEGF 
inhibition, either with monoclonal antibodies to VEGF or with RTKIs involves unwanted 
side effects including hypertension and renal and cardiac toxicity. Although the exact 
underlying pathophysiological mechanisms remain to be elucidated, the literature 
discussed earlier provides several possible explanations. Fortunately, most of the side 
effects seem manageable but likely become more problematic as survival increases. In 
addition, in daily practice, treated patient populations include mainly older individuals 
with co-morbidity, often not meeting the strict inclusion criteria applied in clinical stud-
ies. As a consequence, a higher incidence of cardiovascular side effects than reported in 
clinical studies is likely. Both clinical trials as well as experimental studies are needed to 
further explore the pathophysiological mechanisms of cardiovascular side effects due 
to angiogenesis inhibition. This may lead to the development of more specific angio-
genesis inhibitors, better management of the side effects and may possibly provide new 
insights into the pathogenesis of cardiovascular disease in general.
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Angiogenesis inhibition induced by multitarget RTKIs, such as sunitinib, is not only 
associated with cardiovascular and renal toxicity, but also with thyroid dysfunction, 
mainly hypothyroidism (Table 1).1,3,4,5,7,8,9,10,11 The rise in thyroid stimulating hormone 
(TSH) levels occurs early, generally within 4 weeks of treatment, increases progressively 
during consecutive treatment cycles and fluctuates according to the ‘ON/OFF’ treatment 
regimen of sunitinib.1-3 These observations suggest that the condition is reversible 
once therapy has been discontinued and that the risk of hypothyroidism increases with 
increasing duration of sunitinib therapy. Whether the elevated TSH levels also represent 
overt clinical hypothyroidism remains unclear since differentiation between clinical 
symptoms related to hypothyroidism from those related to malignancy can be difficult. 
For instance, fatigue, one of the major symptoms of hypothyroidism, is also a common 
feature of cancer or cancer therapies and has been reported in patients treated with 
sunitinib in up to 50% (Table 1). Moreover, in one study 50% of patients with sunitinib-
induced hypothyroidism did not show symptomatic improvement with levothyroxine 
(LT4) replacement.
4 These findings suggest that a proportion of patients with abnormal 
thyroid function tests on sunitinib therapy has no clinically overt hypothyroidism.
Sunitinib-associated hyperthyroidism, although to a lesser extent, has also been reported, 
often preceding the hypothyroidism.5 Grossmann et al. have reported thyroid dysfunction 
in 48% of patients with mRCC treated with sunitinib. Of these patients 24% developed 
hyperthyroidism, eventually resulting in permanent hypothyroidism in 32% of patients.5
Thyroid dysfunction has also been reported during treatment with sorafenib, another 
RTKI, although the incidence of hypothyroidism associated with this drug is much lower 
Table 1. Reported incidence in literature of sunitinib-associated altered thyroid function tests and related 
clinical symptoms.
Reference No. of patients Tumor type Altered TFTs
(% patients)
Related symptoms
(% patients)
Rini et al.4 66 mRCC 85 84
Desai et al.7 42 mGIST 62 NR
Mannavola et al.3 24 mGIST 46-71 NR
Demetri et al.8 207 mGIST 4 NR
Schöffski et al.9 33 mRCC/mGIST 37-57 NR
Shaheen et al.10 62 mRCC 65 53
Grossmann et al.5 25 mRCC 48 NR
Wong et al.11 40 various 53 57
Wolter et al.1 59 mRCC/mGIST 61 NR
mGIST, metastatic gastrointestinal stromal tumor; mRCC, metastatic renal cell carcinoma; NR, not 
reported; TFT, thyroid function test.
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than that associated with sunitinib. Riesenbeck et al. reported in a prospective study of 
66 patients with mRCC that 31.8% developed hypothyroidism. Of these patients 38.1% 
was treated with sorafenib and 61.9% with sunitinib.2 Although both sunitinib and 
sorafenib are RTKIs of the VEGFR-1, and -2, they also target a number of other RTKs or tar-
get different receptors. Therefore, the lower incidence of thyroid dysfunction observed 
in patients on sorafenib could be related to the degree of inhibition of these receptors 
by these two drugs. Interestingly, thus far no alterations in thyroid function tests have 
been observed during treatment with bevacizumab, an anti-VEGF monoclonal antibody, 
suggesting that the thyroid dysfunction during angiogenesis inhibition with RTKI is due 
to an ‘off-target’ effect of these drugs rather than due to inhibition of the VEGF signaling 
itself.6
Mechanism of thyroid dysfunction
Since the expression of VEGF and VEGF receptor mRNA and protein, mediated in part 
by TSH, have been demonstrated in normal thyroid follicular cells, it seems logical that 
VEGF inhibition affects thyroid function and histology.4 Several mechanisms for the 
sunitinib-induced thyroid dysfunction have been hypothesized. Firstly, it has been dem-
onstrated that capillaries of the thyroid are extremely susceptible to VEGF inhibition. 
This capillary regression is reversible after withdrawal of the angiogenesis inhibitor.12 
In line with this report, sunitinib might induce thyroidal capillary regression (‘capillary 
regression hypothesis’) leading to thyroid tissue injury and dysfunction.4,13 Indeed, 
in some patients no thyroid tissue could be visualized on ultrasound imaging during 
treatment with sunitinib suggesting atrophy of the thyroid induced by capillary regres-
sion.7 In addition, Mannovola et al. found significant decreases in 123I-uptake in patients 
with sunitinib-induced hypothyroidism, suggesting that the underlying mechanism 
might be impaired iodine uptake.3 These data are contradicted by thyroid cell culture 
studies showing that sunitinib does not inhibit iodide uptake. Moreover, in these cells 
sunitinib caused a slight increase in intracellular iodide and did not reduce iodide efflux 
or sodium-iodide symporter (NIS) gene expression. NIS is a plasma membrane glyco-
protein that mediates active iodide transport into the thyroid follicular cells, the first 
step in thyroid hormone synthesis.14 Because of the critical role of the TSH receptor in 
NIS expression, and therefore in the production of triiodothyronine (T3) and thyroxine 
(T4), it has also been studied whether sunitinib impairs TSH receptor function. No such 
effect was observed.14 Secondly, in a small proportion of patients sunitinib might induce 
a thyroiditis-like syndrome with transient thyrotoxicosis and subsequent hypothyroid-
ism.5 In agreement with such a mechanism lymphocytic infiltration has been reported 
in one patient during treatment with sunitinib.5 On the other hand, no changes in anti-
thyroid peroxidase (TPO) antibody levels have been observed, making an autoimmune-
mediated mechanism less likely.13 Thirdly, a ‘metabolic hypothesis’ has been postulated, 
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based on a case-report of a patient with a history of thyroidectomy in whom an increase 
in LT4 dose was required during treatment with sunitinib, suggesting interference with 
the T4/T3 hormone metabolism.
15 This metabolic hypothesis is further supported by 
the findings of Wong et al., who demonstrated, using various in vitro assay systems, 
that sunitinib has anti-peroxidase activity similar to that of propylthiouracil (PTU), an 
effective peroxidase inhibitor, thereby reducing thyroid hormone synthesis. Since the 
antiperoxidase activity of sunitinib is much weaker (20-30%) than that of PTU not all 
patients will develop hypothyroidism.11 Fourthly, also the iodinated contrast used in 
CT-scanning during follow-up of the malignancy might interfere with thyroid function.13
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AIMs oF THe THesIs
Angiogenesis plays a critical role in tumor growth. During this process, the cells in the 
center will become hypoxic and pro-angiogenic signals such as vascular endothelial 
growth factor (VEGF) will be expressed. VEGF, a key mediator in the angiogenic process, 
binds two receptors, the VEGF receptor (VEGFR)-1 and -2. Biologically, the latter is the 
most important. Binding of VEGF to this receptor leads to an increase in nitric oxide (NO) 
production. VEGFRs contain two tyrosine kinase domains. Angiogenesis inhibition by 
means of blocking these tyrosine kinases with sunitinib has become an important strat-
egy for the treatment of several tumor types, including metastatic renal cell carcinoma 
and imatinib-resistant gastrointestinal stromal tumors. Unfortunately, treatment with 
sunitinib is associated with several side effects: hypertension, renal and cardiac toxicity 
as well as thyroid dysfunction. Since the occurrence of side effects can be a reason to 
lower the sunitinib dose or even to stop therapy, thereby compromising its potential ef-
ficacy, it is from a clinical point of view important to unravel the mechanisms underlying 
these toxicities. The findings of the studies presented in this thesis may help to develop 
therapies to combat these adverse effects.
sunitinib-induced cardiovascular and renal toxicity
Hypertension and renal toxicity
Hypertension during angiogenesis inhibition with sunitinib has been reported in up to 
47% of patients. The incidence of sunitinib-induced renal toxicity, mainly proteinuria, has 
not been well documented since patients were not routinely screened for this condition 
in the initial studies. It has been postulated that inhibition of the VEGF-pathway reduces 
NO bioavailability, which may result in vasoconstriction and contributes directly to the 
development of hypertension. Additionally, decreased NO bioavailability may lead to 
a disturbed balance between NO and the vasoconstrictor endothelin-1 (ET-1), favoring 
ET-1 production, thereby inducing vasoconstriction and contributing to the develop-
ment of hypertension. Furthermore, oxidative stress is involved in the pathogenesis of 
hypertension, cardiovascular disease as well as renal injury, and decreased levels of VEGF 
may contribute to oxidative stress-induced endothelial dysfunction. Since VEGF plays a 
role in podocyte survival and function, it is indirectly involved in the maintenance of the 
glomerular filtration barrier. As a consequence, inhibition of VEGF signaling might affect 
the integrity of this barrier.
In the current studies we aimed to obtain more insight into the mechanisms underlying 
sunitinib-induced hypertension and renal toxicity. Firstly, the effect of sunitinib and 
its withdrawal on blood pressure and renal function and histology was investigated in 
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patients and rats (Chapter 3). Secondly, in rats and swine the roles of ET-1, NO-bioavail-
ability and oxidative stress in the development of sunitinib-associated hypertension and 
renal toxicity were explored (Chapter 4, 5, 6).
Cardiac toxicity
Sunitinib-induced cardiac toxicity has been observed in patients. A decrease in LVEF 
of 10-15% occurs in up to 28% of patients treated with sunitinib. In addition, angina 
pectoris and increases in biomarkers of cardiac damage have been observed. Since car-
diac mitochondrial structural changes have been observed in these patients, it has been 
postulated that impaired ATP generation secondary to mitochondrial dysfunction could 
underlie the contractile ventricular dysfunction, but the exact mechanism underlying 
sunitinib-induced cardiac damage remains unknown.
In the studies presented in this thesis the effect of sunitinib on ex vivo mitochondrial func-
tion in cardiomyocytes obtained from sunitinib-administered rats was studied (Chapter 
3). Additionally, in swine we investigated the effect of sunitinib on cardiac function as 
well as on coronary and pulmonary hemodynamics focusing on the potential activation 
of the endothelin system, decreased NO-bioavailability and increased oxidative stress as 
underlying mechanisms (Chapter 5).
sunitinib-induced thyroid dysfunction
Sunitinib-induced thyroid dysfunction, mainly hypothyroidism, has been reported in up 
to 53-85% of patients in retrospective and in up to 36-46% of patients in prospective 
studies. Since in some patients, already on thyroid hormone replacement therapy before 
sunitinib initiation, a dose-increase was required during sunitinib treatment, it has been 
hypothesized that sunitinib interferes with thyroid hormone metabolism (‘metabolic 
hypothesis’). In mice, administration of an experimental VEGF receptor inhibitor or a 
soluble VEGF receptor, binding circulating VEGF, was associated with a marked increase 
in TSH levels and pronounced regression of capillaries in the thyroid gland (‘capillary 
regression hypothesis’).
In the current study we aimed to investigate the incidence of sunitinib-induced thyroid 
dysfunction, its time-course and pathophysiological mechanisms involved, including 
thyroid hormone metabolism and changes in capillary density, in patients and in rats 
(Chapter 8).
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AbsTRACT
Angiogenesis inhibition with sunitinib, a multitarget tyrosine kinase inhibitor of the 
vascular endothelial growth factor receptor, is associated with hypertension and cardiac 
toxicity of which the underlying pathophysiological mechanism is unknown. We inves-
tigated the effects of sunitinib on blood pressure, its circadian rhythm and potential 
mechanisms involved, including the endothelin-1 system, in 15 patients with metastatic 
renal cell carcinoma or gastrointestinal stromal tumors. In addition, we investigated 
in rats the effect of sunitinib on blood pressure, serum endothelin-1 levels, coronary 
microvascular function, cardiac structure and cardiac mitochondrial function. In pa-
tients, blood pressure increased by almost 15 mm Hg while heart rate decreased after 4 
weeks of treatment. Furthermore, the nocturnal dipping of blood pressure diminished. 
Plasma endothelin-1 concentration increased twofold (P<0.05), plasma renin decreased 
(P<0.05), whereas plasma catecholamines and renal function remained unchanged. 
In rats, 8 days of sunitinib-administration induced an almost 30 mmHg-rise in blood 
pressure, an attenuation of the circadian blood pressure rhythm and a threefold rise in 
serum endothelin-1 and creatinine, which all but the rise in creatinine reversed after 
sunitinib-withdrawal. Coronary microvascular function studies after 8 days of sunitinib-
administration showed decreased responses to bradykinin, angiotensin II and sodium 
nitroprusside, all normalizing after sunitinib-withdrawal. Cardiac structure and cardiac 
mitochondrial function did not change. In conclusion, sunitinib induces a reversible rise 
in blood pressure in patients and in rats associated with activation of the endothelin-1 
system, suppression of the renin-angiotensin system and generalized microvascular 
dysfunction.
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InTRoDuCTIon
Angiogenesis, the formation of new capillaries from an existing vasculature, is critical 
to tumor growth as well as metastasis. This process is regulated by numerous growth 
factors and their receptors among which vascular endothelial growth factor (VEGF) and 
its corresponding receptors play a key role. Angiogenesis inhibition as a therapeutic 
strategy against malignancies was first proposed by Folkman in 1971.1 Meanwhile a 
variety of drugs, targeting VEGF or its receptors, have been approved for the treatment 
of several tumor types. Unfortunately, angiogenesis inhibition is associated with side 
effects, in particular hypertension, which has been reported in up to 60% of patients 
treated with sunitinib, an orally active multitarget VEGF receptor tyrosine kinase inhibi-
tor (RTKI) and one of the most commonly used angiogenesis inhibitors.2 Decreased nitric 
oxide bioavailability might underlie this phenomenon.3,4
VEGF inhibition with sunitinib is also associated with cardiac toxicity, evidenced by 
a decrease in left ventricular ejection fraction (LVEF) in up to 28% of patients.5 Given 
the sunitinib-induced changes in cardiac mitochondrial structure, this could relate 
to impaired adenosine triphosphate (ATP) generation secondary to mitochondrial 
dysfunction.5 However, sunitinib, at clinically relevant concentrations, did not impair 
mitochondrial function in a rat myoblast cell line.6
The occurrence of the mentioned side effects can be a reason to lower the sunitinib dose 
and sometimes even to stop therapy, thereby compromising its potential efficacy. For 
optimal management, it is important to improve insight into the mechanisms underly-
ing the sunitinib-induced toxicities. Our research, involving both patients and rats, was 
aimed to elucidate the pathophysiological mechanism(s) involved in the development 
of hypertension during sunitinib treatment. Simultaneously, we addressed the question 
whether and to what extent sunitinib affects cardiac structure and cardiac mitochon-
drial function.
MeTHoDs
Clinical study
Between January 2008 and January 2009, patients with either metastatic renal cell 
carcinoma (mRCC) or imatinib-resistent gastrointestinal stromal tumor (GIST), who were 
eligible for treatment with sunitinib, were invited to participate in our study. Patients 
were followed for 10 weeks during treatment with sunitinib which was taken according 
to a 4 weeks ‘on’, 2 weeks ‘off’ regimen with a starting dose of 50 mg/day. According to 
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the judgment of the patient’s physician this dose could be adjusted. If blood pressure 
(BP) increased to stage II hypertension or above, antihypertensive treatment was initi-
ated with a calcium channel blocker, an ACE-inhibitor or an angiotensin (Ang) II type 1 
receptor blocker and a diuretic as a first, second and third choice. Nocturnal dipping of 
BP was defined as a more than 10% decrease in systolic, diastolic or mean arterial pres-
sure during sleep. Patients visited the outpatient clinic every 2 weeks. At baseline and at 
the end of the first and second treatment cycle, 24-hour ambulatory BP measurements 
(ABPM) were performed (Suntech Oscar 2 ABP monitor and AccuwinPro soft). During the 
visits, sitting BP was measured during 30 minutes at 5 minutes intervals using an auto-
mated device (Dynamap, Critikon Inc, model 8101) in a private room. Blood samples for 
laboratory measurements were obtained from an intravenous line at baseline and at the 
end of the first and second treatment cycle, after a 30-minutes rest period. 24-Hour urine 
samples for measurement of protein, creatinine and sodium were collected at baseline 
and at weeks 4, 6 and 10. The study was approved by the Institutional Review Board 
and Ethical Committee of the Erasmus MC in Rotterdam. Written informed consent was 
obtained from each patient.
Rat study
Male Wistar-Kyoto rats (280-300 grams), obtained from Charles River, were housed in 
individual cages and maintained on a 12-h light/dark cycle, having access to standard 
laboratory rat chow and water ad libitum. Intra-aortic BP recordings were performed by 
radiotelemetry for which a transmitter (TA11PA-C40, Datascience Inc.) was implanted 
into the abdominal cavity.7 Telemetric data were recorded and digitalized using the 
Dataquest Acquisition & Analysis system (DQ ART 3.1 Silver, Datascience Inc.). Each 
animal was sampled for 10 seconds at 10-minute intervals. All recordings were aver-
aged for the day and night period. Baseline values of mean arterial pressure (MAP) and 
heart rate (HR) were averages of three day recordings before treatment was started. One 
week after recovery the rats were acclimatized to drug administration by oral gavage, 
by administering water for 8 days. The content of sunitinib L-malate capsules, obtained 
from patients who discontinued treatment, was dissolved in HCl (0.1 mol/L), containing 
0.5% polysorbate and 10% polyethylene glycol, after which NaOH (0.1 mol/L) was added 
to adjust pH to 3.5. Two separate experiments were performed. In the first experiment 
rats were randomly administered sunitinib (26.7 mg/kg/day of sunitinib L-malate; n=10) 
or vehicle (see above; n=10) by oral gavage (0.5 mL) for 8 days and were euthanized 
with 60 mg/kg pentobarbital i.p. at the end of this period, at which time blood was 
sampled and the heart and kidneys were rapidly excised. In the second experiment, rats 
(n=7) were administered sunitinib at the same dose for 8 days followed by an 11-day 
recovery period, after which they were sacrificed. Six days before (baseline) and 6 days 
after treatment initiation, rats were housed in metabolic cages for 48 hours; the first day 
Cardiovascular and renal toxicity 57
to acclimatize and the second day for collection of 24-hour urine for protein measure-
ment. In the second experiment rats were also housed in metabolic cages one week 
after treatment discontinuation. All experiments were performed under the regulation 
and permission of the Animal Care Committee of the Erasmus MC.
In vitro studies and histology
Hearts were rapidly excised from euthanized rats and perfused according to Langen-
dorff.8 Coronary flow (CF) was measured with a flow probe (Transonic systems). After 
a stabilization period of 30 minutes, baseline values of CF were obtained. Next, bolus 
injections (100 μL) of Tyrode’s buffer were applied three times to determine injection-
induced changes in CF. Dose-response curves to bradykinin and Ang II were constructed 
by bolus injections, after which the maximum CF was determined by injecting sodium 
nitroprusside (SNP; 10 mmol/L).
Next, the hearts were collected, and the heart weight was determined after removal of 
the atria and large vessels to determine the heart weight/body weight (HW/BW) ratio. 
The apex was removed to isolate cardiomyocyte mitochondria.9 The ventricles were cut 
into 3 transversal slices and fixed in a 3.5-4% formaldehyde solution. After fixation, the 
slices were dehydrated and paraffin-embedded. Gomori’s silver staining was applied 
to deparaffinized 5-μm thick sections to visualize individual cardiomyocytes.10 Only 
transversally cut cells showing a nucleus were used to determine cardiomyocyte area.
Kidneys were collected directly after euthanization and sliced into 2-mm thick trans-
verse sections. After fixation in 3.5-4% formaldehyde solution for 12 hours, the slices 
were routinely processed to paraffin blocks from which 2-μm thick sections were cut and 
stained with Jones silver stain to allow microscopic examination.
Cell culture study
Human umbilical vein endothelial cells (HUVECs) were obtained and cultured as de-
scribed before.11 Cells (passage 5-6) were seeded at 5000 cells/cm2 in 6-well plates, and 
upon reaching confluency exposed to 10 nmol/L sunitinib (a concentration which has 
been reported to inhibit tyrosine phosphorylation of the VEGF receptor 2) or culture 
medium only.12 After 72 hours, medium and cells were collected and stored at -80ºC for 
the determination of endothelin-1 (ET-1).
Biochemical measurements
Plasma renin activity (PRA) was measured by an in house assay as described before.13 
Plasma renin concentration (PRC) was measured by an immunoradiometricassay (Cisbio), 
aldosterone by radioimmunoassay (Coat-A-Count®, Siemens), ET-1 by chemiluminescent 
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ELISA (QuantiGlo®, R&D Systems), VEGF by enzyme immunoassay (Quantikine®, R&D 
Systems) human N-terminal pro-brain natriuretic peptide (NT-proBNP) by radioimmu-
noassay (Phoenix Pharmaceuticals, Inc.), rat B-type natriuretic peptide-45 (BNP-45) by 
enzyme immunoassay (Phoenix Pharmaceuticals Inc.), and total protein by colorimetric 
detection (Pierce® Protein Assay Kit). Catecholamines were measured by electrochemi-
cal detection after separation by high-performance liquid chromatography.14,15 Von 
Willebrand factor (vWf ) antigen was determined with an in-house ELISA assay, using 
polyclonal rabbit anti-human vWF and horseradish peroxidase conjugated anti-human 
vWF (DakoCytomation). Serum creatinine and urinary protein were measured at the 
clinical chemical laboratory of the Erasmus MC.
Cardiac mitochondrial respiratory activity, complex I- and II-dependent respiration, 
mitochondrial ATP production and mitochondrial swelling were measured as described 
in the Supplement.
Data analysis
Data are presented as mean±SEM or geometric mean and 95% confidence intervals. 
Data obtained with the Langendorff preparation were recorded and digitalized as 
previously described.8 Statistical analysis between groups was performed by repeated-
measures ANOVA followed by Newman-Keuls multiple comparison testing, or two-way 
ANOVA. VEGF- and NT-proBNP-levels were analyzed by Wilcoxon rank sum test. For cor-
relation analysis the Pearson r correlation coefficient was used. P<0.05 was considered 
significant. GraphPad Prism version 4.03 was used for all statistical analysis.
ResulTs
Clinical study
Fifteen patients (10 male, 5 female), mean age of 59.8 ± 6.1 years, with mRCC (n=13) or 
GIST (n=2) were included. Five patients had pre-existent hypertension. Twelve patients 
had a history of smoking, 3 were still smoking and 3 had a history of cardiovascular 
disease. Treatment with sunitinib was associated with a rise in BP showing a clear on/off-
effect according to the on/off-treatment regimen, and was accompanied by opposite 
changes in heart rate (Figure 1). ABPM also showed a rise in day and night-time BP that 
sustained during the second treatment cycle (Figure 1). The rise in BP was accompanied 
by an attenuation of the circadian BP rhythm (Figure 1). Initiation or adjustment of 
antihypertensive therapy was indicated in 6 and 2 patients respectively.
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Body weight decreased from 80±3 kg at baseline to 78±4 kg (P=0.31) at week 4 and to 
73±4 kg (P=0.02) at week 10. Serum creatinine (77±6 μmol/L) did not change. Proteinuria 
increased from 0.19±0.02 to 0.44±0.16 g/24h (P=0.14) at week 4, decreased to 0.20±0.04 
g/24h (P=0.97) at week 6 and increased again to 0.35±0.13 g/24h (P=0.19) at week 10.
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Figure 1. Change in blood pressure and heart rate, and nocturnal dipping of blood pressure in response 
to treatment with sunitinib. A. Changes in 24-hour ambulatory systolic, diastolic and mean arterial 
pressure (SBP, DBP and MAP) and heart rate (HR) at baseline and after 4 and 10 weeks of sunitinib 
treatment. B. Nocturnal dipping of SBP and DBP at baseline and after 4 and 10 weeks of sunitinib 
treatment. C. Change in MAP and HR measured with an automated device for 30 minutes at baseline, 
during the first treatment cycle with sunitinib (week 2 and 4), during the ‘off’-treatment period (week 6) 
and at the end of the second treatment cycle (week 10). *P<0.05 compared to baseline.
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Treatment with sunitinib was associated with a fall in PRC and PRA and an increase in 
plasma ET-1 and VEGF concentration, whereas plasma concentrations of aldosterone, 
norepinephrine, epinephrine, NT-proBNP and vWf did not change (Table 1). Changes in 
plasma ET-1 and renin concentration did not correlate with the changes in BP.
Rat study
Daily administration of sunitinib to WKY-rats induced a rise in BP within 1-2 days, reach-
ing a plateau after 6 days. At that time, MAP had increased by almost 30 mmHg whereas 
heart rate had decreased (Figure 2A). The rise in BP was accompanied by an inversion of 
the normally-occurring decrease in BP during sleep (Figure 2A). In control rats BP and 
HR remained stable (Figure 2A). Both the rise in BP and the attenuation of its circadian 
rhythm were reversible after sunitinib-withdrawal (Figure 2B).
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Figure 2. A. Changes in mean arterial pressure (MAP), heart rate (HR) and dipping of MAP during sleep 
(day 6) in response to sunitinib (n=10) or vehicle treatment in rats (n=6). B. Changes in MAP and HR during 
administration and after discontinuation of sunitinib (n=7). MC, metabolic cage. *P<0.05.
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The increase in body weight (from 368±3 to 382±3 g) was lower (P<0.001) in rats on 
sunitinib than in control rats (from 383±3 to 406±3 g). Serum creatinine increased dur-
ing administration of sunitinib and remained elevated after its discontinuation (Figure 
3A). Administration of sunitinib was associated with proteinuria that normalized after 
sunitinib withdrawal (Figure 3B). Histological evaluation of the kidney using light mi-
croscopy showed marked glomerular changes following sunitinib treatment (Figure S1, 
Supplement). Comparable to findings in patients, administration of sunitinib was as-
sociated with an almost 3-fold increase in plasma ET-1 concentration, which normalized 
after its discontinuation (Figure 3C).
Circulating BNP-45 levels were almost two-fold higher in the sunitinib-administered 
group compared to the control group (164±34 vs 93±15 ng/ml; P=0.03) and normalized 
after sunitinib-withdrawal (93±9 ng/ml; P=0.03). Heart weight-to-body weight ratio 
(3.0±0.04 vs 3.1±0.06 g/kg; P=0.18) and cardiomyocyte area (513±37 vs 552±42 µm2; 
P=0.51) were not different between the sunitinib and control group.
In the Langendorff preparation, CF responses to bradykinin, Ang II and SNP were mark-
edly attenuated in sunitinib-administered rats (Figure 4; P<0.05), and all responses 
normalized after discontinuation of sunitinib.
Complex I- and II-dependent basal respiratory activity (state 2), as well as the ADP-stim-
ulated (state 3) respiration were not different between groups (Figure S2A, B, Supple-
Table 1. Plasma concentrations of neurohormones, von Willebrand factor antigen (vWf-Ag) and vascular 
endothelial growth factor (VEGF), at baseline and at the end of the first (week 4) and second (week 10) 
treatment cycle of sunitinib in patients.
Plasma parameters Week 0 Week 4 P-value Week 10 P-value
PRC (pg/ml) 9.9±2.1 3.6±0.8 0.02 5.2±1.9 0.16
PRA
(pmol Ang I/ml/h)
1.3±0.3 0.5±0.1 0.001 0.75±0.2 0.28
Aldosterone (pg/ml) 44.5±13.1 36.8±8.6 0.34 55.2±16.6 0.98
Endothelin-1 (pg/ml) 3.0±0.4 5.2±0.8 0.004 6.0±1.2 0.008
Norepinephrine (pg/ml) 265.5±23.3 258.3±37.4 0.95 351.3±83.5 0.38
Epinephrine (pg/ml) 31.7±8.9 25.8±4.9 0.51 41.2±14.7 0.59
vWf-Ag (U/ml) 1.6±0.2 1.7±0.2 0.55 1.4±0.2 0.79
NT-proBNP (pg/ml) 850.5
(648.1-1116)
885.6
(637.4-1230)
0.54 729.2
(521.2-1020)
0.76
VEGF (pg/ml) 35.5
(22.9-55.2)
153.6
(83.9-280.9)
0.002 150.6
(63.0-360.1)
0.005
PRA, plasma renin activity; PRC, plasma renin concentration. Data shown as mean±SEM. VEGF and NT-
proBNP values are shown as geometric mean and 95% CIs. P value compared with baseline (week 0).
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ment). The RCI’s did not change either (data not shown). Complex I- and II-dependent 
ATP-production were not different in the sunitinib compared to the control group or 
after sunitinib withdrawal (Figure S2C, Supplement). The calcium-induced mitochon-
drial swelling was lower in the sunitinib than in the control group and remained low 
after sunitinib withdrawal (Figure S2D, Supplement).
Cell culture study
ET-1 production by sunitinib-treated HUVECs was identical to that in control cells (22±5 
vs 20±5 ng/µg protein; P=0.73, n=9).
DIsCussIon
Hypertension is a frequent and sometimes severe adverse effect of anti-angiogenic ther-
apy. With our clinical and experimental studies we aimed to obtain more insight into the 
mechanisms underlying the development of hypertension. In agreement with previous 
reports we found that the RTKI sunitinib induced a substantial rise in BP.5,16 Evaluation 
of the time course of the BP rise in our experimental study revealed that this already 
Figure 3. Serum creatinine (panel A), proteinuria (panel B) and serum endothelin-1 (ET-1, panel C) in rats 
after administration of sunitinib (n=10-13), vehicle (control; n=6) or sunitinib withdrawal (stop; n=7). 
*P<0.05 compared to baseline/control.
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occurred one day after its administration. Furthermore, both in humans and in rats the 
BP response showed an on/off-effect that paralleled the on/off-administration regimen. 
In patients the rise in BP was accompanied by attenuation and in rats by reversal of the 
circadian BP variation and in both species it was accompanied by a decline in heart rate. 
Remarkably, both in our clinical and experimental study sunitinib administration was 
associated with a substantial rise in circulating ET-1 levels. To our knowledge, increased 
plasma ET-1 levels in response to sunitinib have not been reported before. Although 
ET-1 is predominantly produced by endothelial cells, sunitinib did not affect ET-1 release 
from HUVECs. This suggests that the ET-1 increase has a non-endothelial origin.
The question whether activation of the endothelin-system is involved in the sunitinib-
induced rise in BP cannot be answered at this moment. In a recent study performed in 
telemetry-instrumented rats, pre-treatment with the selective ETA-receptor antagonist 
atrasentan completely prevented the rise in BP induced by a RTKI.17 Since the same 
ETA-receptor blocker also lowered BP in control rats, definite conclusions about the role 
of the endothelin-system, in particular activation of ETA-receptors, in the rise of BP as-
sociated with the use of anti-angiogenic therapy cannot be drawn. Notably, increased 
plasma ET-1 levels have also been described in patients with preeclampsia.18 There is 
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Figure 4. Coronary flow responses to bradykinin (BK, n=6-10; panel A), angiotensin (Ang) II (n=7-9; panel 
B) and a single injection of sodium nitroprusside (SNP; 10 mmol/L; n=6-10; panel C) in isolated rat hearts 
after administration of sunitinib, vehicle (control) or sunitinib withdrawal (stop). The x-axis in panel A and 
B displays the concentration in the injection fluid. T, Tyrode’s buffer. *P<0.05 compared to control.
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accumulating evidence that increased placental production of soluble fms-like tyrosine 
kinase 1 (sFlt-1), a VEGF-binding factor, is involved in the pathogenesis of preeclamp-
sia.19,20 Indeed, recently Murphy et al reported the development of hypertension in 
pregnant rats during infusion of sFlt-1 for 6 days.21 Such infusion was accompanied by a 
3-fold increased expression of pre-proendothelin mRNA in the renal cortex, but not by 
increased expression in the renal medulla or aorta. ETA-receptor blockade in this model 
completely prevented the BP rise. As sFlt-1 impairs VEGF signalling, its infusion may 
therefore create a condition comparable to that induced by sunitinib and the increased 
ET-1 levels in our studies might be of renal origin as well.
Since the rise in BP was associated with a decrease in renin, involvement of the renin-an-
giotensin system could be excluded as an underlying mechanism. Despite the decrease 
in renin, aldosterone levels did not change. The possibility that mineralocorticoid-
receptor activation has played a role in the development of hypertension can therefore 
not be excluded. The sunitinib-induced rise in blood pressure was not associated with 
an increase in plasma catecholamine levels, indicating that sympathetic nervous system 
activation was not involved in the BP elevation. This is supported by the observation 
that the rise in BP was accompanied by a decrease in heart rate. To some extent, our 
findings disagree with those reported by Veronese et al, as these authors did not report 
an increase in plasma ET-1 concentration or a decrease in PRA during treatment with the 
RTKI sorafenib.22 Sorafenib has partly different receptor targets compared to sunitinib 
which might account for the different findings in both studies. Furthermore, in the study 
of Veronese et al, baseline blood samples were taken in the first two weeks after treat-
ment initiation and changes in hormone levels might therefore have been missed.
Renal function impairment, apart from the development of hypertension, is also a well-
documented side effect of angiogenesis inhibition.23-25 In our clinical study no change 
in serum creatinine concentration was observed, but proteinuria tended to increase. In 
contrast, in our experimental study sunitinib was associated with a marked impairment 
of renal function, development of pronounced proteinuria as well as glomerular chang-
es. For several reasons it is unlikely that impairment of renal function accounted for the 
rise in BP. First, and in accordance with other clinical and experimental studies, the rise 
in BP already occurred within 1-2 days after administration of sunitinib.17,26 Second, after 
sunitinib withdrawal in rats, BP completely normalized, whereas renal function did not. 
Third, in our clinical study the BP elevation was not accompanied by any deterioration in 
renal function. Since body weight or NT-proBNP-levels did not increase in our patients, 
fluid retention is also unlikely to be involved in the rise in BP.
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VEGF has been reported to increase the expression of eNOS. Inhibition of VEGF-signal-
ling may therefore result in impaired NO-production, leading to hypertension.2,3 We 
used the Langendorff model to investigate whether sunitinib administration impaired 
endothelium-dependent vasodilation. We found that not only the response to the 
endothelium-dependent vasodilator bradykinin, but also the responses to the endo-
thelium-independent vasodilator sodium-nitroprusside, as well as the vasoconstrictor 
Ang II were all considerably impaired in sunitinib-administered rats. These findings 
indicate that exposure to sunitinib is associated with a generalized impaired function of 
the vascular smooth muscle cell. From our studies we cannot conclude whether this is 
related to inhibition of VEGF-signalling and/or interaction of sunitinib with other target 
receptors or a consequence of the elevated BP.
Not only hypertension, but also left ventricular dysfunction in patients and cardio-
myocyte hypertrophy and changes in mitochondrial structure in endomyocardial 
biopsy samples of patients have been observed during sunitinib treatment.5 Impaired 
ATP-generation secondary to mitochondrial dysfunction has been proposed as an 
underlying mechanism for the development of cardiac dysfunction.27 However, stud-
ies performed in isolated rat heart mitochondria have shown that sunitinib, contrary 
to sorafenib, impairs mitochondrial function only at supra-therapeutic concentrations.6 
In accordance with these findings in our ex-vivo studies no evidence was found that 
sunitinib administration, at a dose that markedly increased BP, affected mitochondrial 
ATP production. Due to the large inter-animal variation in cardiac mitochondrial ATP 
production and the necessity to perform the studies in different groups of animals, we 
cannot completely exclude the possibility that an effect of sunitinib on ATP production 
has been missed. In our current opinion the observed increase in plasma BNP levels in 
the rats is more likely a consequence of elevated BP as well as a decreased renal clear-
ance rather than reflecting direct cardiac damage by sunitinib.
Some limitations of our studies should be addressed. First, we did not perform a ran-
domized controlled trial. Since sunitinib is a first-line treatment of patients with mRCC 
or imatinib-resistent GIST it is not possible to perform a placebo-controlled trial in 
these patients. Second, the number of included patients in our study was rather limited. 
Despite this limited number we still found relevant changes in blood pressure and vari-
ous neurohormones because the responses of these parameters among patients were 
quite uniform. Third, because of our extensive experience with this cell-line, we have 
used HUVECs to investigate the effect of sunitinib on ET-1 release. Since no increased 
ET-1 release in response to sunitinib could be demonstrated, it would be worthwhile to 
study the effect of sunitinib on ET-1 release in other endothelial cell-lines to ascertain 
the uniformity of this finding.
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PeRsPeCTIVes
Inhibition of VEGF signaling with the multitarget RTKI sunitinib is associated with a 
substantial rise in BP according to an on/ off-mechanism in both humans and rats, and 
is accompanied by a rise in circulating ET-1 concentration. Whether this activation of the 
endothelin-system is instrumental for the rise in BP cannot be concluded at this moment 
and requires further investigation. Experimental evidence that the endothelin-system 
plays a role in the development of hypertension during administration of anti-angio-
genic agents is emerging.17,21 If such a mechanism can also be established in patients, 
antihypertensive treatment with an endothelin-receptor blocker would be a logical 
choice. Finally, in our clinical study the development of hypertension was associated 
with renin suppression. The implication of this finding could be that agents interfer-
ing with the renin-angiotensin system are less effective in reducing blood pressure in 
anti-angiogenic therapy-induced hypertension and that calcium-channel blockers or, as 
discussed earlier, endothelin-receptor blockers may be preferable instead. Since the use 
of anti-angiogenic agents is expected to increase, future clinical and experimental stud-
ies have to be performed to establish which antihypertensive therapy is most effective 
for the management of hypertension associated with these drugs.
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suPPleMenT
expanded methods
Cardiac mitochondrial function assessment
Mitochondrial respiratory activity, measured as the oxygen consumption rate (flux in 
pmol oxygen/second/mg mitochondrial protein) was assessed at 37°C by high-resolution 
respirometry (Oxygraph-2k, Oroboros Instruments). Complex I- and II-dependent respi-
ration were measured in state 2 (respectively, in the presence of 2 mmol/L malate and 
10 mmol/L glutamate, and in the presence of 10 mmol/L succinate) and state 3 (in the 
presence of substrates and 0.25 mmol/L ADP).1 To prevent retrograde flux of electrons 
via complex I, complex II-dependent respiration was measured in the presence of 0.5 
μmol/L of the complex I inhibitor rotenone. The respiratory adenylate control index (RCI) 
was calculated by dividing the oxygen flux in state 3 by the flux in state 2. Mitochondrial 
ATP production was determined by incubating mitochondrial protein (1, 10 and 100 ng/
mL) in medium as described by Korsten et al, but without digitonin, in 96-well black mi-
croplates (Optiplate; PerkinElmer).2 Mitochondrial swelling was measured as described 
by Wang et al.3 Pore opening was induced by 2 µmol/L CaCl2 with or without 30 nmol/L 
cyclosporine A. Swelling was measured as a change in light (520 nm) absorption/min 5 
minutes after addition of CaCl2.
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A B
Figure s1. Kidney sections from WKY-rats treated with vehicle (A) and sunitinib (B) stained with Jones 
silverstaining (magnification ×800). The glomerulus of the vehicle-treated rat is nicely unfolded showing 
wide capillary lumina, filled with numerous erythrocytes, normal-sized endothelial cells (white arrowhead) 
and epithelial cells (arrow). After administration of sunitinib, the glomerulus appears more shrinked with 
narrowing of the capillary lumina and swelling of endothelial (arrowhead) and epithelial cells (arrow).
0
500
1000
1500
2000
2500 state 2
state 3
Control Sunitinib Stop
O
2-
flu
x
(p
m
ol
 O
2/
se
c/
m
g 
m
ito
ch
on
dr
ia
l p
ro
te
in
)
0
50
100
150
200
250
Control Sunitinib Stop
state 2
state 3
O
2-
flu
x
(p
m
ol
 O
2/
se
c/
m
g 
m
ito
ch
on
dr
ia
l p
ro
te
in
)
0
250
500
750
1000
1250
1500
1750
Control Sunitinib Stop
complex I-dependent
complex II-dependent
A
T
P
-p
ro
du
ct
io
n
(n
m
ol
/m
g 
m
ito
ch
on
dr
ia
l p
ro
te
in
/3
0m
in
)
Control Sunitinib Stop
0.0
0.2
0.4
0.6
0.8
1.0
1.2
*
Δ 
A
b
s/
m
in
 (x
10
3 )
A. B.
C.
D.
Figure s2. Complex I-dependent (panel A), complex II-dependent (panel B) state 2 and state 3 
mitochondrial respiratory activity (measured as oxygen consumption or O2-flux), ATP production (panel 
C) and swelling (panel D) in mitochondria isolated from cardiomyocytes of rats after administration of 
sunitinib (n=6-13), vehicle (control; n=7) or sunitinib withdrawal (stop; n=7). *P<0.05 compared to control.
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AbsTRACT
Angiogenesis inhibition is an established treatment for several tumor types. Unfortu-
nately, this therapy is associated with side effects, including hypertension and renal 
toxicity, referred to as preeclampsia. Recently, we demonstrated in patients and in rats 
that the multitarget tyrosine kinase inhibitor sunitinib induces a rise in blood pressure 
(BP), renal dysfunction and proteinuria associated with activation of the endothelin sys-
tem. In the current study we investigated the effects of sunitinib on rat renal histology, 
including the resemblance with preeclampsia, and the role of endothelin-1, decreased 
nitric oxide-bioavailability as well as of increased oxidative stress in the development of 
sunitinib-induced hypertension and renal toxicity. In rats on sunitinib, light and electron 
microscopic examination revealed marked glomerular endotheliosis, a characteristic 
histological feature of preeclampsia, which was partly reversible after sunitinib discon-
tinuation. The histological abnormalities were accompanied by an increase in urinary 
excretion of endothelin-1 and diminished nitric oxide-metabolite excretion. In rats on 
sunitinib alone, BP increased (ΔBP 31.6±0.9 mmHg). This rise could largely be prevented 
with the endothelin receptor antagonist macitentan (ΔBP 12.3±1.5 mmHg) and only 
mildly with tempol, a superoxide dismutase mimetic (ΔBP 25.9±2.3 mmHg). Both 
compounds could not prevent the sunitinib-induced rise in serum creatinine or renal 
histological abnormalities and had no effect on urine nitrates, but decreased proteinuria 
and urinary endothelin-1 excretion. Our findings indicate that both the endothelin sys-
tem and oxidative stress play important roles in the development of sunitinib-induced 
proteinuria and that the endothelin system rather than oxidative stress is important for 
the development of sunitinib-induced hypertension.
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InTRoDuCTIon
Angiogenesis, the formation of new capillaries from an existing vasculature, is critical to 
tumor growth as well as to metastasis. Vascular endothelial growth factor (VEGF) and its 
corresponding receptors play key roles in the regulation of this process. Angiogenesis 
inhibition, by targeting VEGF or its receptors, has become an established treatment of 
several tumor types. Common adverse effects of angiogenesis inhibition are hyperten-
sion and renal toxicity.1 Hypertension has been reported in up to 36% of patients treated 
with bevacizumab, a monoclonal antibody against VEGF, and in up to 60% of patients 
treated with sunitinib, an orally active multitarget VEGF receptor tyrosine kinase inhibi-
tor (RTKI) used in the first-line treatment of metastatic renal cell carcinoma or imatinib-
resistent gastrointestinal stromal tumors.1 Renal toxicity, mainly proteinuria, has been 
reported in 41-63% of patients treated with bevacizumab.2 The incidence of proteinuria 
in patients treated with RTKIs is less well known, as in the initial studies patients were 
not routinely screened for this adverse effect.
It has been suggested that inhibition of the VEGF-pathway reduces nitric oxide (NO) bio-
availability leading to a disturbed balance between NO and endothelin-1 (ET-1) and so 
promotes the development of hypertension.1 Indeed, we recently reported that the rise 
in blood pressure (BP), renal dysfunction and proteinuria induced by the RTKI sunitinib 
was associated with a two-to-three-fold rise in circulating ET-1 levels in both patients 
and rats.3 Whether activation of the endothelin system plays a pathophysiological role in 
sunitinib-induced hypertension and renal toxicity remains to be established.
There is abundant evidence that oxidative stress is involved in the development of renal 
injury and that decreased levels of VEGF may contribute to oxidative stress-induced en-
dothelial dysfunction.4-7 In addition, in various hypertensive rat models administration 
of tempol, a superoxide-dismutase mimetic, which metabolizes superoxide and other 
reactive oxygen species (ROS), has been shown to reduce BP.8 Whether increased ROS 
production is involved in sunitinib-induced hypertension and renal toxicity is unknown.
Hypertension and proteinuria during angiogenesis inhibition are also referred to as a 
preeclampsia-like syndrome.9 Preeclampsia is a pregnancy-related disorder character-
ized by proteinuria and hypertension as well as increased circulating ET-1 levels.10 One of 
the underlying pathophysiological mechanisms is thought to be an increased placental 
production of soluble fms-like tyrosine kinase 1 (sFlt-1).11,12 Within the maternal circula-
tion sFlt-1 binds VEGF thereby abrogating the VEGF-VEGF receptor axis activity and thus 
creating a condition similar to that induced by VEGF receptor inhibitors.
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The aim of our current studies was to explore the effects of sunitinib on renal histology, 
including the resemblance with preeclampsia, and the role of ET-1, decreased NO-
bioavailability as well as of ROS in the development of sunitinib-induced hypertension 
and renal side effects.
MeTHoDs
In vivo study
Male Wistar Kyoto rats (WKY, 280-300 gram) obtained from Charles River, were housed 
in individual cages and maintained on a 12-h light/dark cycle, having access to standard 
laboratory rat chow and water ad libitum. Intra-aortic BP recordings were performed 
by radiotelemetry and the sunitinib and vehicle solution prepared and administered by 
oral gavage as described previously.3 Macitentan (ACT-064992), a dual ETA / ETB recep-
tor antagonist kindly provided by Actelion, was dissolved in vehicle containing 0.5% 
methylcellulose aqueous solution and 0.05% Tween80. Tempol (4-Hydroxy-Tempo, 97%; 
Sigma-Aldrich) was dissolved in 0.9% saline. Four separate experiments were performed. 
At the end of each experiment, rats were euthanized with 60 mg/kg pentobarbital i.p. 
and blood was sampled for measurement of plasma ET-1 as well as serum creatinine 
levels, and kidneys were rapidly excised. In the first experiment rats were randomly 
administered sunitinib (26.7 mg/kg/day of sunitinib L-malate; n=10) or vehicle (n=10) by 
oral gavage (0.5 mL) for 8 days. In the second experiment, rats (n=7) were administered 
sunitinib at the same dose for 8 days followed by an 11-day recovery period, after which 
they were sacrificed. In the third experiment, rats (n=8) were orally administered the 
combination of sunitinib and macitentan 30mg/kg/day, for 8 days.13 At the end of this 
treatment period, 4 rats were anesthetized using isoflurane to monitor the BP response 
to bolus injections of ET-1 to test the degree of macitentan-induced ET-1 receptor 
blockade as described in the Data Supplement. In the fourth experiment, rats were 
administered the combination of sunitinib by oral gavage and Tempol 200 nmol/kg/min 
s.c. using osmotic minipumps (Alzet 2ml2) for 8 days (n=6).14 In all experiments, 6 days 
before (baseline) and 6 days after treatment initiation, rats were housed in metabolic 
cages for 48 hours with free access to food and water; the first day to acclimatize and 
the second day to collect 24-hour urine samples for determination of protein, ET-1, nitric 
oxide (NO) metabolites (NO2+NO3 [NOx]) and thiobarbituric acid reactive substances 
(TBARS). Urine was collected on antibiotics (A5955, Sigma) to prevent formation of NO 
metabolites. In the second experiment, rats were also housed in metabolic cages one 
week after treatment discontinuation.
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Male spontaneous hypertensive rats (SHR, 280-300 gram, 8-9 weeks old; MAP 
146±3mmHg; n=2), obtained from Charles River (Germany), were used as hypertensive 
controls to compare renal histology obtained from WKY-rats exposed to sunitinib to that 
of SHR.15 All experiments were performed under the regulation and permission of the 
Animal Care Committee of the Erasmus MC.
In vitro studies and renal histology
Langendorff studies
Langendorff studies were performed as described in the Data Supplement. Dose-
response flow curves to bolus injections of bradykinin (BK) and angiotensin II (Ang II) 
were constructed, after which the maximum coronary flow was determined by injecting 
sodium nitroprusside (SNP; 10 mmol/L).
Light microscopy
Details of the light microscopy in this study are available in the online Data Supplement. 
Briefly, transversely sliced kidney sections were stained for Haematoxylin-eosin (HE), pe-
riodic acid Schiff (PAS) and Jones silver. PAS-stained sections were blindly evaluated by 
a pathologist for the presence or absence of endothelial cell and epithelial cell swelling 
in 50 glomeruli, as well as semi-quantitatively scored for the presence of ischemia and 
intra-epithelial protein.
Electron microscopy
One glomerulus in each biopsy section was examined by electron microscopy and the 
occurrence of glomerular endotheliosis (endothelial cell swelling, encroachment of the 
capillary spaces and loss of endothelial fenestration) and podocyte morphology were 
registered.
Determination of preproET-1 mRNA levels in renal cortex and medulla
Immediately after euthanization of the rats, the kidneys were harvested and renal cortex 
and medulla separated. All tissues were quickly frozen in nitrogen and stored at -80ºC. 
Total RNA was isolated from kidneys using the Trizol reagent (Gibco-BRL) and reverse 
transcribed. The resulting cDNA was amplified in 40 cycles (denaturation at 95° C for 
10 min; thermal cycling at 95°C for 15 sec, annealing/extension at 60°C for 1 min) with 
a Step-One cycler (NYSE, Applied Biosystems) using the SYBR Green Q-PCR core KIT 
(Applied Biosystem). Primer of rat preproET1 (forward AGGGAACAGATGCCAGTGTGCT, 
reverse TGCATGGTACTTTGGGCTCGGA) was from Invitrogen. The comparative cycle time 
method (∆∆CT) was used for relative quantification of gene expression. Messenger RNA 
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expression was normalized versus actin and expressed as the ratio of target to control 
value.16
Biochemical measurements
ET-1 was assessed using a chemiluminescent ELISA (QuantiGlo®, R&D Systems), urine 
albumin by enzyme immunoassay (Spi-Bio, France) and TNF-alpha by colorimetric sand-
wich ELISA (R&D Systems). Urine NOx concentration was determined by fluorimetric 
quantification of nitrite content (Cayman Chemicals, Ann Arbor, MI) and lipid peroxida-
tion in urine by measurement of TBARS.17 Serum creatinine and urinary protein were 
measured at the clinical chemical laboratory of the Erasmus MC.
statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls or 
Dunnett’s multiple comparison testing. For correlation analysis the Pearson r correlation 
coefficient was used. P<0.05 was considered significant. GraphPad Prism version 4.03 
was used for all statistical analysis.
ResulTs
In vivo study
BP dose-response curves to ET-1 bolus injections in macitentan-treated rats, showed 
effective blockade of the ET-1-induced rise compared to control rats (Figure S1, 
Supplement). The sunitinib-induced rise in BP was largely prevented by concomitant 
administration of macitentan and mildly attenuated by tempol (Figure 1A), whereas 
the sunitinib-induced decrease in heart rate (HR) was not affected by either compound 
(Figure 1B). The previously reported sunitinib-induced loss of circadian BP rhythm was 
not reversed by either macitentan or tempol (data not shown).3
Kidney weight-to-body weight (KW/BW)-ratio, proteinuria, albuminuria and urinary ET-1 
excretion increased during sunitinib administration (Table 1), in parallel to the previously 
described increase in BP, serum creatinine and circulating ET-1 levels.3 All parameters, 
with the exception of serum creatinine and urinary ET-1 excretion, returned to baseline 
after discontinuation of sunitinib administration (Table 1). Sunitinib-induced changes in 
urinary ET-1 excretion and BP were not correlated (r = -0.50; p=0.25; N=7), neither were 
changes in urinary ET-1 excretion and proteinuria (r = 0.47; p=0.20; N=7). Circulating 
TNF-α levels were mostly below the lowest detection limit in both the vehicle- and suni-
tinib-administered groups (data not shown). Urine nitrates decreased during sunitinib 
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administration (Figure 2) and partly returned after sunitinib withdrawal. Urine TBARS did 
not change (0.80±0.19 µmol/kg BW/24h at baseline versus 0.87±0.08 µmol/kg BW/24h 
after 8 days of treatment; p=0.69) during treatment with sunitinib. The sunitinib-induced 
decrease in urinary nitrate excretion was not reversed by macitentan or tempol (data 
not shown). Macitentan did not change KW/BW-ratio compared to sunitinib alone (data 
not shown) nor did it change serum creatinine, but it significantly decreased proteinuria 
and urinary ET-1 excretion, whereas circulating ET-1 levels increased (Figure 3A, B, C, D). 
Treatment with tempol did also not change KW/BW-ratio compared to sunitinib alone 
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Figure 1. Changes in MAP (A) and HR (B) in response to administration of vehicle (n=6), sunitinib and 
vehicle (n=12), sunitinib and macitentan (n=8), or sunitinib and tempol (n=6) in rats.
*p<0.05 vs sunitinib + vehicle.
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(data not shown), nor did it change serum creatinine or circulating ET-1 levels, although 
it did decrease proteinuria and urinary ET-1 excretion (Figure 3A, B, C, D).
Table 1. Parameters in rats after 8 days of treatment with sunitinib (N=10) and after treatment 
discontinuation (N=7) compared to baseline values or vehicle-treated rats (N=6).
Parameters Control / 
Baseline
Sunitinib P-value Stop P-value
MAP (mmHg) 94±3 124±1 <0.001 92±8 >0.05
Left KW/BW-ratio (g/kg) 3.0±0.04 3.4±0.05 <0.001 3.3±0.05 0.001
Right KW/BW-ratio (g/kg) 3.0±0.04 3.5±0.04 <0.001 3.3±0.03 <0.001
Serum creatinine (μmol/L) 8.0±2.7 28.8±6.4 0.03 25.1±1.2 <0.001
Plasma endothelin-1 (pg/ml) 0.6±0.1 1.8±0.2 0.003 0.7±0.1 0.40
Urinary endothelin-1 (pg/day) 3.6±0.8 7.3±1.0 0.007 7.6±0.6 0.007
Proteinuria (mg/day) 9.1±1.4 39.2±5.2 <0.001 12.4±0.7 >0.05
Albuminuria (mg/day) 0.2±0.02 13.1±3.1 <0.001 0.6±0.2 >0.05
Mean arterial pressure (MAP), serum creatinine, plasma endothelin-1 and proteinuria are from Kappers et al.3
KW, kidney weight; BW, body weight; NA, not applicable. Data are shown as mean±SEM. P-value 
compared to control/baseline.
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Figure 2. Nitric oxide metabolites (NOx) excretion in urine of WKY rats (n=4) at baseline, after 8 days of 
administration of sunitinib and after sunitinib withdrawal. * p<0.05 vs baseline, † p<0.05 vs sunitinib.
In vitro studies and renal histology
Langendorff studies
In the Langendorff preparation, coronary flow (CF) responses to bradykinin, Ang II or 
SNP were not significantly changed after co-administration of sunitinib and macitentan 
or tempol compared to sunitinib alone (Figure S2A-C, Supplement).
Renal histology
Light microscopic examination showed marked abnormalities including periodic acid 
Schiff (PAS)-positive intra-epithelial protein droplets and epithelial, as well as endothe-
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lial cell swelling in glomeruli from rats exposed to sunitinib compared to control rats 
(Figure 4). In addition, these glomeruli were more shrunken with narrowed capillary 
lumina containing less erythrocytes (ischemia) compared to those of control rats (Figure 
4). The semi-quantative scores of the renal abnormalities are provided in Table 2. The 
percentage of glomeruli in renal biopsy sections with a score 2 for intra-epithelial protein 
was not correlated with the change in proteinuria (r = 0.51; p=0.38; N=5), the change 
in protein/creatinine-ratio (r = 0.45; p=0.19; N=10) or circulating ET-1 levels at the end 
of treatment (r = 0.14; p=0.71; N=10). In SHR, used as hypertensive controls, none of 
the mentioned renal changes were present (Figure 4). All renal abnormalities observed 
on light microscopic examination completely reversed after sunitinib withdrawal. Re-
markably, on light microscopic examination all evaluated sections showed subcortical 
dilatation of proximal tubules with swelling and vacuolization of epithelial cells and also 
some collapse of subcapsular glomeruli, suggestive of agonal ischemic changes. These 
changes can probably be attributed to short-term ischemia which develops between 
sacrificing the rats and processing the kidneys.
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Figure 3. Serum creatinine (A), change in proteinuria (B), circulating ET-1 levels (C) and change in urinary 
ET-1 excretion (D) in rats after administration of vehicle (n=6), sunitinib and vehicle (n=16), sunitinib and 
macitentan (n=4-6), or sunitinib and tempol (n=4-6) for 8 days.
*p<0.05 vs sunitinib + vehicle; †p<0.05 vs vehicle.
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Figure 4. Kidney sections from WKY rats administered vehicle (A, D, G) or sunitinib (B, E, H) compared to 
SHR rats (C, F, I), stained with HE-, PAS- and Jones silver stain (magnification ×800). After administration 
of sunitinib for 8 days marked glomerular changes could be observed, including intra-epithelial protein 
droplets (arrowhead), epithelial cell swelling (arrow), endothelial cell swelling (open arrow) with 
narrowing of the capillary lumina. None of these abnormalities were observed in kidney sections of 9 
weeks-old SHR rats.
Table 2. Light microscopic evaluation of kidney sections obtained from rats exposed to sunitinib, 
sunitinib and macitentan or sunitinib and tempol for 8 days (N=10) compared to controls (N=6).
Group Glomerular ischemia
(% glomeruli)
Endothelial 
cell swelling
(% glomeruli)
Epithelial cell 
swelling
(% glomeruli)
Intra-epithelial protein
(% glomeruli)
Score None Moderate Severe 0 1 0 1 0 1 2
Control 60±13 32±10 8±4 100 0 100 0 99±1 1±1 0
Sunitinib 17±2* 54±4* 29±5* 78±3* 22±3* 63±5* 37±5* 29±4* 48±2* 23±4*
Sunitinib + 
Macitentan
15±6* 35±2† 51±4*† 85±3* 15±3* 77±6* 23±6* 33±8* 59±7* 8±3*†
Sunitinib + Tempol 16±2* 41±4 44±3* 84±4* 16±4* 56±5* 44±5* 30±11* 50±10* 20±14*
All evaluations were performed in 50 glomeruli of a PAS-stained section and the numbers of glomeruli 
with each score were counted. Endothelial and epithelial cell swelling were scored as present (1) or absent 
(0) in each glomerulus. The presence of intra-epithelial protein was evaluated using a semiquantative 
scale: 0 (no protein in the epithelial cells of a glomerulus), 1 (protein present in 1-50% of the epithelial 
cells of a glomerulus), 2 (protein present in >50% of the epithelial cells of a glomerulus). * p<0.05 vs 
control; † p<0.05 vs sunitinib.
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G. Figure 5. Transmission electron micrographs of 
representative kidney sections from rats administered 
vehicle (A, magnification ×3500; B, magnification 
×14.000) or sunitinib (C, magnification ×3500; 
D, magnification ×11.000) and after sunitinib 
discontinuation (E, magnification ×14.000), compared 
to SHR rats (F, magnification ×3500; G, magnification 
×11.000). After sunitinib administration for 8 days 
intra-epithelial resorption droplets (C, arrows), 
glomerular endotheliosis (D), i.e. endothelial cell 
swelling (D, black arrows), loss of endothelial 
fenestration (black arrows) and obliteration of capillary lumen (D, asterix), effacement (D, black 
arrowhead) and fusion of podocyte foot processes (D, white arrowhead) and narrowing of the slit 
pores (D, white arrows) could be observed. These changes were only partly reversible after sunitinib 
discontinuation with persistent fusion of podocyte foot processes (E, asterix), persistent narrowing of 
slit pores (E, arrows) and only local reappearance of endothelial fenestrations. None of the abnormalities 
mentioned above could be observed in kidney sections from 8-9 weeks-old SHR rats (F, G).
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Electron microscopic examination revealed intra-epithelial resorption droplets, glomer-
ular endotheliosis (endothelial cell swelling with encroachment of the capillary spaces 
and loss of endothelial fenestration), effacement and fusion of podocyte foot processes, 
as well as narrowing of the slit pores in renal sections from rats exposed to sunitinib, 
whereas none of these changes could be demonstrated in sections of control rats or 
of SHR (Figure 5). The basement membrane was normal in sunitinib-administered rats. 
Changes were only partly and locally reversible after sunitinib discontinuation (Figure 5).
In macitentan-administered rats, moderate ischemia was less observed compared to the 
rats administered sunitinib alone (Table 2). In addition, macitentan tended to decrease 
intra-epithelial protein deposits whereas no significant effects on endothelial and 
epithelial cell swelling were observed (Table 2). Tempol had no effect on either of the 
mentioned sunitinib-induced renal abnormalities (Table 2).
PreproET-1 mRNA levels in renal cortex and medulla
PreproET-1 mRNA levels in renal cortex (0.5±1.0 versus 1.3±0.4 fold change; N=6 and 
N=10; p=0.06) and medulla (1.04±0.09 versus 1.01±0.08 fold change; N=4 and N=10; 
p=0.88) were not different between sunitinib-administered and control rats.
DIsCussIon
Recently we have reported in both patients and rats that the multitarget VEGF-receptor 
tyrosine kinase inhibitor sunitinib induces a rise in BP, loss of circadian BP rhythm, renal 
dysfunction and proteinuria that is associated with a two-to-three-fold rise in circulat-
ing ET-1 levels.3 Our current study shows that sunitinib administration is also associated 
with marked renal histopathological changes, especially glomerular endotheliosis. This 
renal toxicity was accompanied by increased urinary excretion of ET-1. Importantly, 
renal histopathology and urinary ET-excretion were not or only partly reversible after 11 
days of sunitinib-withdrawal, although BP had already returned to baseline at that time.3
Since sunitinib-induced hypertension and renal toxicity are associated with activation of 
the endothelin system we evaluated whether these adverse effects could be prevented 
by the dual ETA- and ETB-receptor antagonist macitentan. Compared to sunitinib alone, 
co-administration of macitentan diminished renal injury as reflected by a decrease in 
proteinuria, urinary ET-1 excretion and severe glomerular intra-epithelial protein depo-
sition, but the sunitinib-induced rise in serum creatinine was not prevented. Initially, co-
administration of macitentan completely blocked the sunitinib-induced rise in BP, but 
after 4 days a secondary rise in BP was observed, although less pronounced than with 
Cardiovascular and renal toxicity 85
sunitinib alone. Since the BP response to ET-1 bolus injections was abolished with the 
dose of macitentan applied, this secondary rise in BP cannot be explained by ineffective 
ET-receptor blockade, indicating that apart from activation of the endothelin system 
other factors are likely to be involved in the sunitinib-induced hypertension. Of note, 
in contrast to the current findings, hypertension induced by the multitarget tyrosine 
kinase inhibitor ABT-869 could completely be prevented by the selective ETA-receptor 
blocker atrasentan.18 Whether selective ETA-receptor blockade could also prevent renal 
toxicity has not been evaluated in that study.
Although, ETB-receptor-dependent systemic vasodilation has been observed in healthy 
volunteers, this effect is lost in pathological conditions such as atherosclerosis and type 
II diabetes, possibly due to upregulation of contractile smooth muscle cell ETB recep-
tors.13,19,20,21 Thus, in pathological conditions dual ETA/ETB receptor blockade may be more 
favorable than selective ETA receptor blockade. However, chronic kidney disease (CKD) 
might be an exception because in this condition ETB receptor-mediated vasoconstriction 
has been reported to be less important than ETB receptor-mediated vasodilation. 
22 If in 
CKD renal histopathological changes are mainly ETA-receptor-mediated, selective ETA 
receptor blockade might be preferred.23 Indeed, in young hypertensive Ren-2 transgenic 
rats on a high salt diet immediately after weaning, chronic administration of the selec-
tive ETA receptor blocker atrasentan diminished proteinuria and renal injury to a greater 
extent than the dual ET receptor antagonist bosentan.24 However, in adult hypertensive 
Ren-2 transgenic rats on a high salt diet, no differences regarding proteinuria and renal 
histology between both compounds were found.25 Furthermore, the dual ETA/ETB recep-
tor blocker macitentan that was used in the present study reduced renal injury in the 
streptozotocin-induced diabetic rat.13 Taken together, these findings provide strong 
evidence that dual ETA/ETB receptor blockade, like selective ETA antagonism, exerts renal 
protective effects in various models of renal injury.
Co-administration of sunitinib and macitentan did not lower serum creatinine and 
had only modest effects on renal histology, but did reduce urinary ET-1 excretion and 
proteinuria. How to explain this discrepancy? Since urinary ET-1 excretion is kidney-
derived and reflects renal injury when increased, a decrease in this parameter indicates 
improvement of renal injury.26 Apparently, this decrease in urinary ET-1 excretion is 
not necessarily accompanied by reversal of the renal histological abnormalities or nor-
malization of serum creatinine concentration, suggesting that increased urinary ET-1 
excretion is a very sensitive marker of renal injury. ET-1 is known to increase glomerular 
permeability to albumin. This effect is BP-independent and is mediated by a direct effect 
on the cytoskeleton of podocytes.27,28 Thus, the observed decrease in proteinuria with 
macitentan might be a direct consequence of renal ET receptor blockade. In addition, BP 
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decreased by 60% during administration of macitentan. This decrease in BP might have 
contributed to the decrease in proteinuria by lowering glomerular filtration pressure.
Oxidative stress is a common pathway for the development of renal injury and has 
been shown to be involved in the development of hypertension in several animal 
models.4,5 Therefore we explored whether the superoxide-dismutase mimetic tempol 
had a beneficial effect on sunitinib-induced renal toxicity and hypertension. Although 
co-administration of tempol had only a small effect on the development of hyperten-
sion induced by sunitinib and no effect on renal histological abnormalities, proteinuria 
and urinary ET-1 excretion were markedly reduced, thus indicating that oxidative stress 
is more important for sunitinib-induced renal functional toxicity than for sunitinib-
induced hypertension. Urinary excretion of TBARS did not increase in response to 
sunitinib administration suggesting that this is a measure of global rather than of renal 
oxidative stress.
Urinary excretion of nitrates as a measure of NO-availability decreased during sunitinib 
administration. This is in agreement with observations that NO-synthesis is activated 
by VEGF through Akt-dependent phosphorylation of endothelial NO synthase (NOS).29 
Moreover, administration of a specific antibody against the VEGF2-receptor was associ-
ated with a reduced expression of endothelial and neuronal NOS in the mouse kidney.30 
Using the Langendorff coronary perfusion model we reported impaired coronary flow 
responses to the endothelium-dependent vasodilator bradykinin in the hearts obtained 
from rats exposed to sunitinib.3 However, in this model responses to the endothelium-
independent vasodilator sodium nitroprusside and the vasoconstrictor angiotensin II 
were also impaired, indicating generalized microvascular dysfunction rather than selec-
tive endothelial dysfunction in response to sunitinib administration.3 Co-administration 
of macitentan or tempol did not normalize the impaired microvascular function induced 
by sunitinib, although the vasodilator response to SNP tended to improve.
 Because the hypertension, proteinuria, renal function impairment and activated endo-
thelin system induced by sunitinib closely resemble the features of preeclampsia, we 
explored whether there is also resemblance with regard to renal histopathology in this 
disease.10 Indeed, kidneys of sunitinib-exposed rats showed pronounced glomerular 
endotheliosis, a characteristic renal abnormality in preeclamptic women (Figure S3, 
Supplement).31 Sunitinib-associated toxicity not only resembles preeclampsia with 
regard to the mentioned clinical and histopathological features, but also with regard 
to the underlying pathophysiology. Preeclampsia is associated with increased placental 
production of sFlt-1, a soluble VEGF-binding receptor with anti-angiogenic proper-
ties.11,12 Furthermore, injection of recombinant adenovirus encoding the murine sFlt-1 
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gene product in pregnant rats induced a rise in BP and proteinuria, as well as glomerular 
endotheliosis, intra-epithelial protein resorption droplets and foot-process effacement, 
all changes fully identical to the abnormalities found in our rats.12 Increased oxidative 
stress is also likely to play a role in the development of preeclampsia as demonstrated by 
decreased symptoms of preeclampsia in sFlt-1-injected rats administered tempol during 
pregnancy.6
Recently, Murphy et al showed that infusion of sFlt-1 in healthy-pregnant rats was ac-
companied by a 3-fold increased expression of preproET-1 mRNA in the renal cortex, 
whereas the expression in the aorta and placenta was not increased.32 In contrast to 
these findings, no increased expression of preproET1 mRNA levels in renal cortex or 
medulla was found in our rat model, although we did observe an increase in circulating 
ET-1 levels and urinary ET-1 excretion. This rise may therefore be due to other mecha-
nisms, e.g. an increase in endothelin-converting enzyme activity and/or a reduction in 
ETB receptor number. Blockade of the latter (clearance) receptor by macitentan explains 
why the circulating ET-1 levels increased even further during co-administration of suni-
tinib and macitentan. Yet, urinary ET-1 excretion decreased during co-administration of 
macitentan. Given clinical observations that urinary ET-1 excretion is a marker for renal 
injury (vide supra), this most likely reflects the beneficial renal effects of macitentan.26 
A dissociation between circulating and renal ET systems has also been described in pa-
tients with systemic inflammatory disease and active renal involvement.33 Furthermore, 
our findings showing normalization of circulating ET-1 levels after sunitinib-withdrawal, 
whereas the increased urinary ET-1 excretion as well as renal functional and histological 
abnormalities did not (completely) normalize, are also in agreement with the concept of 
separate mechanisms regulating systemic and renal ET-1 levels.
Since sunitinib administration is associated with a marked rise in BP, the sunitinib-
induced renal toxicity might be secondary to the BP-rise. Nonetheless, the rise in BP and 
renal toxicity associated with sunitinib are more likely to be independent side effects. 
Firstly, the rise in blood pressure occurred as soon as after 1 day of administration of 
sunitinib. Secondly, despite BP normalization after sunitinib withdrawal renal histologi-
cal abnormalities were still present. Thirdly, it has been demonstrated that conditional 
gene targeting to delete selectively VEGF from renal podocytes in adult mice results in 
profound glomerular injury that precedes the development of hypertension.34 VEGF is 
produced by glomerular podocytes and is necessary for maintaining a healthy fenes-
trated glomerular endothelium by interacting with endothelial cell VEFGRs. Fourthly, 
the independency of the sunitinib-induced hypertension and renal toxicity is also 
supported by our observations in 8-9 week-old SHR rats. Although these rats were hy-
pertensive since birth with BPs as high as 146±3mmHg, glomerular injury was absent.15 
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Lastly, as previously mentioned, ET-1 has been reported to increase glomerular perme-
ability independent of BP.27
PeRsPeCTIVes
Angiogenesis inhibition with sunitinib induces hypertension and marked renal abnor-
malities associated with activation of the endothelin system that are partly reversible 
after sunitinib- withdrawal. Endothelin receptor antagonism with macitentan can to a 
large extent prevent the sunitinib-induced rise in BP, whereas tempol only mildly reduc-
es this rise in BP. However, both compounds reduce sunitinib-induced proteinuria and 
urinary ET-1 excretion, with little effect on sunitinib-induced renal histological changes. 
Therefore, oxidative stress appears to be mainly important for the development of 
sunitinib-induced proteinuria and urinary ET-1 excretion, whereas the ET-1 system plays 
a role in the sunitinib-induced hypertension as well as urinary excretion of protein and 
ET-1. Considering these findings and taking into account that ET-1 has also been shown 
to promote angiogenesis in cancer, ET-1 receptor antagonists seem logical candidates 
for treatment of sunitinib-induced cardiovascular and renal adverse effects and may 
even provide complementary therapeutic anti-angiogenic effects.35,36 However, further 
studies in patients are warranted. Our current findings and the previously reported 
cases of severe renal injury in patients treated with an angiogenesis inhibitor, support 
our recommendation to closely monitor renal function and blood pressure in patients 
subjected to angiogenesis inhibition.34
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suPPleMenT
expanded methods
ET-1 challenge study
After 8 days of administration of sunitinib and macitentan, in 4 rats the carotid artery 
and jugular vein were canulated (canule 0.58x0.99, SciComInc) under isoflurane anes-
thesia. Blood pressure was measured (ADinstruments, Powerlab, Labchart) in response 
to increasing intravenous bolus injections (100, 300, 600, 800 and 1000 pmol/kg) of 
endothelin-1 (ET-1) and compared to the responses in control rats (n=3). At the end of 
the experiment, rats were sacrificed.
In vitro studies and renal histology
Langendorff studies
Hearts were rapidly excised from euthanized rats and perfused according to Langen-
dorff.1 Coronary flow (CF) was measured with a flow probe (Transonic systems). After 
a stabilization period of 30 minutes, baseline values of CF were obtained. Next, bolus 
injections (100 μL) of Tyrode’s buffer were applied three times to determine injection-
induced changes in CF. Dose-response curves to bradykinin and Ang II were constructed 
by bolus injections, after which the maximum CF was determined by injecting sodium 
nitroprusside (SNP; 10 mmol/L).
Light microscopy
The left kidney was rapidly excised from euthanized rats, decapsulated, weighed and 
sliced transversely. One slice was fixed in a 3.5-4% formaldehyde solution for light 
microscopic and another slice was fixed in 2% glutaraldehyde for electron microscopic 
evaluation. After fixation in the formaldehyde solution, tissue was dehydrated and 
paraffin-embedded. Deparaffinized 2-μm thick sections were stained for Haematoxilin-
eosine (HE), PAS and Jones silver. Sections were blindly evaluated by a pathologist for 
the presence (score 1) or absence (score 0) of endothelial cell and epithelial cell swelling 
in 50 glomeruli. Glomerular ischemia was scored semiquantitatively and defined as the 
degree of open glomerular capillaries, wrinkling of the glomerular basement membrane 
and filling of Bowmans space. Wide open glomerular capillaries filling Bowman’s space 
entirely corresponded with no ischemia. Partially open glomerular capillaries with 
mild wrinkling of the glomerular basement membrane and Bowman’s glomerular 
space largely filled was classed as moderate ischemia. Totally collapsed glomeruli and 
extensive wrinkling of the glomerular basement membrane and only partial filling of 
Bowman’s space corresponded with severe ischemia. Furthermore, the presence of 
intra-epithelial protein was evaluated using a semiquantative scale: 0 (no protein in the 
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glomerular epithelium), 1 (protein present in 1-50% of the epithelial cells of a glomeru-
lus), 2 (protein present in >50% of the epithelial cells of a glomerulus). Fifty glomeruli 
per kidney section (PAS staining) were evaluated.
ReFeRenCes
 1. van Esch JHM, Oosterveer CR, Batenburg WW, van Veghel R, Danser AHJ. Effects of angiotensin II 
and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the 
angiotensin AT(2) receptor? Eur J Pharmacol. 2008; 588: 286-293.
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Figure s1. Change of mean arterial pressure (MAP; A) and heart rate (HR; B) compared to baseline in 
response to bolus injections of endothelin-1 (ET-1) in rats administered sunitinib and macitentan (n=4) for 
8 days and in control rats administered vehicle (n=3).
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Figure s2. Coronary flow responses to bradykinin (BK; A), ang II (B) and a single injection to sodium 
nitroprusside (SNP; 10 mmol/L); C) in isolated rat hearts after administration of vehicle (n=9), sunitinib and 
vehicle (n=10), sunitinib and macitentan (n=4), and sunitinib and tempol (n=6) for 8 days. The x-axis in A 
and B displays the concentration in the injection fluid. T indicates Tyrode’s buffer. *P<0.05 vs sunitinib + 
vehicle; †P<0.05 vs vehicle.
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Figure s3. A. Electron micrograph of a normal glomerulus in a healthy pregnant women (magnification 
×4000). Note the open capillary lumen, endothelial fenestrations (white arrowheads) and normal 
podocytes (white asterix) with open slit pores (white arrow). B, C. Electron micrographic overviews of 
glomeruli in patients with preeclampsia (magnifications ×2500 and ×5000 respectively). Note the narrow 
or completely occluded capillary lumen (white asterix) due to extreme swelling of endothelial cells. The 
glomerular basement membrane is only slightly irregular but mostly within normal limits. The cytoplasm 
of the endothelial cells shows some degenerative vacuolization (white arrow). The epithelial cells are 
swollen and show intra-cytoplasmatic resorption droplets (black asterix). Furthermore, there is extensive 
fusion of the podocyte foot processes with narrowing of the slit pores (white arrowheads).
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AbsTRACT
Angiogenesis inhibition with agents targeting tyrosine kinases of vascular endothelial 
growth factor receptors (VEGFR) is an established anticancer treatment, but is, unfortu-
nately, frequently accompanied by systemic hypertension and cardiac toxicity. Whether 
VEGFR-antagonism also has adverse effects on the pulmonary and coronary circulations 
is presently unknown. In chronically instrumented awake swine, the effects of the 
VEGFR-antagonist sunitinib on the systemic, pulmonary and coronary circulation were 
studied. One week after sunitinib (50 mg p.o. daily) mean aortic blood pressure (MABP) 
had increased from 83±5 at baseline to 97±6 mmHg (P<0.05) due to a 57±20% increase 
in systemic vascular resistance as cardiac output decreased. In contrast, sunitinib had no 
discernible effects on pulmonary and coronary hemodynamics or cardiac function. We 
subsequently investigated the mechanisms underlying the sunitinib-induced systemic 
hypertension. Intravenous administration of NO-synthase inhibitor Nω-nitro-L-arginine 
increased MABP by 24±1 mmHg under baseline conditions, while it increased MABP 
even further following sunitinib administration (32±3 mmHg,P<0.05). Reactive oxygen 
species scavenging with a cocktail of antioxidants lowered MABP by 13±2 mmHg before, 
but only by 5±2 mmHg (P<0.05) after sunitinib administration. However, intravenous 
administration of the dual ETA/ETB receptor blocker tezosentan, which did not lower 
MABP at baseline, completely reversed MABP to pre-sunitinib values. These findings 
indicate that sunitinib produces vasoconstriction selectively in the systemic vascular 
bed, without affecting pulmonary or coronary circulations. The sunitinib-mediated 
systemic hypertension is principally due to an increased vasoconstrictor influence of 
endothelin-1, with no apparent contributions of a loss of NO-bioavailability or increased 
oxidative stress.
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InTRoDuCTIon
Angiogenesis inhibition, by targeting the tyrosine kinases of the vascular endothe-
lial growth factor (VEGF) receptors (VEGFRs), has become an established treatment 
of several tumor types. This therapy is associated with adverse effects including the 
development of hypertension and cardiac and renal toxicity.1 Hypertension has been 
reported in up to 60% of patients treated with sunitinib, an orally active multitarget 
receptor tyrosine kinase inhibitor (RTKI), targeting amongst others the VEGFR-1 and -2, 
that is used as first-line treatment of metastatic renal cell carcinoma or imatinib-resistant 
gastrointestinal stromal tumors.1 In addition, impaired cardiac function, as reflected by 
a decrease in left ventricular ejection fraction (LVEF) of 10-15%, has been observed in 
up to 28% of patients treated with sunitinib.2 Angina pectoris and increased levels of 
biomarkers reflecting ischemic myocardial damage may also occur during sunitinib 
treatment.3 Thus far, clinical and experimental studies on the cardiovascular side effects 
of angiogenesis inhibition only focused on the systemic vasculature. Whether adverse 
effects of angiogenesis inhibition with sunitinib also occur in the pulmonary and/or 
coronary circulation is unknown. It should be mentioned that pulmonary arterial hyper-
tension has recently been reported during treatment with dasatinib, a RTKI used for the 
treatment of chronic myeloid leukemia.4
VEGF, through activation of VEGFR-2, stimulates endothelial NO synthase (eNOS) result-
ing in enhanced NO production and vasodilation.5,6 It has therefore been suggested 
that NO bioavailability is reduced during inhibition of the VEGF-pathway, resulting in 
vasoconstriction and the development of hypertension. Indeed, in mice administration 
of an anti-VEGFR-2 antibody, attacking the same receptor as RTKIs, caused a rapid in-
crease in mean aortic blood pressure (MABP) and a marked reduction in the expression 
of endothelial and neuronal NOS in the kidney.7 Furthermore, prior administration of 
the eNOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) in mice abolished the 
difference in MABP between vehicle and anti-VEGFR-2 treated groups, suggesting that 
decreased NO-bioavailability in response to anti-angiogenic agents is one of the mecha-
nisms causing hypertension.7 However, clinical studies, using flow-mediated dilatation 
(FMD) as an index of NO-bioavailability, do not unequivocally support the hypothesis 
that a decrease in NO-bioavailability underlies the increase in BP, as decreases in both 
endothelium-dependent and endothelium-independent vasodilatation have been 
reported in patients treated with RTKIs.8,9 In previous clinical and experimental studies 
we and others have shown that activation of the endothelin system is involved in the 
sunitinib induced rise in MABP.10-12 Apart from inducing vasoconstriction, ET-1 activates 
vascular NADPH-oxidase, leading to an increase in oxidative stress through enhanced re-
active oxygen species (ROS) production.13,14 Since oxidative stress is generally increased 
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in hypertension and plays a pathogenic role in the development and progression of 
cardiovascular disease, we hypothesized that enhanced formation of ROS, contributes 
to the sunitinib-induced cardiovascular side effects.15
To further explore the cardiovascular side effects of sunitinib we performed detailed 
studies in chronically instrumented awake swine. Firstly, we studied the effects of 
angiogenesis inhibition on the systemic, pulmonary and coronary circulations, as well 
as on cardiac performance under resting conditions and during exercise. Secondly, we 
explored to what extent alterations in NO-mediated vasodilator tone, ET-1-mediated 
vasoconstriction and oxidative stress contribute to the cardiovascular side effects of 
angiogenesis inhibition.
MeTHoDs
Animals
Studies were performed in accordance with the American Physiological Society’s “Guid-
ing Principles in the Care and Use of Laboratory Animals” and with approval of the Animal 
Care Committee of Erasmus MC. Six crossbred Yorkshire x Landrace swine of either sex (2 
to 3 months old; 21 ± 1 kg at the time of surgery) were entered into the study.
surgical Procedures
Swine were sedated (20 mg/kg ketamine i.m. + 1 mg/kg midazolam i.m.), anesthetized 
(thiopental sodium 15 mg/kg iv), intubated and ventilated with a mixture of O2 and N2 
(1:2).16 Anesthesia was maintained with midazolam (2 mg/kg + 1 mg kg-1 h-1 i.v.) and 
fentanyl (10 μg kg-1h-1, i.v.). Subsequently, animals were instrumented under sterile 
conditions as previously described.17,18 Briefly, a thoracotomy was performed through 
the left fourth intercostal space. Subsequently, a polyvinylchloride catheter was inserted 
into the aortic arch, for the measurement of aortic pressure and blood sampling for the 
determination of PO2, PCO2, pH, O2 saturation and hemoglobin concentration (ABL800, 
Radiometer). A high fidelity Konigsberg pressure transducer was inserted into the left 
ventricle (LV) via the apex for measurement of LV pressure and maximum rate of rise 
and fall of LV pressure (LVdP/dtmax, LVdP/dtmin) as indices for contractility and relaxation. 
Fluid-filled catheters were implanted for measurement of blood pressures in the LV, left 
atrium (LA) and pulmonary artery (PA). Flow probes were placed around the proximal left 
anterior descending coronary artery (LAD, 2.5-3 mm, Transonic Systems) for measure-
ment of coronary blood flow (CBF) and around the aorta (16 mm, Transonic Systemic) for 
measurement of cardiac output and stroke volume (SV).17,18 Electrical wires and catheters 
were tunneled subcutaneously to the back. The chest was closed and the animals were 
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allowed to recover. Animals received analgesia (0.3 mg buprenorphine i.m.) for 2 days 
and antibiotic prophylaxis (25 mg/kg amoxicillin and 5 mg/kg gentamycin i.v.) for 5 days.
experimental protocols
Sunitinib
Studies were performed 1-4 weeks after surgery with swine resting and/or exercising on 
a motor-driven treadmill. Excellent reproducibility of exercise trials has been reported 
previously.17,18 After obtaining hemodynamic measurements with swine lying quietly on 
a treadmill, a five-stage (1-5 km/h) treadmill exercise protocol was started with each 
exercise stage lasting 2-3 min. Hemodynamic variables were continuously recorded 
and both arterial and mixed venous blood samples were collected during the last 60 
seconds of each exercise stage for the determination of body oxygen consumption.18 
Sunitinib L-malate was given in a daily oral dose of 50 mg, i.e. the same dose as used in 
patients. Sunitinib was mixed with food and administered early in the morning. Rest-
ing hemodynamics were measured 4 hours after the first dose of sunitinib and after 
1 week of daily sunitinib administration. After 1 week of sunitinib administration the 
exercise protocol was repeated to assess the effects of sunitinib on exercise-induced 
hemodynamic responses.
Acute pharmacological interventions
After measuring systemic, pulmonary and coronary hemodynamics at rest, acute intra-
venous doses of an endothelial NO-synthase (NOS) inhibitor, a dual ETA and ETB receptor 
(ETA/B) antagonist or a ROS scavenger cocktail were given on separate days in random 
order and cardiovascular effects were assessed. Subsequently, swine were exposed to 
sunitinib for 7-10 days and the pharmacological interventions were repeated, in random 
order on separate days, to assess the roles of NO, ET-1 and ROS in sunitinib-induced 
cardiovascular effects.
Pharmacological agents
The eNOS inhibitor Nω-nitro-L-arginine (LNNA [Sigma]) was given as a single intravenous 
dose of 20 mg/kg.19 The dual ETA and ETB receptor (ETA/ETB) antagonist tezosentan (a 
kind gift from Dr Clozel, Actelion Pharmaceuticals Ltd.) was intravenously administered 
over 10 min in a dose of 3 mg/kg, followed by a continuous infusion of 6 mg·kg-1·h-1 
iv.20 For ROS scavenging, the superoxide dismutase (SOD)-mimetic 4-Hydroxy-2,2,6,6-
tetramethylpiperidine-N-oxyl (TEMPOL; 30 mg/kg iv), in combination with N-Acetyl-
cysteine (NAC, 150 mg/kg iv), and N-Mercaptoproprionylglycine (MPG, 1 mg/kg/min iv) 
were infused in 10 minutes prior to the measurements.21-24
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Data acquisition and analysis
Digital recording and off-line analysis of hemodynamic data and computation of body 
O2 consumption (BVO2) have been described in detail elsewhere.
18 To correct for growth 
of swine, cardiac index (CI) and stroke volume index (SVi) were calculated as cardiac 
output and stroke volume, respectively, divided by body weight. Systemic vascular resis-
tance index (SVRi) was computed as MABP divided by CI. Pulmonary vascular resistance 
index (PVRi) was computed as mean pulmonary artery pressure (MPAP) minus mean 
left atrial pressure (MLAP) divided by CI. Finally, coronary vascular resistance (CVR) was 
calculated as MABP divided by CBF. Statistical analysis was performed using regression 
analysis with each animal as a dummy variable and with BVO2, heart rate, as well as 
sunitinib as independent variables. Statistical significance was accepted at P≤0.05. Data 
are presented as mean ± SEM.
ResulTs
effect of sunitinib on hemodynamic parameters at rest
Oral administration of the first dose of sunitinib resulted in an increase in MABP within 
4 hours in 5 out of 6 animals (Table 1). The increase in MABP was associated with an 
Table 1. Resting hemodynamic responses prior to and 4 hours and 7 days after sunitinib administration.
Parameters Baseline 4h Sunitinib 1wk Sunitinib
HR (beats/min) 112 ± 6 111 ± 10 105 ± 7*
MABP (mmHg) 83 ± 5 93 ± 5* 97 ± 6*
CI (ml min-1 kg-1) 155 ± 11 162 ± 17 132 ± 12*
SVRi (mmHg L-1 min kg) 547 ± 45 607 ± 69 780 ± 108*
LVSP (mmHg) 110 ± 6 115 ± 8 116 ± 10
SVi (ml kg-1) 1.38 ± 0.06 1.46 ± 0.06* 1.26 ± 0.10
LV dP/dtmax (mmHg s
-1) 2800 ± 460 2870 ± 260 2620 ± 250
LV dP/dtmin (mmHg s
-1) -2220 ± 160 -2280 ± 130 -2320 ± 190
MPAP (mmHg) 15 ± 2 17 ± 2 14 ± 2
MLAP (mmHg) 5 ± 2 7 ± 2 4 ± 1
PVRi (mmHg L-1 min kg) 64 ± 12 59 ± 5 68 ± 6
CBF (ml/min) 48 ± 2 44 ± 2 47 ± 3
CVR (mmHg ml-1 min) 1.64 ± 0.14 1.90 ± 0.23 2.00 ± 0.17*
Values are mean ± SE. CBF, coronary bloodflow; CI, cardiac index; CVR, coronary vascular resistance; HR, 
heart rate; LV dP/dt, left ventricular rate of rise in pressure; LVSP, left ventricular systolic pressure; MABP, 
mean aortic blood pressure; MLAP, mean left atrial pressure; MPAP, mean pulmonary artery pressure; PVRi, 
pulmonary vascular resistance index; SVi, stroke volume index; SVRi, systemic vascular resistance index.
*P <0.05 vs baseline.
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increase in LVSP, but LVdP/dtmax, LVdP/dtmin and SVi did not change (Table 1). Also, no 
change in CBF occurred, while CVR slightly increased, likely reflecting an autoregulatory 
increase in coronary vasomotor tone in response to the increase in MABP. The first dose 
of sunitinib had no effect on either PAP or PVRi (Table 1).
Seven days of daily sunitinib administration resulted in sustained systemic vasoconstric-
tion as evidenced by an increase in SVRi and MABP in all animals (Table 1). The increase 
in MABP was accompanied by a decrease in heart rate and CI and an increase in LVSP, 
while LVdP/dtmax, LVdP/dtmin and SVi were unchanged. The first dose or repeated doses of 
sunitinib had no effect on the coronary or the pulmonary vasculature, as CBF, CVR, MPAP 
and PVRi were similar to values before sunitinib administration (Table 1).
effect of sunitinib on hemodynamic parameters during exercise
Sunitinib did not influence the exercise-induced increase in heart rate or CI, while the 
sunitinib-induced increase in MABP and SVRi decreased with increasing exercise inten-
sity (Figure 1), indicating that the vasoconstrictor effect of sunitinib diminished with 
increasing exercise intensity. Sunitinib also had no effect on MPAP, PVRi or CBF during 
exercise, while the sunitinib-induced increase in CVR decreased with exercise-intensity 
(Figure 1), reflecting the waning effect of sunitinib on MABP during exercise.
effect of sunitinib on hemodynamic parameters during no, eT and Ros inhibition
Administration of LNNA resulted in systemic vasoconstriction as evidenced by an in-
crease in SVRi that resulted in increases in MABP and LVSP (Figure 2). The increase in 
MABP was associated with a, likely baroreflex-mediated decrease in heart rate and CI 
(Table 2). The effect of LNNA on systemic hemodynamics was slightly more pronounced 
after 1 week of sunitinib treatment (Figure 2). Under baseline conditions, LNNA also 
increased PVRi, reflecting pulmonary vasoconstriction, while the effect of LNNA on PVRi 
after sunitinib treatment failed to reach statistical significance (P=0.13, Figure 2). LNNA 
had no effect on CBF, but CVR increased. Sunitinib did not affect the LNNA-induced 
increase in CVR (Figure 2).
Prior to sunitinib, ETA/B receptor blockade with tezosentan had no effect on MABP or 
SVRi (Figure 2). In contrast, in the presence of sunitinib, MABP and SVRi decreased in 
response to tezosentan administration (Figure 2). The tezosentan-induced decrease 
in SVRi was identical to the increase in SVRi induced by sunitinib. In the absence of 
sunitinib, administration of tezosentan resulted in a decrease in PVR. This tezosentan-
induced pulmonary vasodilation was not altered by administration of sunitinib (Figure 
2). Tezosentan had no effect on the coronary vasculature (Figure 2) or on LVSP, LVdP/
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dtmax, LVdP/dtmin and SVi in the absence of sunitinib, while SVi increased slightly during 
sunitinib administration (Table 2).
Prior to sunitinib, ROS scavenging resulted in systemic vasodilation as evidenced by 
the decreases in MABP and SVRi (Figure 2). This effect was reduced following sunitinib 
(Figure 2). In the pulmonary circulation, ROS scavenging resulted in a decrease in PAP 
prior to sunitinib, while it had no effect on PAP in the presence of sunitinib. Moreover, 
ROS scavenging did not affect PVRi either in the absence or presence of sunitinib (Figure 
2). ROS scavenging had no effect on CBF either before or after sunitinib. Finally, ROS 
scavenging did not affect LVSP, dP/dtmax, dP/dtmin or Svi, either before or after sunitinib 
(Table 2).
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Figure 1. Effect of sunitinib on systemic, pulmonary and coronary hemodynamic parameters at rest and 
during graded treadmill exercise.
BVO2i: Body oxygen consumption; MABP: mean aortic blood pressure; SVRi: systemic vascular resistance; 
MPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; RPP: rate pressure product; 
CBF: coronary blood flow; CVR: coronary vascular resistance; *P < 0.05 sunitinib vs control; ** P<0.06 vs 
control.
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DIsCussIon
The main findings of the present study in chronically instrumented awake swine are (i) 
administration of the RTKI sunitinib induces a rapid rise in systemic BP due to an increase 
in systemic vascular resistance, without affecting the pulmonary or coronary circulation; 
(ii) the vasoconstrictor effect of sunitinib on the systemic circulation waned with increas-
ing exercise intensities; (iii) sunitinib had no adverse effects on cardiac function either 
at rest or during exercise; (iv) the systemic hemodynamic effects of sunitinib were fully 
reversed upon administration of the ETA/ETB receptor blocker tezosentan, confirming 
previous findings that an increase in endogenous ET-mediated vasoconstrictor tone is 
involved in the sunitinib-induced rise in MABP; and finally, (v) no evidence was found 
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Figure 2. Effect of inhibition of eNOS with LNNA, ETA/B receptor blockade with tezosentan (tezo) and ROS 
scavenging on systemic, pulmonary and coronary hemodynamic parameters in the absence and presence 
of sunitinib. Data are shown as changes form corresponding baseline. MABP: mean aortic blood pressure; 
SVRi: systemic vascular resistance; MPAP: mean pulmonary artery pressure; PVR: pulmonary vascular 
resistance; CBF: coronary blood flow; CVR: coronary vascular resistance; *P < 0.05 vs control; **P<0.10 vs 
control; †P<0.05, ††P<0.10, pre- vs postsunitinib.
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that a decrease in NO-bioavailability or an increase in oxidative stress contributed to the 
systemic vasoconstriction produced by sunitinib.10-12
In accordance with data in both rats and patients, administration of sunitinib induced 
a rapid and sustained increase in systemic MABP in swine.10-12 Since VEGF is not only 
important for the formation, but also for the maintenance of blood vessels, a sunitinib-
induced decrease in microvessel density per unit of volume has been proposed as a 
potential mechanism underlying the MABP rise during anti-angiogenic therapy.5 In-
deed, prolonged treatment with the RTKIs sunitinib and telatinib has been reported to 
be associated with capillary rarefaction.9,25,26 Yet, the observation that the main increase 
in MABP occurred within 4 h after administration of the first dose of a RTKI in the pres-
ent study, and within 24 h in studies in rats, makes rarefaction a less likely cause of the 
increase in vascular resistance and MABP.10,11 Moreover, a hemodynamic model based 
on the cheek pouch circulation of the hamster indicates that 40% rarefaction of fourth 
Table 2. Changes in hemodynamic parameters as a result of eNOS inhibition, ETA/B blockade and ROS 
scavenging in the absence and presence of sunitinib.
LNNA Tezosentan ROS
ΔHR Control -11 ± 7 6 ± 3 22 ± 8*
(beats/min) Sunitinib -24 ± 3*† 0 ± 5 22 ± 7*
ΔMABP Control 24 ± 1* 0 ± 3 -13 ± 2*
(mmHg) Sunitinib 32 ± 3*† -12 ± 4* -5 ± 2*†
ΔCI Control 42 ± 8* 12 ± 5 35 ± 6*
(ml min-1 kg-1) Sunitinib 47 ± 8* 13 ± 4* 22 ± 4*
ΔLVSP Control 18 ± 5* 4 ± 3 -5 ± 5
(mmHg) Sunitinib 24 ± 7* -9 ± 6 -10 ± 3*
ΔSVi Control -0.23 ± 0.10 0.02 ± 0.04 0.05 ± 0.06
(ml/kg) Sunitinib -0.16 ± 0.07 0.10 ± 0.03* -0.03 ± 0.06
ΔLV dP/dtmax Control -123 ± 216 -20 ± 123 158 ± 152
(mmHg/s) Sunitinib -580 ± 342 217 ± 69* 118 ± 129
ΔLV dP/dtmin Control -185 ± 46* -27 ± 135 22 ± 78
(mmHg/s) Sunitinib -202 ± 70* 82 ± 170 156 ± 69†
Abbreviations as in table 1. * P<0.05 effect of LNNA, Tezosentan or ROS scavenging vs corresponding 
baseline;
†P<0.05 effect of LNNA, Tezosentan or ROS scavenging altered as a result of sunitinib.
Cardiovascular and renal toxicity 107
order vessels is required to increase vascular resistance in that particular vascular bed 
by 5%.27 It is inconceivable that such an extensive degree of systemic rarefaction can 
occur within 4 h after initiation of angiogenesis inhibition. In view of the rapid increase 
in MABP and the knowledge that dramatic rarefaction is required to increase vascular 
resistance, we consider vasoconstriction the most important mechanism involved in 
the MABP rise during anti-angiogenesis therapy. In addition, the current observations 
that the sunitinib-induced systemic vasoconstriction diminished with increasing levels 
of exercise and the immediate normalization of MABP and SVRi with subsequent ETA/
ETB blockade, further argue against rarefaction as a mechanism underlying the BP rise 
associated with angiogenesis inhibition (Fig. 2).
To explore potential mechanisms underlying the sunitinib-induced rise in vascular 
resistance and MABP we investigated the acute effects of ETA/ETB receptor blockade, 
eNOS inhibition and ROS scavenging prior and following one week of sunitinib treat-
ment. In previous studies we have shown that administration of sunitinib in patients 
and rats is associated with an increase in circulating ET-1 levels.10 In addition, we and 
others have demonstrated in rats that co-administration of an ET-1 receptor antagonist 
with a RTKI can largely or completely prevent the rise in MABP, suggesting that activa-
tion of the endothelin pathway plays an important role in the sunitinib-induced MABP 
rise.11,12 These observations in rats are fully supported by the present findings in swine, 
as the sunitinib-induced increase in SVRi and MABP completely reversed to pre-sunitinib 
values in response to acute administration of ETA/B receptor blocker tezosentan.
ET-1 exerts part of its vasoconstrictor effect through activation of NADPH-oxidase and 
generation of ROS.28-30 In addition, hypertension has been reported to be associated 
with an increase in ROS.15 Since ROS can be derived from multiple sources within the cir-
culation, including NADPH-oxidase, mitochondrial respiration, and neutrophils, we used 
a cocktail of antioxidants, including the SOD-mimetic TEMPOL, to achieve extensive 
ROS scavenging.24,31,32,33 Using this approach, no evidence for an increase in sunitinib-
induced ROS-mediated vasoconstriction was found. On the contrary, the effect of ROS-
scavenging on MABP was reduced, while the effect on SVRi was unchanged following 1 
week of sunitinib treatment. Of note, activation of NADPH-oxidase is also a critical step 
in the VEGF-receptor signaling cascade.34 If this pathway is blocked following sunitinib 
administration, it is possible that activation of NADPH-oxidase via the ET-1 pathway is 
offset by a decreased activation of NADPH-oxidase due to VEGF-receptor inhibition.
Since VEGF is known to stimulate eNOS via the phosphatidylinositol 3-kinase-AKT 
pathway through activation of the VEGFR2 receptor, the enhanced vasoconstrictor re-
sponse to acute eNOS inhibition after sunitinib administration observed in the present 
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study was unexpected.6,35,36 This finding implies that the sunitinib-induced rise in MABP 
is accompanied by an increase in the NO-dependent vasodilator tone. This contrasts 
with observations that sunitinib treatment for 8 days was accompanied by a decreased 
urinary nitrate excretion in rats and in patients receiving various inhibitors of the VEGF-
pathway, as well as with the observation that the RTKI vandetanib decreases systemic 
plasma nitrate/nitrite levels in treated patients.8,12,37 Results of clinical studies using 
FMD of the brachial artery as an index of NO bioavailability are conflicting. In one study, 
administration of the RTKI telatinib was associated with a decrease in FMD from 6.0% 
to 3.9%, while in another study, administration of the RTKI vandetanib had no effect on 
FMD (12.0% before and 13.8% after vandetanib).8,9 In a study by Steeghs et al., the vaso-
dilation to nitroglycerin was also reduced (from 17.0% to 9.7%) to a comparable extent 
as the decrease in FMD, indicating a diminished response of the vascular smooth muscle 
cells to NO rather than a selective decrease in NO-bioavailability.9 In the coronary micro-
circulation of rats exposed to sunitinib for 8 days we found, using the Langendorff heart 
model, that the vasodilator responses to both bradykinin (endothelium-dependent) 
and sodium-nitroprusside (endothelium-independent) were impaired.10 Remarkably, 
in this model we also found an attenuated vasoconstrictor response to angiotensin II. 
These findings suggest generalized impairment of vascular smooth muscle function 
during sunitinib administration that is still unexplained. Altogether, until now evidence 
is lacking to conclude that a decrease in NO-bioavailability is a predominant factor in 
RTKI-induced vasoconstriction. Given the complex interaction between NO and ET, it 
is possible that the enhanced NO-mediated vasodilator tone is due to increased ETB 
stimulation while simultaneously limiting ET-induced vasoconstriction.
Our study is the first to investigate potential adverse effects of the RTKI sunitinib on the 
pulmonary vasculature. Contrary to its vasoconstrictor effect in the systemic circulation, 
sunitinib did not cause pulmonary vasoconstriction either at rest or during exercise. 
Variation in expression and function of ETA and ETB receptors between these two circu-
lations may provide an explanation for this difference. The ETA receptor predominates 
in the systemic and coronary vasculature, whereas the ETB receptor predominates in 
the pulmonary microcirculation, where it is present on both the endothelium and the 
vascular smooth muscle cells and also functions as a clearance receptor.38 In a previous 
study, using the same animal model as in the present study, we found that the dose of 
ET-1 required to induce vasoconstriction in the systemic circulation is lower than the 
dose to induce pulmonary vasoconstriction.20 Apparently, the sunitinib-induced activa-
tion of the endothelin-pathway was not sufficient to induce pulmonary vasoconstriction 
thereby precluding adverse effects of RTKI on the pulmonary circulation.
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In the present study, administration of sunitinib was without adverse effects on stroke 
volume or LVdP/dtmax and LVdP/dtmin, indices of left ventricular systolic and diastolic 
function, either at rest or during exercise. Moreover, no evidence was found for coronary 
vasoconstriction as CBF did not change during sunitinib administration. In contrast, 
sunitinib treatment of patients with imatinib-resistant, metastatic gastrointestinal 
stromal tumors was associated with the development of congestive heart failure in 8% 
of patients and a decrease in LVEF of at least 10% in 28% of patients.2 This discrepancy 
might in part be explained by the difference in exposure time to sunitinib as well as the 
fact that our intervention was performed in young and healthy animals, whereas in the 
clinical study pre-existent coronary artery disease remained as the only statistically sig-
nificant predictor for congestive heart failure in a multivariate logistic regression model.
PeRsPeCTIVes
Angiogenesis inhibition with sunitinib induces a marked rise in MABP, which is inde-
pendent of changes in endogenous ROS and NO production, but completely reversed 
by endothelin receptor antagonism with tezosentan. These findings support previous 
observations that sunitinib-induced hypertension is endothelin-mediated, whereas 
decreased NO-bioavailability or enhanced oxidative stress do not appear to be involved. 
Since we recently showed that endothelin receptor antagonism could also prevent 
sunitinib-induced proteinuria and urinary ET-1 excretion (markers of renal injury), 
endothelin receptor antagonists appear logical candidates to counteract the sunitinib-
induced cardiovascular and renal adverse effects.12 In addition, ET-1 has been shown 
to promote angiogenesis in cancer and therefore ET-1 receptor antagonism may have 
complementary therapeutic effects.39,40 However, carefully conducted clinical trials are 
required to demonstrate whether indeed endothelin receptor antagonists may be the 
preferred agents to treat the cardiovascular and renal side effects associated with anti-
angiogenesis therapy in patients with cancer.
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AbsTRACT
Angiogenesis inhibition, an established treatment for several tumor types, is associated 
with hypertension and renal toxicity. In patients and in rats we demonstrated that the 
multitarget tyrosine kinase inhibitor sunitinib induces a rise in blood pressure (BP), renal 
dysfunction, proteinuria, and marked renal histological abnormalities associated with 
activation of the circulating and renal endothelin system. Moreover, these side effects 
could partly be prevented by the dual ETA/ETB endothelin receptor blocker macitentan. 
In the current study we investigated whether the macitentan-induced decrease in BP 
accounts for the decrease in proteinuria and urinary ET-1 excretion or whether the renal 
toxicity is BP-independent due to activation of the renal endothelin system. Normoten-
sive Wistar Kyoto rats were administered sunitinib alone, sunitinib and macitentan or 
sunitinib and the calcium channel blocker amlodipine for 8 days, at which time point 
they were sacrificed and blood and kidneys collected. At baseline and at the end of treat-
ment 24 h urine samples were collected. In rats on sunitinib alone, BP increased (ΔBP 
31.6±0.9 mmHg). Co-administration of macitentan (ΔBP 12.3±1.5 mmHg) or amlodipine 
(ΔBP 11.4±1.7 mmHg) largely and equally prevented this rise. Both compounds could 
not prevent the sunitinib-induced rise in serum creatinine. Macitentan diminished suni-
tinib-induced proteinuria, urinary ET-1 excretion and glomerular intra-epithelial protein 
deposition, whereas amlodipine did not, despite a similar decrease in BP. In conclusion, 
hypertension and proteinuria are independent side effects of sunitinib treatment and 
are due, at least in part, to activation of the circulating and renal endothelin system.
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InTRoDuCTIon
Angiogenesis, the formation of new capillaries from an existing vasculature, is critical 
to tumor growth as well as to metastasis and is regulated by numerous factors among 
which vascular endothelial growth factor (VEGF) and its corresponding receptors. 
Angiogenesis inhibition, by targeting VEGF or its receptors, has become an established 
treatment of several tumor types. Common adverse effects of angiogenesis inhibition 
are hypertension and renal toxicity.1 Hypertension has been reported in up to 36% of pa-
tients treated with bevacizumab, a monoclonal antibody against VEGF, and in up to 60% 
of patients treated with sunitinib, an orally active multitarget VEGF receptor tyrosine 
kinase inhibitor (RTKI) used in the first-line treatment of metastatic renal cell carcinoma 
or imatinib-resistant gastrointestinal stromal tumors.1 Renal toxicity, mainly proteinuria, 
has been reported in 41-63% of patients treated with bevacizumab.2 The incidence of 
proteinuria in patients treated with RTKIs is less well defined, as in the initial studies 
patients were not routinely screened for this adverse effect.
It has been suggested that inhibition of the VEGF-pathway reduces nitric oxide (NO) 
bioavailability leading to a disturbed balance between NO and endothelin-1 (ET-1), 
favoring ET-1-mediated vasoconstriction and thus promoting the development of hy-
pertension.1 This is in accordance with our recent findings, showing that the rise in blood 
pressure (BP), renal dysfunction and proteinuria induced by the RTKI sunitinib were 
associated with a two-to-three-fold rise in circulating ET-1 levels in both patients and 
rats.3 Moreover, the sunitinib-induced proteinuria and increased urinary ET-1 excretion 
were largely diminished during co-administration of the dual ETA/ETB-receptor blocker 
macitentan.4 Since macitentan also diminished the sunitinib-induced rise in BP by 60%, 
the question whether the decrease in BP per se rather than blockade of the sunitinib-
activated renal endothelin system mainly accounted for the decrease in proteinuria 
could not be answered. To address this point we initiated the current study in which 
we compared the effect of the calcium channel blocker amlodipine and macitentan on 
sunitinib-induced hypertension, renal injury and microvascular function when given at 
doses that lowered blood pressure identically.
MeTHoDs
In vivo study
Male Wistar Kyoto rats (WKY, 280-300 gram) obtained from Charles River, were housed 
in individual cages and maintained on a 12-h light/dark cycle, having access to standard 
laboratory rat chow and water ad libitum. Intra-aortic BP recordings were performed 
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by radiotelemetry and the sunitinib and vehicle solution were prepared and adminis-
tered by oral gavage as described previously.3 Macitentan (ACT-064992), a dual ETA / 
ETB receptor antagonist kindly provided by Actelion, was dissolved in vehicle contain-
ing 0.5% methylcellulose aqueous solution and 0.05% Tween 80. Amlodipine besylate 
(Bioconnect, Huissen, The Netherlands) was suspended in 1% tragacanth gum solution. 
Three separate experiments were performed. At the end of each experiment, rats were 
euthanized with 60 mg/kg pentobarbital i.p. and blood was sampled for measurement 
of plasma ET-1 as well as serum creatinine levels, and kidneys were rapidly excised. 
In the first experiment rats were randomly administered sunitinib (26.7 mg/kg/day of 
sunitinib L-malate; n=10) or vehicle (n=10) by oral gavage (0.5 mL) for 8 days. In the sec-
ond experiment, rats (n=8) were orally administered the combination of sunitinib and 
macitentan 30mg/kg/day, for 8 days.5 In the third experiment, rats were administered 
the combination of sunitinib and amlodipine 3mg/kg/day by oral gavage for 8 days.6,7 In 
all experiments, 6 days before (baseline) and 6 days after administration of the various 
agents, rats were housed in metabolic cages for 48 hours with free access to food and 
water; the first day to acclimatize and the second day to collect 24-hour urine samples for 
determination of protein, ET-1, nitric oxide (NO) metabolites (NO2+NO3 [NOx]) and thio-
barbituric acid reactive substances (TBARS). Urine was collected on antibiotics (A5955, 
Sigma) to prevent formation of NO metabolites. All experiments were performed under 
the regulation and permission of the Animal Care Committee of the Erasmus MC.
In vitro studies
Microvascular function
To assess coronary microvascular function, hearts were rapidly excised from euthanized 
rats and perfused according to Langendorff.8 Coronary flow (CF) was measured with 
a flow probe (Transonic systems). After a stabilization period of 30 minutes, baseline 
values of CF were obtained. Next, bolus injections (100 μL) of Tyrode’s buffer were ap-
plied three times to determine injection-induced changes in CF. Dose-response curves 
to the endothelium-dependent vasodilator bradykinin and the vasoconstrictor Ang II 
were constructed by bolus injections. In addition, endothelium-independent maximal 
vasodilatation was assessed by a single bolus injection of sodium nitroprusside (SNP; 
10 mmol/L).
Renal histology
The left kidney was rapidly excised from euthanized rats, decapsulated, weighed and 
sliced transversely. One slice was fixed in a 3.5-4% formaldehyde solution for light 
microscopic and another slice was fixed in 2% glutaraldehyde for electron microscopic 
evaluation. After fixation in the formaldehyde solution, tissue was dehydrated and 
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paraffin-embedded. Deparaffinized 2-μm thick sections were stained for Haematoxilin-
eosine (HE), PAS and Jones silver. PAS-stained sections were blindly evaluated by a pa-
thologist for the presence (score 1) or absence (score 0) of endothelial cell and epithelial 
cell swelling in 50 glomeruli. Glomerular ischemia was scored semiquantitatively and 
defined as the degree of open glomerular capillaries, wrinkling of the glomerular base-
ment membrane and filling of Bowmans space. Wide open glomerular capillaries filling 
Bowman’s space entirely corresponded with no ischemia. Partially open glomerular 
capillaries with mild wrinkling of the glomerular basement membrane and Bowman’s 
glomerular space largely filled was classed as moderate ischemia. Totally collapsed 
glomeruli and extensive wrinkling of the glomerular basement membrane and only 
partial filling of Bowman’s space corresponded with severe ischemia. Furthermore, 
the presence of glomerular intra-epithelial protein deposition was evaluated using a 
semiquantative scale: 0 (no protein), 1 (protein present in 1-50% of the epithelial cells), 
2 (protein present in >50% of the epithelial cells). Fifty glomeruli per kidney section (PAS 
staining) were evaluated.
biochemical measurements
ET-1 was assessed using a chemiluminescent ELISA (QuantiGlo®, R&D Systems) and 
urine albumin by enzyme immunoassay (Spi-Bio, France). Urine NOx concentration was 
determined by fluorimetric quantification of nitrite content (Cayman Chemicals, Ann 
Arbor, MI) and lipid peroxidation in urine by measurement of TBARS.9 Serum creatinine 
and urinary protein concentrations were measured at the clinical chemical laboratory of 
the Erasmus MC.
statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls or 
Dunnett’s multiple comparison testing. GraphPad Prism version 4.03 was used for all 
statistical analysis.
ResulTs
In vivo study
Co-administration of macitentan or amlodipine comparably diminished the sunitinib-
induced rise in BP, whereas the sunitinib-induced decrease in heart rate (HR) was not 
affected by both compounds (Figure 1).
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Macitentan did not change the sunitinib-induced increases in kidney weight-to-body 
weight-ratio (KW/BW-ratio) (data not shown) and serum creatinine, but it decreased pro-
teinuria and urinary ET-1 excretion, whereas circulating ET-1 levels increased (Figure 2).4 
Treatment with amlodipine did also not diminish the sunitinib-induced increase in KW/
BW-ratio (data not shown), nor did it decrease the rise in serum creatinine, circulating 
ET-1 levels or urinary ET-1 excretion, whereas proteinuria tended to increase (Figure 2). 
The sunitinib-induced decrease in urinary nitrate excretion was not reversed by either 
macitentan or amlodipine (Figure 3).4
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Figure 1. Changes in mean arterial pressure (MAP, A) and heart rate (HR, B) in response to administration 
of vehicle (n=6), sunitinib and vehicle (n=12), sunitinib and macitentan (n=8), or sunitinib and amlodipine 
(n=8). Vehicle, sunitinib and vehicle, and sunitinib and macitentan are from Kappers et al.4 *p<0.05 vs 
sunitinib + vehicle.
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Figure 2. Serum creatinine (A), change in proteinuria (B), circulating ET-1 levels (C) and change in urinary 
ET-1 excretion (D) in rats after administration of vehicle (n=6), sunitinib and vehicle (n=16), sunitinib 
and macitentan (n=4-6), or sunitinib and amlodipine (n=8) for 8 days. Vehicle, sunitinib and vehicle, and 
sunitinib and macitentan are from Kappers et al.4
*p<0.05 vs sunitinib + vehicle; †p<0.05 vs vehicle.
Co
ntr
ol 
(bs
)
Co
ntr
ol 
(d8
)
SU
 
(bs
)
SU
 
(d8
)
SU
+M
ac
 
(bs
)
SU
+M
ac
 
(d8
)
SU
+A
m
lo(b
s)
SU
+A
m
lo 
(d8
)0
1
2
3
4
5
* * *
NO
x 
(µ
m
o
l/1
00
g 
BW
/2
4h
)
NOx.pzf:Figure 3 (JHypertens) - Wed May 11 14:53:10 2011
Figure 3. Nitric oxide metabolites (NOx) excretion in urine of WKY rats at baseline and after an 8-days 
administration of vehicle (n=4), sunitinib (n=9), sunitinib and macitentan (n=7) or sunitinib and 
amlodipine (n=8). Vehicle and sunitinib are from Kappers et al.4
 * p<0.05 vs baseline, † p<0.05 vs sunitinib.
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In vitro studies
Microvascular function
The bradykinin and SNP-induced increase in CF was markedly diminished in rats exposed 
to sunitinib, as was the Ang II-induced decrease in CF (Figure 4). The sunitinib-induced 
alterations of the responses to bradykinin and Ang II were not reversed by macitentan 
or amlodipine. In contrast, the sunitinib-induced diminished response to SNP slightly 
reversed with amlodipine but not with macitentan (Figure 4).
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Figure 4. Coronary flow responses to bradykinin (BK; A), angiotensin II (AngII, B) and a single injection 
to sodium nitroprusside (SNP 10 mmol/L, C) in isolated rat hearts after administration of vehicle (n=9), 
sunitinib and vehicle (n=10), sunitinib and macitentan (n=4), and sunitinib and amlodipine (n=8) for 8 
days. The x-axis in A and B displays the concentration in the injection fluid. T indicates Tyrode’s buffer. 
Vehicle, sunitinib and vehicle, and sunitinib and macitentan are from Kappers et al.4 *P<0.05 vs sunitinib + 
vehicle; †P<0.05 vs vehicle.
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Renal histology
Light microscopic examination of PAS-stained kidney sections showed that macitentan 
did not reverse the previously observed sunitinib-induced glomerular ischemia or endo-
thelial and epithelial cell swelling. However, consistent with the decrease in proteinuria, 
glomerular intra-epithelial protein deposition diminished during co-administration 
of macitentan (Table 1). In rats co-administered sunitinib and amlodipine, glomerular 
ischemia and endothelial and epithelial cell swelling were more prominent compared to 
rats exposed to sunitinib alone, as was the glomerular intra-epithelial protein deposition 
(Table 1).
Table 1. Light microscopic evaluation of kidney sections obtained from rats exposed to sunitinib, 
sunitinib and macitentan or sunitinib and amlodipine for 8 days compared to controls.
Glomerular ischemia
(% glomeruli)
Endothelial cell 
swelling
(% glomeruli)
Epithelial cell 
swelling
(% glomeruli)
Intra-epithelial protein
(% glomeruli)
Group None Moderate Severe 0 1 0 1 0 1 2
Control 60±13 32±10 8±4 100 0 100 0 99±1 1±1 0
Sunitinib 17±2* 54±4* 29±5* 78±3* 22±3* 63±5* 37±5* 29±4* 48±2* 23±4*
Sunitinib + 
Macitentan
15±6* 35±2† 51±4*† 85±3* 15±3* 77±6* 23±6* 33±8* 59±7* 8±3*†
Sunitinib + 
Amlodipine
12±3* 40±4† 47±6*† 53±10*† 47±10*† 16±4*† 84±4*† 7±2*† 18±4*† 75±5*†
All evaluations were performed in 50 glomeruli of a PAS-stained section and the numbers of glomeruli 
with each score were counted. Endothelial and epithelial cell swelling were scored as present (1) or absent 
(0) in each glomerulus. The presence of intra-epithelial protein was evaluated using a semiquantative 
scale: 0 (no protein in the epithelial cells of a glomerulus), 1 (protein present in 1-50% of the epithelial 
cells of a glomerulus), 2 (protein present in >50% of the epithelial cells of a glomerulus). Control, sunitinib, 
and sunitinib and macitentan are from Kappers et al.4 * p<0.05 vs control; † p<0.05 vs sunitinib.
DIsCussIon
Recently, we have reported in both patients and rats that the multitarget VEGF-receptor 
tyrosine kinase inhibitor sunitinib induces a rise in BP, a loss of circadian BP rhythm and 
renal toxicity, including a rise in serum creatinine, proteinuria and urinary ET-1 excretion 
as well as histopathological changes, all associated with a rise in circulating ET-1 lev-
els.3,4 Furthermore, co-administration of the dual ETA/ETB-receptor blocker macitentan 
in rats diminished the sunitinib-induced rise in BP almost completely, indicating that 
this rise is largely ET-1-mediated. Co-administration of macitentan also decreased the 
sunitinib-induced increase in proteinuria and urinary ET-1 excretion, both markers of 
renal injury, suggesting that the sunitinib-induced renal toxicity is ET-1-mediated as 
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well.4 Since the decrease in BP with macitentan might have contributed to the decrease 
in proteinuria by lowering glomerular filtration pressure, the possibility that renal 
toxicity observed during angiogenesis inhibition with sunitinib is mainly BP-dependent 
could not be excluded in our previous study. To further explore the separate roles of BP 
and the endothelin-system in the development of renal toxicity during angiogenesis 
inhibition we administered rats the combination of sunitinib and amlodipine to induce 
a decrease in BP comparable that induced by macitentan. Contrary to macitentan, 
amlodipine could not prevent the sunitinib-induced rise in proteinuria and urinary ET-1 
excretion despite an identical decrease in BP, strongly suggesting that these aspects 
of sunitinib-induced renal toxicity are ET-1-mediated and BP-independent, which is in 
line with studies showing that ET-1 increases glomerular permeability to albumin by a 
direct effect on the podocyte cytoskeleton.10,11 Furthermore, conditional gene target-
ing to selectively delete VEGF from renal podocytes in adult mice has been shown to 
result in profound glomerular injury that precedes the development of hypertension, 
additionally supporting our observation that hypertension and renal toxicity are two 
independent sunitinib-associated adverse effects.12
Our studies revealed that proteinuria was not only diminished, but even tended to 
increase during co-administration of sunitinib and amlodipine, and concomitant with 
this increase, glomerular intra-epithelial protein deposition was also more prominent. 
Dihydropyridine calcium antagonists, such as amlodipine, diminish glomerular afferent 
vasoconstrictor tone and thereby can cause an increase in renal blood flow and glomeru-
lar filtration pressure.13 These renal haemodynamic effects of amlodipine might explain 
why despite a decrease in BP renal histological abnormalities, proteinuria and increased 
urinary ET-1 excretion did not improve but even deteriorated during amlodipine co-
administration. Of note circulating ET-1 levels did also not decrease during amlodipine 
co-administration, whereas these levels, due to blockade of the ETB clearance receptor, 
increased during co-administration of macitentan.
It is difficult to explain why macitentan diminished the sunitinib-induced proteinuria 
and urinary ET-1 excretion, but had no effect on elevated serum creatinine levels and 
only small effects on renal histopathology. In this regard it would be interesting to 
investigate whether serum creatinine concentration and renal histological changes 
completely normalize when macitentan is administrated for an extended period after 
sunitinib withdrawal. In a previous study we showed that serum creatinine concen-
tration was still increased 11 days after sunitinib withdrawal.3 Urinary ET-1 has been 
reported to be completely kidney-derived and its increased urinary excretion reflects 
renal injury.14 Consequently, reversal of the increased urinary ET-1 excretion indicates 
remission of renal injury. Interestingly, the current findings show that the decrease in 
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urinary ET-1 excretion observed during co-administration of macitentan is not neces-
sarily accompanied by reversal of the renal histological abnormalities or normalization 
of serum creatinine concentration, suggesting that increased urinary ET-1 excretion is 
possibly a sensitive but incomplete marker of renal injury.
Since binding of VEGF to its receptors on endothelial cells is important for their survival 
and increases NO-production through Akt-dependent phosphorylation of endothelial 
NO synthase, it has been postulated that VEGF-inhibition leads to endothelial dysfunc-
tion and decreased NO-bioavailability.15 However, hypertension itself can also induce 
endothelial dysfunction and a decrease in NO-bioavailablity.16-18 Recently we reported 
that urinary excretion of nitrates (a measure of NO availability) decreased during suni-
tinib administration.4 However, neither macitentan nor amlodipine could reverse the 
decreased nitrate excretion despite a marked decrease in BP. These findings suggest that 
the decreased NO-bioavailability during sunitinib administration is directly related to its 
interaction with the VEGF-pathway. This is supported by the findings in the Langendorff 
model. In this model, endothelium-dependent vasodilation induced by bradykinin 
did not improve during co-administration of macitentan or amlodipine. In contrast, 
amlodipine did improve endothelium-independent vasodilation induced by sodium 
nitroprusside, indicating improved vascular smooth muscle cell vasodilatory function.
In conclusion, angiogenesis inhibition with the tyrosine kinase receptor inhibitor suni-
tinib induces hypertension and proteinuria, a rise in urinary ET-1 excretion and renal 
histological abnormalities that are independent side effects, in part due to activation 
of the endothelin system. The endothelin receptor blocker and the calcium channel 
blocker in the dosages used were equally effective in preventing the sunitinib-induced 
rise in BP and therefore can both be used to treat sunitinib-induced hypertension. 
Considering our finding that endothelin receptor blockade also diminished proteinuria 
and elevated urinary ET-1 excretion, whereas these two parameters tended to increase 
with the calcium channel blocker, endothelin receptor blockade might be preferred in 
patients who develop hypertension and proteinuria during treatment with sunitinib. Fi-
nally, although not the focus of the present study, it would be worthwhile to explore the 
effect of antihypertensive drugs with a renal protective profile such as ACE-inhibitors or 
Ang II type 1-receptor blockers on sunitinib-induced hypertension and renal toxicity in 
our rat model.
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Rini et al. reported a large retrospective analysis that showed that patients with meta-
static renal cell carcinoma who developed hypertension when treated with the tyrosine 
kinase inhibitor sunitinib have improved overall survival and progression-free survival 
compared with patients who remained free of hypertension.1 The authors concluded 
that the development of hypertension is a potential valuable biomarker for the predic-
tion of treatment response. However, we wonder whether a categorical division of 
patients is the most appropriate way to look at the data. Hypertension is defined as a 
systolic blood pressure of 140 mm Hg or greater and/or a diastolic blood pressure of 90 
mm Hg or greater and this definition was also used in the analysis by Rini et al.1 However, 
it is well known that within the so-called normotensive range a higher blood pressure 
is associated with an increased cardiovascular risk, indicating that the cut-off values of 
140 mm Hg and 90 mm Hg are arbitrary. If a patient has a baseline blood pressure of 138 
mm Hg systolic, an only 2 mm Hg increase in blood pressure will classify him or her as 
being hypertensive, whereas a patient with a baseline systolic blood pressure of 110 mm 
Hg experiencing a 28 mm Hg increase would not. According to this reasoning we think 
that the patient’s absolute or relative blood pressure increase rather than the presence 
or absence of hypertension is a more appropriate way of analyzing the data. Perhaps the 
authors can perform an analysis based on blood pressure increases rather than on the 
subdivision in hypertension and normotension.
With regard to the mechanism leading to hypertension, the authors mentioned several 
possibilities. One of these is rarefaction, i.e. presence of less perfused microvessels and/
or a diminished number of microvessels. Indeed rarefaction of skin capillaries during 
sunitinib treatment in patients with metastatic renal cell carcinoma has been reported.2 
In that study, an inverse association between the degree of rarefaction and the in-
crease in blood pressure was observed. This association does not imply causality. The 
rarefaction could be a consequence of the blood pressure rise. Rarefaction is present 
in patients with untreated hypertension, but is absent when the elevated blood pres-
sure is normalized with an antihypertensive treatment.3 Another point to consider is 
how much rarefaction is needed to cause blood pressure to increase. A mathematical 
model based on the hamster cheek pouch microcirculation indicates that 42% rarefac-
tion of the fourth order arterioles is necessary to increase resistance in that particular 
vascular bed by 5%.4 This estimate suggests that a considerable amount of rarefaction in 
various vascular beds is required to induce an increase in vascular resistance and hence 
in blood pressure, assuming that cardiac output remains unchanged. Furthermore, in 
unrestrained rats in which blood pressure was continuously recorded by telemonitoring, 
we observed an increase in blood pressure within 1 day of sunitinib administration by 
oral gavage.5 From this result, it appears that it is highly unlikely that rarefaction is an 
initial cause of sunitinib-induced hypertension.
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One mechanism that was not mentioned by Rini et al. but could potentially underlie the 
occurrence of hypertension by sunitinib is activation of the endothelin-1 pathway. In 
the experimental model just described and in patients treated with sunitinib we found 
that the rise in blood pressure is accompanied by an activation of endothelin-1 path-
way.1,5 Because renin was suppressed in these patients and we observed no evidence of 
activation of the sympathetic nervous system or fluid retention, we think that activation 
of the endothelin-1 pathway is an important mediator of the blood pressure increase 
induced by sunitinib. This conclusion fits well with the observation that the rise in blood 
pressure induced by a VEGF receptor tyrosine kinase inhibitor can be largely prevented 
by endothelin-receptor antagonism.6,7 The mechanism by which sunitinib activates the 
endothelin-1 pathway is still not clear.
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AbsTRACT
Context – Anticancer treatment with the tyrosine kinase inhibitor sunitinib causes 
thyroid dysfunction.
objective – Our objective was to investigate the time course and underlying mecha-
nisms of sunitinib-induced thyroid dysfunction.
Design – Thyroid function tests of 83 patients on sunitinib were collected retrospec-
tively for their total treatment duration between January 2006 and November 2009, and 
prospectively in 15 patients on sunitinib for 10 wk. Additionally, thyroid function and 
histology were assessed in rats on sunitinib (8 d; n=10) and after sunitinib withdrawal 
(11 d; n=7), and compared to controls (n=7).
setting – Patients were seen at a university outpatient oncology clinic.
Patients / animals – Patients with metastatic renal cell carcinoma or gastrointestinal 
stromal tumors participated in the clinical study and Wistar Kyoto rats were used in the 
rat study.
Intervention – Sunitinib was taken according to a 4 wk ‘on’, two wk ‘off’ treatment 
regimen. Blood samples for measurement of thyroid function were collected at baseline, 
and at wk 4 and 10. In rats, blood, liver and thyroid were collected to assess thyroid 
hormones, deiodinase activity and thyroid histology.
Main outcome Measure(s) – TSH and free T4 levels, deiodinase activity, and thyroid 
histology were assessed.
Results – Forty-two percent of patients in the retrospective study developed elevated 
TSH levels. Prospective analysis showed increased TSH levels within 10 wk of treatment, 
accompanied by a decreased T3/rT3 ratio. In rats, serum T4 and T3 decreased, hepatic type 
3 deiodinase activity increased, and thyroid histology showed marked capillary regres-
sion, which all but thyroid hormones reversed after sunitinib withdrawal.
Conclusion – Sunitinib induces hypothyroidism due to alterations in T4/T3 metabolism 
as well as thyroid capillary regression.
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InTRoDuCTIon
Inhibition of angiogenesis by means of blocking vascular endothelial growth factor 
(VEGF)-mediated signaling has become an established treatment for various malignan-
cies. Sunitinib, an oral multitarget tyrosine kinase inhibitor of among others the VEGF 
receptor, is approved for the treatment of metastatic renal cell carcinoma (mRCC) and 
imatinib-resistent metastatic gastrointestinal stromal tumors (GIST).1-2 A frequently 
observed side effect of sunitinib treatment is thyroid dysfunction, mainly hypothyroid-
ism, with a reported incidence of 53-85% in retrospective and 36-46% in prospective 
studies.3 Sporadically, suppression of TSH preceded the development of hypothyroidism 
compatible with transient thyroid hormone (TH) overproduction.4 Thyroid dysfunction 
not only is associated with sunitinib treatment but has also been reported during treat-
ment with other receptor tyrosine kinase inhibitors (RTKIs) such as nilotinib, dasatinib 
and sorafenib.5-7 The precise mechanism underlying sunitinib and other RTKI-induced 
thyroid dysfunction has not been elucidated yet. In a patient with a history of thyroid-
ectomy for which he was on levothyroxine (LT4) replacement therapy, an increased 
dose of LT4 was required during treatment with sunitinib, suggesting induction of TH 
metabolism by sunitinib (‘metabolic hypothesis’).8
In mice, administration of an experimental VEGF receptor inhibitor or soluble VEGF 
receptor was associated with pronounced regression of capillaries in the thyroid gland 
and a marked increase in serum TSH levels (‘capillary regression hypothesis’).9 A pos-
sibly correlated clinical finding is the observed reduction in thyroid volume in patients 
treated with sunitinib.10,11 In addition, impaired uptake of radiolabeled iodine during 
sunitinib treatment has also been reported.12
Our research, using a clinical and experimental approach, was aimed at further inves-
tigating the incidence of sunitinib-induced thyroid dysfunction, its time-course and 
the pathophysiological mechanisms involved. Our focus was on T4/T3 metabolism and 
on capillary density of the thyroid gland during sunitinib administration and after its 
withdrawal.
MeTHoDs
Retrospective patient study
Between January 2006 and November 2009, patients with either mRCC or imatinib-
resistant GIST receiving sunitinib at the Department of Medical Oncology of the Erasmus 
Medical Center (Rotterdam, The Netherlands) were evaluated retrospectively for the 
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development of thyroid dysfunction. Sunitinib was taken according to a 4 wk ‘on’, 2 wk 
‘off’ regimen with a starting dose of 50 mg/d. During treatment this dose was adjusted 
according to the judgment of the patient’s physician. Only patients with thyroid function 
tests (TFT) available on at least two consecutive time points were included. Patients with 
abnormal TFT before initiation of sunitinib or with previous TH replacement therapy due 
to underlying thyroid disease were excluded. Serum TSH levels >5.0 mU/liter or <0.4 
mU/liter and free T4 (FT4) levels above 25 or below 11 pmol/liter were considered to be 
abnormal. TH replacement therapy was initiated according to the judgment of the pa-
tient’s physician, which was mainly based on the degree of both elevated TSH levels and 
accompanying decreased FT4 levels with or without aggravation of clinical symptoms 
such as fatigue.
Prospective patient study
Between January 2008 and January 2009, patients who were eligible for treatment with 
sunitinib, were invited to participate in a prospective study in which they were followed 
for 10 wk. Sunitinib was taken according to the above-mentioned treatment regimen. 
Blood samples for measurement of TSH, FT4, T3, rT3 and antibodies against thyroid per-
oxidase (TPO) were obtained at baseline and at the end of the first and second treatment 
cycle. The study was approved by the Institutional Review Board and Ethical Committee 
of the Erasmus MC in Rotterdam. Written informed consent was obtained from each 
patient.
Rat study
Male Wistar-Kyoto rats (280-300 grams), obtained from Charles River Laboratories (Köln, 
Germany), were housed in individual cages and maintained on a 12-h light, 12-h dark 
cycle, having access to standard laboratory rat chow and water ad libitum. The sunitinib 
and vehicle solutions were prepared and administered by oral gavage as previously de-
scribed.13 Three separate experiments were performed. In the first experiment rats were 
randomly administered sunitinib (26.7 mg/kg/d of sunitinib L-malate; n=10) or vehicle 
(n=7) by oral gavage (0.5 ml) for 8 d and were euthanized with 60 mg/kg pentobarbital 
i.p. at the end of this period, at which time blood was sampled for measurement of T3, 
T4 and TSH. Furthermore, sections of liver tissue for measurement of type 1 (D1) and 
type 3 (D3) deiodinase activities were collected, snap frozen and stored at -80°C. Both 
thyroid lobes were also collected and fixed in a 4% formaldehyde solution for histo-
logical examination. In the second experiment, rats (n=7) were administered sunitinib 
at the same dose for 8 d followed by an 11-d recovery period, after which they were 
sacrificed. Six days before (baseline) and 6 d after treatment initiation, rats were housed 
in metabolic cages for 48 h with free access to food and water; the first day to acclimatize 
and the second day for collection of 24-h urine for protein and T3 and T4 measurement. 
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In the second experiment rats were also housed in metabolic cages 1 wk after sunitinib 
withdrawal. In the third experiment, rats (n=8) were treated with the combination of 
sunitinib and macitentan (ACT-064992) 30 mg/kg/d for 8 d. Macitentan, a dual type A 
and type B endothelin (ET) receptor antagonist which was kindly provided by Actelion, 
was dissolved in vehicle containing 0.5% methylcellulose aqueous solution and 0.05% 
Tween 80. All experiments were performed under the regulation and permission of the 
Animal Care Committee of the Erasmus MC.
ex vivo studies and histology
Liver tissue was homogenized in 0.1 M phosphate, 2 mM EDTA, 10 mM dithiothreitol 
(PED10), and hepatic D1 and D3 activities were measured essentially as previously 
described.13 D1 assay mixtures contained 0.1 µM [125I]rT3 and 0.1 mg/ml homogenate 
protein in PED10, and were incubated for 30 min at 37 °C. D3 assay mixtures contained 
1 nM [125I]T3 without or with 0.5 µM unlabeled T3 and 1.5 mg/ml homogenate protein 
in PED10, and were incubated for 2 h at 37 °C. D3 but not D1 is saturated at 0.5 µM T3. 
Therefore, difference in percentage conversion at low (1 nM) and high (0.5 µM) T3 con-
centration represents D3 activity. Assay mixtures were processed and reaction products 
were analyzed by HPLC as previously described.14
After fixation in a 4% buffered formaldehyde solution, the thyroids were dehydrated 
and paraffin-embedded. Hematoxilin-eosine (HE) staining and actin staining were ap-
plied to deparaffinized 2-μm-thick sections. In each section in five consecutive fields 
(magnification, ×400) the total number of follicles and vessels was counted and the 
vessel-to-follicle-ratio calculated.
biochemical measurements
Human serum TSH, FT4 and T3 were measured by chemoluminescence assays (Vitros ECi 
Immunodiagnostic System, Ortho-Clinical Diagnostics, Amersham, UK). Serum rT3 was 
measured by radioimmunoassay. Anti-TPO antibodies were assessed using the immu-
noCAP method (Phadia® 250, Uppsala, Sweden). Rat serum and urinary T4 and T3 levels 
were measured by radioimmunoassay.14
statistics
Data are presented as mean±SEM or median and interquartile ranges. Statistical analysis 
between groups was performed by unpaired t-testing or repeated-measures ANOVA 
followed by Newman-Keuls multiple comparison testing. P<0.05 was considered signifi-
cant. GraphPad Prism version 5.02 was used for all statistical analyses.
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Retrospective patient study
In total, 83 of the 108 patients were eligible for evaluation. Twenty-five patients were 
excluded: in 17 patients no TFTs were available on two consecutive time points; three 
patients had a history of thyroid dysfunction; and in five patients initial measurements 
showed abnormal TFTs. Demographics, disease, treatment duration and TFTs are pre-
sented in Table 1. Thirty-five (42%) of the 83 patients developed elevated TSH values 
during treatment with sunitinib. In four patients no baseline TFTs were performed; 
however, the first TFTs available during treatment were within the normal range and 
patients were therefore included in the study. In 5 patients (14%), the elevation of TSH 
was preceded by suppressed TSH values (Table 2).
Table 1. Characteristics and TFTs of patients developing TSH above 5.0 mU/L during treatment with 
sunitinib.
Characteristic Result
No. of patients [n (%)]a 35 (42)
Male [n (%)] 18 (51)
Female [n (%)] 17 (49)
Age at baseline (yr) 61.4±1.0
Malignancy
mRCC [n (%)] 32 (91)
GIST [n (%)] 3 (9)
Time to onset [d (range)] 90 (14-856)
Baseline TSH (mU/L) 2.43±0.19
Maximum TSH (mU/L) 31.39±6.66
Time to onset [d (range)] 221 (20-1033)
Initiation of LT4-Rx [n (%)] 7 (20)
TSH>10 mU/Lb
No. of patients [n (%)]c
Time to onset
20 (57)
221 (34-1021)
Patients with TSH above 5.0 mU/L at initial measurement or a history with hypothyroidism were excluded; 
FT4 reference range is 11-25pmol/L; TSH reference range is 0.4-4.3mU/L; LT4-Rx, TH replacement therapy 
with LT4. apercentage of total number of patients (83) with TFTs available. b highest TSH level measured in 
a patient was 150mU/L.  cpercentage of the number of patients (35) with TSH above 5.0mU/L
Prospective patient study
Fifteen patients (10 male, 5 female), mean age 59.8 ± 6.1 years, with mRCC (n=13) or GIST 
(n=2) were included. One patient with a history of hypothyroidism (Hashimoto’s disease) 
required an increased LT4 replacement dose during sunitinib therapy. Mean serum TSH 
values increased 2-fold after 10 wk of treatment with sunitinib. Although no statistically 
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Table 2. Characteristics and biochemical data of patients who developed hypothyroidism with preceding 
suppressed serum TSH-levels during treatment with sunitinib.
Patient 
no.
Sex Age
(years)
Malignancy TSH T0
(mU/L)
FT4 T0
(pmol/L)
TSH Lo
(mU/L)
FT4
(pmol/L)
Time to 
onset Lo
(days)
TSH Hi
(mU/L)
FT4
(pmol/L)
Time to 
onset Hi 
(days)
1 F 51 mRCC 2.58 NA 0.080 24.2 352 26.0 11.9 587
2 F 58 mRCC 3.31 18.6 0.014 26.2 200 133.0 6.9 317
3 M 60 mRCC 1.42 NA 0.010 49.5 201 31.5 16.8 345
 4a M 71 mRCC 2.36 15.6 0.008 40.0 82 11.4 15.9 296
5 F 62 mRCC 2.89 18.0 0.026 33.2 152 108 7.8 305
F, female; M, male; NA, not available; T0, basal level of TSH and FT4 before initiation of sunitinib treatment; 
TSH Hi, highest level of TSH and its corresponding FT4 level during treatment with sunitinib; TSH Lo, 
lowest level of TSH and its corresponding FT4 level during treatment with sunitinib
aIn this patient antibodies against TPO and the TSH receptor (TR) were assessed: TPO antibodies were 
negative, TR antibodies were 0.50 IU/L.
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Figure 1. Thyroid function tests at baseline and after 4 and 10 weeks of treatment in patients treated with 
sunitinib according to a 4 week ‘on’ and 2 weeks ‘off’ treatment regimen (N=15). Plasma TSH levels increased 
twofold during 2 treatment cycles (panel A) whereas no changes in plasma FT4 (panel B), T3 (panel C) and 
rT3 (panel D) were observed. T3/rT3-ratio decreased during treatment with sunitinib (panel E). * P<0.05
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different changes in FT4, T3 and rT3 were observed, the T3/rT3 ratio significantly decreased 
during treatment with sunitinib (Fig. 1). Baseline circulating anti-TPO levels were low [1.6 
iU/ml (0.5-5.5 iU/ml)] and did not change during sunitinib treatment.
Rat study
The increase in body weight in the sunitinib group (from 368±3 to 384±3 grams) was 
smaller than in the control group (from 383±3 to 406±3 grams, p=0.0002).
Serum T4 and T3 levels decreased during sunitinib administration and did not return to 
control levels after its withdrawal (Fig. 2A). Urinary excretions of T3 and T4 were very 
low at baseline (below detection limit and 0.02±0.01nmol/d, respectively) and did not 
change during sunitinib administration. During co-administration of sunitinib and ma-
citentan, serum T3 levels tended to be higher (control, 0.8±0.1 nmol; sunitinib, 0.4±0.1 
nmol; sunitinib + macitentan, 0.6±0.1 nmol; n=3; p=0.06 for sunitinib + macitentan 
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Figure 2. A. Circulating thyroid hormone levels in rats after administration of sunitinib (n=9), vehicle (n=6) 
and discontinuation of sunitinib (n=7) B. Deiodinase activities in isolated rat liver after administration of 
sunitinib (n=5), vehicle (n=5) or sunitinib withdrawal (n=7).
* P<0.05 (in panel B sunitinib and stop vs control)
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vs. sunitinib) compared to administration of sunitinib alone, whereas serum T4 levels 
were identical (control, 46.3±4.3 nmol; sunitinib, 31.3±1.9 nmol; sunitinib + macitentan, 
33.8±3.3 nmol; n=3; p=0.59 for sunitinib + macitentan vs. sunitinib).
ex vivo studies and histology
Measurement of hepatic deiodinase activities showed a significant induction of D3 
activity corresponding with the observed decreases in serum T4 and T3 levels (Fig. 2). 
Also a decrease in D1 activity after sunitinib administration was found (Fig. 2B). Changes 
in both deiodinase activities were reversible after sunitinib discontinuation.
Histological examination of the thyroid sections stained with HE showed a marked 
decrease in the total number of vessels as well as a decreased vessel-to-follicle ratio 
after administration of sunitinib (Fig. 3, 4). Staining of thyroid sections for actin, which 
marks large vessels containing smooth muscle cells rather than small capillaries stained 
by HE, showed no changes in the number of actin-positive vessels or vessel-to-follicle 
ratio after sunitinib administration compared to controls (18±2 vs. 20±4; p=0.64 and 
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Figure 3. Total number of vessels (A) and vessel-to-follicle ratio (B) counted in 5 high power fields 
(magnification ×400) of thyroid sections stained with HE obtained from WKY rats administered vehicle 
(control, n=7), sunitinib (n=9), sunitinib and macitentan (SU+Mac, n=8) or after sunitinib withdrawal (stop, 
n=4). * P<0.05 compared to control, † P<0.05 compared to sunitinib.
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0.14±0.07 vs. 0.27±0.02; p=0.14, respectively). Inflammation or epithelial cell destruc-
tion were not observed. Intra-epithelial vacuoles and colloidal resorption vacuoles 
appeared to be more prominent in HE-stained sections of control rats than in sections 
of sunitinib-administered rats (Fig. 4). After withdrawal of sunitinib for 11 d the histo-
logical abnormalities in the thyroid observed with HE-staining completely reversed. The 
number of actin-positive vessels (16.8±3.5) or vessel-to-follicle ratio (0.21±0.04) after 
sunitinib withdrawal were not statistically different from those of controls (p=0.79 and 
p=0.81, respectively) or sunitinib-administered rats (p=0.26 and p=0.15, respectively). 
In rats treated with the combination of sunitinib and macitentan, the total number of 
HE-stained vessels and the vessel-to-follicle ratio was significantly higher than in rats 
administered sunitinib alone (Figure 3).
A.
B.
C.
*
A.
B.
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*
Figure 4. Thyroid sections stained with HE (magnification ×400) of a control rat (A), after 8 days of 
sunitinib administration (B) and after 11 days of sunitinib withdrawal (C). Note in A the numerous small 
capillaries (arrows) around most of the thyroid follicles (asterix), whereas in B the number of capillaries is 
markedly decreased. In rats after sunitinib withdrawal the number of capillaries is even higher compared 
to that of control rats (C).
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DIsCussIon
Thyroid dysfunction, mainly hypothyroidism, is a frequently reported adverse effect 
of sunitinib treatment.4,10,12,15-20 With our clinical and experimental studies we aimed 
to obtain more insight into the time course, incidence and mechanisms involved in 
sunitinib-associated thyroid dysfunction. In agreement with previous reports we found 
that sunitinib-induced hypothyroidism, as reflected by increased serum TSH values, de-
velops in a substantial proportion of patients.3 Prospective evaluation of the time course 
of ensuing thyroid dysfunction showed an increase in TSH levels already within 10 wk 
of treatment, although values at this time were still within the normal reference range. 
Retrospective analysis showed a wide range in time to onset of elevated TSH levels: in 
some patients, thyroid dysfunction developed as soon as after 4 wk of treatment, in oth-
ers, only after years. Because TFT were not performed at fixed time points, the number of 
patients with an early onset of thyroid dysfunction is probably underestimated. Whether 
the rise in TSH levels in our retrospective study was accompanied by clinical symptoms 
was not routinely documented. Differentiation between clinical symptoms related to 
hypothyroidism from those related to malignancy can be difficult. For instance, fatigue, 
one of the major symptoms of hypothyroidism, is also a common feature of cancer and 
of cancer therapies, while weight gain, another symptom of hypothyroidism, might be 
masked by malignancy- or treatment-induced anorexia.
The observation in our retrospective study that in a small proportion of patients the 
development of elevated TSH levels was preceded by depressed TSH levels and 
elevated FT4 levels may be indicative of a thyroiditis-like mechanism underlying the 
development of sunitinib-induced hypothyroidism. For several reasons this is probably 
not autoimmune-mediated. Firstly, in our prospective study as well as in other studies 
the rise in TSH was not accompanied by increased circulating anti-TPO antibodies.4,12,15 
Secondly, the incidence of autoimmune-mediated thyroiditis is much higher in women 
than in men. The observation that the incidence of transiently elevated TSH levels was 
similar in women and men in our study, makes an auto-immune-mediated mechanism 
less likely. Thirdly, histological examination of the thyroid of rats exposed to sunitinib 
did not show an inflammatory reaction that would have been suggestive for immune-
mediated damage.
Sunitinib may also cause thyroid tissue injury, eventually leading to thyroid tissue 
destruction, by inducing capillary regression (rarefaction). Indeed, ultrasound and 
computed tomographic evaluations have reported a reduction in thyroidal volume dur-
ing sunitinib treatment.10,11 In addition, impaired uptake of radiolabeled iodine during 
sunitinib treatment has been reported.12 Because sunitinib did not inhibit iodide uptake 
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in cultured rat FRTL-5 thyroid cells, the impaired iodide uptake during sunitinib treat-
ment probably also reflects the decreased number of (functional and / or structural) 
capillaries necessary for the delivery of iodide to the thyroid.12,21 Indeed, in the rats 
exposed to sunitinib for 8 d, we observed a marked decrease in the total number of 
thyroid vessels as well as a decreased vessel-to-follicle ratio upon histological examina-
tion. Interestingly, this appeared to be limited to the capillaries as the total number of 
larger vessels containing actin-positive smooth muscle cells or the vessel-to-follicle ratio 
was not reduced. Dose-dependent regression of capillaries has also been reported in 
mice exposed to soluble VEGF-receptors or a small-molecule VEGF-RTKI for 1-3 wk.9 Of 
the various endocrine organs examined in these mice, capillary regression (up to 68%) 
was most pronounced in the thyroid.9 The capillary regression was reversible after anti-
VEGF treatment was stopped for 1 wk. Also in our rat study thyroid capillary regression 
reversed after sunitinib had been withdrawn for 11 d and even resulted in a, possibly 
compensatory, overshoot. To explore whether functional rarefaction (a decrease in 
perfused microvessels) contributed to the observed decrease in microvessels we treated 
rats with the combination of sunitinib and the endothelin receptor blocker macitentan, 
as we have demonstrated that administration of sunitinib is associated with a rise in 
plasma ET-1 levels.13 ET-1 is a potent vasoconstrictor and could have induced functional 
rarefaction.22 In rats exposed to the combination of sunitinib and macitentan the de-
crease in vessel-to-follicle ratio was less pronounced compared to rats administered 
sunitinib alone. These findings are compatible with the hypothesis that, apart from 
structural rarefaction (a reduction in capillary density), also functional rarefaction con-
tributes to the decrease in thyroidal microvessels observed during sunitinib exposure. 
Since co-administration of macitentan only resulted in maintenance of T3 but not of T4 
secretion, macitentan probably does not completely prevent the effects of sunitinib on 
the thyroid. In normal rats, as much as 50% of circulating T3 may be derived directly 
from thyroidal secretion.23 In a relatively iodine-deficient gland this may be even more. 
Fenestrated capillaries with a high expression of VEGF-receptors are especially present 
in endocrine organs and depend on VEGF for their survival.9 The repeated periods of 
capillary regression in the thyroid related to the ‘on’ and ‘off’ treatment cycles with suni-
tinib in patients may cause destructive thyroiditis. In a small proportion of patients this 
may be accompanied by a transient increase in TH release.10 It is also possible that the 
mere decreased number of capillaries into which TH can be secreted is involved in the 
development of hypothyroidism.
Apart from capillary regression, interference with T4/T3 metabolism seems to be a 
second mechanism involved in sunitinib-induced hypothyroidism. In our patients a 
decrease in T3/rT3 ratio was observed, reflecting enhanced T4/T3 metabolism. These 
clinical findings are supported by our experimental data showing increased hepatic D3 
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activity and decreased D1 activity in rats exposed to sunitinib for 8 d. The changes in 
deiodinase activities were accompanied by corresponding decreases in serum T3 and T4 
hormone levels. It has previously been reported that hypoxia-inducible factor 1 (HIF-1) 
is a positive modulator of the gene encoding D3.24 Although the expression of HIF-1 is 
not increased by sunitinib, HIF-1 might be up-regulated indirectly because of sunitinib’s 
anti-angiogenic effect.25 Interestingly, after sunitinib withdrawal, deiodinase activities 
reversed, whereas TH levels remained low. Although capillary regression was also revers-
ible after sunitinib discontinuation, apparent restoration of capillaries is not necessarily 
paralleled by simultaneous normalization of TH synthesis and secretion. Thus, it would 
be interesting in this respect to measure TH stores in the thyroid gland during and after 
sunitinib treatment in future studies.
Chronic conditions, such as cancer and fasting can be associated with low T3 levels and 
increased rT3 levels, also referred to as non-thyroidal illness syndrome (NTIS).
26,27 Al-
though we did not measure rT3 levels in our retrospective study, and in the prospective 
study, rT3 levels did not change to support NTIS, this condition cannot be completely 
ruled out. However, the increase in TSH levels after initiation of sunitinib treatment, 
makes the involvement of NTIS in sunitinib-induced hypothyroidism less likely as NTIS is 
usually associated with suppressed TSH levels. Of note, Wong et al have demonstrated 
that sunitinib, like propylthiouracil and methimazole, inhibits thyroid peroxidase activ-
ity at concentrations in the micromolar range, which may further contribute to the 
development of sunitinib-induced hypothyroidism.20
Our study has some limitations. Firstly, part of the human data were collected using a 
retrospective design, resulting in the sporadic assessment of FT4 levels, at least initially, 
and the lack of symptom recording related to thyroid dysfunction, as well as the lack of 
FT3 and rT3 assessment. Secondly, although no changes in circulating anti-TPO antibod-
ies were observed making an autoimmune-mediated destructive mechanism less likely, 
assessment of thyroglobulin antibodies could have further supported this conclusion.
In conclusion, inhibition of VEGF signaling with the receptor tyrosine kinase inhibitor 
sunitinib induces thyroid dysfunction in both patients and rats and is due to capillary 
regression in the thyroid and alterations in the T4/T3 metabolism. Considering the 
treatment duration of patients, who are treated with sunitinib for months to years, it 
seems likely that in patients the sunitinib-induced rarefaction induces thyroid tissue 
injury and eventually tissue destruction. Since sunitinib-induced thyroid dysfunction 
occurs in a significant proportion of patients and has been observed as soon as after 34 
d of treatment, routine monitoring of thyroid function during treatment with sunitinib 
is recommended. Whether all patients with abnormal TFTs should be prescribed TH 
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remains unclear. Even in patients reporting fatigue in association with sunitinib and 
developing abnormal TFTs, symptomatic improvement was not observed in nearly 50% 
of the patients with LT4 replacement therapy.
15 As suggested by the American Thyroid 
Association, TH should be withheld in asymptomatic patients with only mild elevation 
of TSH (5-10 mIU).28 In patients with TSH levels above 10 mIU and low FT4 levels, or TSH 
levels above 10 mIU and symptoms of hypothyroidism, treatment with a low-dose of LT4 
should be considered.29 In patients already on TH replacement, extra attention should 
be paid to the thyroid function, and an earlier increase in the LT4 dose during treat-
ment with sunitinib might be considered as sunitinib is associated with enhanced TH 
metabolism.
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suMMARy
Angiogenesis is critical to tumor growth as well as to metastasis. Vascular endothelial 
growth factor (VEGF) and its receptors play key roles in the regulation of this process. In-
hibition of VEGF signaling by means of blocking the VEGF receptor tyrosine kinases has 
become an established treatment for various tumor types. Sunitinib, an oral VEGF recep-
tor tyrosine kinase inhibitor, is currently approved for the treatment of metastatic renal 
cell carcinoma and imatinib-resistent gastrointestinal stromal tumors. Unfortunately, 
this therapy is associated with several side effects among which hypertension, renal 
toxicity, cardiac toxicity and thyroid dysfunction in a substantial proportion of patients. 
The studies presented in this thesis have unravelled pathophysiological mechanisms 
that are involved in the development of these adverse effects and provide directions for 
their most appropriate clinical management, thereby optimizing the potential efficacy 
of angiogenesis inhibition as anticancer treatment.
sunitinib-induced cardiovascular and renal toxicity
Hypertension
Sunitinib-induced hypertension has been reported in up to 47% of patients (Chapter 
1). Since experimental data indicate that binding of VEGF to its receptors increases 
endothelial nitric oxide synthase (eNOS) and thus nitric oxide (NO) bioavailability, it has 
been suggested that inhibition of the VEGF-pathway reduces NO bioavailability result-
ing in vasoconstriction and a rise in blood pressure (BP). Additionally, decreased NO 
bioavailability disturbs the balance between the vasodilator NO and the vasoconstrictor 
endothelin-1 (ET-1), favoring ET-1 production, thereby inducing further vasoconstric-
tion and an additional rise in BP (Chapter 1).1 Apart from inducing vasoconstriction, 
ET-1, by activating NADPH-oxidase, increases oxidative stress through an increase in 
reactive oxygen species (ROS) production.2,3 Hypertension is generally associated with 
an increase in oxidative stress. Moreover, TEMPOL, a superoxide-dismutase mimetic, 
that metabolizes superoxide and other ROS, has been shown to reduce BP in several 
experimental hypertension models.4 The effect of sunitinib on BP in patients, rats and 
swine, as well as the roles of ET-1, decreased NO-bioavailability and/or enhanced oxida-
tive stress in its effect were explored in this thesis.
In patients, sunitinib treatment, when given according to a 4 weeks ‘on’, two weeks ‘off’ 
regimen (one cycle), induced a rise in mean BP of almost 15 mmHg and a decrease in HR 
of 8 beats/min after 4 weeks of treatment. Both hemodynamic effects were reversible 
during the 2-weeks off-treatment period. The normally occurring decrease in BP dur-
ing sleep (‘dipping’ ≥ 10%) was diminished after 4 weeks of sunitinib treatment. The BP 
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increase was associated with a rise in plasma ET-1 levels and a decrease in plasma renin 
levels, whereas plasma catecholamine levels remained unchanged, indicating that acti-
vation of the endothelin system, but not the renin-angiotensin system or sympathetic 
nervous system, is involved in the sunitinib-induced rise in BP (Chapter 3).
In rats, 8 days of sunitinib administration induced an increase in BP of 30 mmHg that 
was accompanied by a decrease in HR and a loss of circadian BP rhythm. These changes 
disappeared after sunitinib withdrawal and were associated with a reversible rise in 
circulating ET-1 levels. Moreover, the sunitinib-induced rise in BP in rats could largely 
be prevented by concomitant administration of the dual ETA/ETB-receptor antagonist 
macitentan, confirming a crucial role for the ET system in the development of sunitinib-
induced hypertension. Urinary excretion of nitric oxide metabolites, which is regarded a 
measure of global NO-bioavailability, decreased during administration of sunitinib, but 
did not normalize after sunitinib withdrawal. This indicates that administration of suni-
tinib is associated with a long-term decrease in NO-bioavailability. The ROS-scavenger 
TEMPOL only modestly prevented the sunitinib-induced rise in BP, indicating that oxi-
dative stress does not play an important role in the development of sunitinib-induced 
hypertension (Chapter 3, 4).
In chronically instrumented awake swine, sunitinib induced a rise in BP of 10±5 mmHg 
within 4 hours following sunitinib administration reaching a maximum of 14±5 mmHg 
after one week of daily administration, whereas HR decreased. The rise in BP was due to 
an increase in systemic vascular resistance. Administration of the dual ETA/ETB receptor 
blocker tezosentan in sunitinib-treated swine, induced a larger decrease in systemic 
vascular resistance and BP compared to control conditions, indicating enhanced ET-
1-mediated sunitinib-induced vasoconstriction. Thus, also in swine activation of the 
endothelin system is involved in the development of sunitinib-induced rise in BP. The 
vasoconstrictor effect of the eNOS inhibitor LNNA was increased after treatment with 
sunitinib, indicating an increased NO-mediated vasodilator tone during sunitinib admin-
istration, likely counteracting the ET-1-mediated vasoconstriction. Administration of a 
cocktail of ROS scavengers, including TEMPOL, provided no evidence that the sunitinib-
induced vasoconstriction is due to enhanced oxidative stress. Thus, neither decreased 
NO bioavailability nor increased production of ROS are involved in the sunitinib-induced 
rise in BP in this swine model (Chapter 5).
Renal toxicity
The incidence of sunitinib-induced renal toxicity, mainly reported as proteinuria, is 
not well known because in the initial studies patients were not routinely screened for 
this condition. In a phase I trial of the investigational receptor tyrosine kinase inhibitor 
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KRN951 3 (20%) of the 15 patients developed dose-limiting proteinuria (Chapter 1). 
VEGF is important for the maintenance of podocyte function and survival via regulation 
of nephrin expression, a protein that prevents podocyte apoptosis. Therefore, VEGF is 
important for the maintenance of the glomerular filtration barrier. Inhibition of the VEGF 
signaling pathway might affect the integrity of this filtration barrier leading to protein-
uria (Chapter 1). In chronic kidney disease, renal histopathological changes are thought 
to be ET-1-mediated, mainly via stimulation of the ETA-receptor and ET-1 has shown to 
increase glomerular permeability, independent of BP.5 Furthermore, abundant evidence 
indicates that oxidative stress is involved in the development of renal injury in general.
The effect of sunitinib on renal function and histology in patients and rats, as well as 
the roles of ET-1 and oxidative stress in mediating this effect, were further explored in 
this thesis.
In patients, serum creatinine did not change after 10 weeks of treatment with sunitinib, 
but urinary creatinine clearance, as an estimate of glomerular filtration rate, decreased 
within 4 weeks of treatment with sunitinib (Kappers et al., unpublished results) whereas 
proteinuria tended to increase (Chapter 3).
In rats, sunitinib induced a rise in serum creatinine, proteinuria, albuminuria and 
urinary ET-1 levels. All parameters, except for serum creatinine and urinary ET-1 levels 
reversed after sunitinib withdrawal. Renal histological examination, using light and 
electron microscopy, showed that sunitinib induced marked abnormalities, including 
intra-epithelial protein droplets, epithelial and endothelial cell swelling leading to oblit-
eration of the capillary lumen, loss of endothelial fenestration as well as podocyte foot 
process effacement. The combination of endothelial cell swelling, loss of fenestration 
and obliteration of the capillary lumen is also referred to as glomerular endotheliosis. 
Interestingly, preeclampsia, a condition occurring in the third trimester of pregnancy, 
is also characterized by hypertension, proteinuria, increased circulating ET-1 levels 
and glomerular endotheliosis. One of the underlying pathophysiological mechanisms 
is thought to be an increased placental production of soluble fms-like tyrosine kinase 
(sFlt-1), the extracellular domain of the VEGF receptor (VEGFR)-1, which binds circulat-
ing VEGF, thereby abrogating the VEGF-VEGFR signaling pathway and thus creating a 
condition similar to that induced by sunitinib. Therefore, hypertension and proteinuria 
during angiogenesis inhibition with sunitinib are often referred to as a preeclampsia-
like syndrome (Chapter 4).
To further explore the independent roles of ET-1 and BP and the role of oxidative stress 
in the development of sunitinib-induced renal toxicity, rats on sunitinib were concomi-
tantly administered the dual ETA/ETB-receptor antagonist macitentan, amlodipine or 
the ROS scavenger TEMPOL. Both macitentan and amlodipine equally diminished the 
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sunitinib-induced rise in BP. Macitentan diminished proteinuria and urinary ET-1 excre-
tion whereas the elevated serum creatinine concentration remained unchanged. In 
contrast, amlodipine at an equipotent BP-lowering dose as macitentan, did not reduce 
sunitinib-induced proteinuria and the increase in urinary ET-1 excretion (Chapter 6). 
Administration of the ROS scavenger TEMPOL also decreased proteinuria and urinary 
ET-1 excretion while it only marginally reduced BP. Neither macitentan, nor amlodipine 
or TEMPOL diminished the sunitinib-induced renal histological abnormalities, although 
intra-epithelial protein deposition was diminished with macitentan (Chapter 4). From 
these findings it can be concluded that sunitinib-induced renal toxicity is ET-1-mediated 
and occurs independently of BP. Moreover, oxidative stress appears not to be involved 
in the sunitinib-induced rise in BP, but plays an important role in sunitinib-induced renal 
toxicity.
Cardiac toxicity
Impaired cardiac function has been observed in up to 28% of patients treated with 
sunitinib. In addition, angina pectoris and increases in biomarkers for cardiac damage 
have been reported (Chapter 1). In patients developing cardiac dysfunction during 
treatment with sunitinib, myocardial biopsy specimens showed structural changes in 
mitochondria of cardiomyocytes. Impaired ATP generation secondary to mitochondrial 
dysfunction could therefore underlie the contractile ventricular dysfunction occurring in 
some patients on sunitinib treatment. Additionally, oxidative stress is generally increased 
in hypertension and plays a pathogenic role in the development and progression of 
cardiovascular disease. Therefore, enhanced formation of ROS may also be involved in 
the sunitinib-induced cardiovascular side effects. Apart from the effects on the systemic 
circulation, no studies on the effects of angiogenesis inhibition on the coronary and 
pulmonary circulation have been reported.
The effects of sunitinib on cardiac mitochondrial function and coronary microvascular 
function in rats as well as its effect on the pulmonary and coronary circulation and car-
diac function in swine, and the possible roles of ET-1, NO-bioavailability and oxidative 
stress were further explored in this thesis.
Ex vivo studies in rat cardiac mitochondria demonstrated that sunitinib did not affect 
ATP production, suggesting that impaired cardiac mitochondrial ATP-production is not 
involved in the sunitinib-induced decrease in cardiac contractile function (Chapter 3). 
Coronary microvascular function studies in hearts obtained from sunitinib-administered 
rats using the Langendorff model demonstrated that, not only coronary flow responses 
to the endothelium-dependent vasodilator bradykinin, but also responses to the 
endothelium-independent vasodilator sodium nitroprusside and the vasoconstrictor 
angiotensin II were diminished. These findings indicate that sunitinib induces general 
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coronary vascular smooth muscle cell dysfunction that, in part, may also account for 
the observed decrease in coronary endothelial dysfunction as represented by the di-
minished response to bradykinin (Chapter 3). The mechanism behind this generalized 
impaired microvascular smooth muscle cell function remains to be clarified.
In swine, administration of sunitinib had no effect on the pulmonary vasculature and 
coronary blood flow. Acute administration of the ETA/ETB receptor blocker tezosentan 
reversed the systemic hemodynamic effects of sunitinib, supporting previous observa-
tions that an increase in endogenous ET-mediated vasoconstrictor tone underlies the 
sunitinib-induced rise in BP (Chapter 3, 4). No evidence was found that the systemic 
vasoconstriction induced by sunitinib was caused by a decrease in NO-mediated va-
sodilator tone or an increase in oxidative stress. Furthermore, although sunitinib has 
been shown to induce a decline in left ventricular ejection fraction in patients, in swine 
it had no effect on LVdP/dtmax or LVdP/dtmin, as respective indices of left ventricular 
systolic and diastolic function, or on stroke volume (Chapter 5). It should be noted that 
the exposure time to sunitinib in swine was short. Therefore, prolonged exposure to 
sunitinib might also be associated with left ventricular dysfunction in swine, although 
differentiation between BP-dependent and BP-independent effects remains difficult.
sunitinib-induced thyroid dysfunction
Thyroid dysfunction, mainly hypothyroidism, has retrospectively been reported in 
up to 53-85% of patients and prospectively in up to 36-46% of patients treated with 
sunitinib (Chapter 2).6 Since especially the capillary bed of the thyroid is susceptible 
to VEGF inhibition, it has been hypothesized that capillary regression is involved in 
sunitinib-associated thyroid dysfunction (‘capillary regression hypothesis’).7 In addition, 
in patients with a history of hypothyroidism already on levothyroxine (LT4) replacement 
therapy, LT4 dose increments were needed during treatment with sunitinib, indicating 
interference of sunitinib with thyroxine 4 (T4) and triiodothyronine (T3) metabolism 
(‘metabolic hypothesis’) (Chapter 2).
The effect of sunitinib on thyroid function and the potential mechanisms involved in 
its effect, including thyroid vasculature and thyroid hormone metabolism, in patients 
and in rats were further explored in this thesis.
Retrospective analysis in 108 patients demonstrated that 42% of patients developed 
elevated thyroid stimulating hormone (TSH) levels (TSH > 5.0 mU/l), which in 5 patients 
was preceded by TSH suppression. Prospective analysis in 15 patients showed a 4-fold 
increase in TSH levels, within 10 weeks of treatment, whereas the thyroid hormone levels 
FT4 and T3 remained unchanged. Nonetheless, this was accompanied by a decrease in 
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T3/rT3-ratio, indicating enhanced thyroid hormone metabolism. No changes in thyroid 
peroxidase antibodies were observed (Chapter 8).
In rats, sunitinib administration was associated with increased type 3 deiodinase activ-
ity, converting T3 and T4 into the less active metabolites T2 and rT3, and decreased type 
1 deiodinase activity, converting T4 and rT3 into T3 and T2. Correspondingly, circulating 
thyroid hormone levels decreased. Both deiodinase activities reversed after sunitinib 
discontinuation. Histological examination of the thyroid showed marked capillary 
regression after sunitinib administration, which resulted in a, probably compensatory, 
capillary overshoot after sunitinib withdrawal. Interestingly, in rats on both sunitinib and 
the dual ETA/ETB receptor blocker macitentan, that induces vasodilation in conditions 
with an activated endothelin system, capillary regression was less pronounced com-
pared to rats on sunitinib alone (Chapter 8). This finding indicates that sunitinib induces 
not only structural but also functional rarefaction within the thyroid. In conclusion, our 
results demonstrate that sunitinib-induced hypothyroidism is due to a combination of 
alterations in deiodinase activity affecting the T4/T3 metabolism and capillary regression 
within the thyroid.
DIsCussIon
sunitinib-induced cardiovascular and renal toxicity
Hypertension and renal toxicity
As can be concluded from the findings in this thesis, the sunitinib-induced rise in BP and 
renal toxicity are mainly due to activation of the endothelin system. Although blockade 
of ET-1 signaling can to a large extent prevent these toxicities, the exact mechanism 
causing this activation of the endothelin system is currently unknown and several mech-
anisms can be proposed. Firstly, VEGF plays an important role in endothelial cell survival 
and function. VEGF receptor inhibition with sunitinib might thus induce endothelial 
cell activation leading to increased production of ET-1 by these cells. We investigated 
the effect of sunitinib on ET-1 production by human umbilical vascular endothelial cells 
(HUVECs) and demonstrated that sunitinib did not increase the ET-1 production by 
these cells (Chapter 3). However, this might be a cell type-specific finding and studies 
using other endothelial cell lines, for example human coronary endothelial cells, still 
have to be performed. Secondly, although others have demonstrated increased expres-
sion of preproET-1 mRNA in the renal cortex obtained from rats that were administered 
sFlt-1, a soluble VEGF-receptor that binds circulating VEGF, we observed no change in 
preproET-1 mRNA expression in rat renal cortex and medulla after 8 days of sunitinib 
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administration.8 This finding makes enhanced ET-1 gene transcription as a cause of 
increased circulating ET-1 levels in our model unlikely. Thirdly, an increase in ET-1 con-
verting enzyme activity might account for the observed elevated circulating ET-1 levels, 
but this was not explored in the current thesis. Fourthly, binding of VEGF to its receptors 
leads to an increase in NO production and, as a consequence, VEGF receptor inhibition 
with sunitinib might induce a decrease in NO bioavailability, thereby disturbing the 
balance between NO and ET-1, favoring the production of ET-1 (Chapter 1). Indeed, 
a decrease in urinary NO metabolites excretion, considered a global measure of (sys-
temic) NO-bioavailability, was observed in our rats on sunitinib (Chapter 4). In contrast, 
in swine, the vasoconstriction induced by administration of the eNOS inhibitor LNNA 
was increased after sunitinib exposure, indicating an increased NO-mediated vasodi-
lator tone during sunitinib administration (Chapter 5). This increase in NO-mediated 
vasodilator tone might be secondary to the rise in BP, counteracting the ET-1 mediated 
vasoconstriction. With respect to the observed decrease in urinary excretion of nitrates 
in rats on sunitinib, our findings indicate that this is not equivalent to a diminished basal 
NO-mediated vasodilator tone or, alternatively, that urinary NO-metabolites excretion 
is more likely to be a reflection of local renal NO-bioavailability rather than of systemic 
NO-bioavailability.
ET-1 is known to activate vascular NADPH oxidase, one of the major sources of ROS, 
leading to an increase in oxidative stress.2,3 Since oxidative stress is generally increased 
in hypertension and has been implicated in the development and progression of 
cardiovascular disease, we investigated whether oxidative stress was involved in 
sunitinib-induced hypertension and renal toxicity. We demonstrated that enhanced 
oxidative stress was mainly involved in sunitinib-induced renal toxicity, but not in the 
sunitinib-induced rise in BP (Chapter 4, 5). Of note, the effects of ROS on vascular tone 
as well as on angiogenesis are complex. Activation of NADPH oxidase is also a critical 
step in the VEGF-receptor signaling cascade, which is blocked following sunitinib ad-
ministration.9 Therefore, the increased activation of NADPH oxidase by increased activity 
of the endothelin system might be offset by a decreased activation of NADPH oxidase 
by VEGF inhibition, resulting in a net decrease rather than an increase in oxidative stress, 
limiting rather than enhancing the vasodilator effect of ROS scavenging on the systemic 
vasculature.
Since microvessels (arterioles and capillaries) constitute the main determinant of vascu-
lar resistance, functional (a decrease in perfused microvessels) or structural (a reduction 
in capillary density) rarefaction might be involved in the rise in BP during angiogenesis 
inhibition. Using nailfold capillary microscopy in patients on sunitinib, a 12% decrease 
in structural capillary density was reported after 14 days and a 6% decrease after 28 
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days of treatment, whereas MAP at that time had increased by 7%.10 In these patients 
no significant changes in functional rarefaction were observed. Whether the decrease 
in capillary density accounts for observed rise in BP during treatment with sunitinib is 
questionable. A mathematical model based on the hamster cheek pouch microcircula-
tion indicates that 42% rarefaction of the 4th order arterioles is needed to increase resis-
tance in that particular vascular bed by 5%.11 This indicates that a considerable amount 
of rarefaction in various vascular beds is required to induce an increase in vascular 
resistance and hence in BP, assuming that cardiac output remains unchanged. Based on 
this knowledge, it seems highly unlikely that rarefaction is an important determinant in 
the rise in BP during angiogenesis inhibition. Additionally, considering the short time 
interval at which hypertension develops (within 4 hours after administration of the first 
dose in swine and within 1 day in rats and patients), structural rarefaction as a cause 
of sunitinib-induced rise in BP is highly unlikely (Chapter 3, 5).12 Finally, a decrease 
in capillary density might be a consequence rather than the cause of the rise in BP as 
rarefaction is present in patients with hypertension not yet treated, but absent when the 
elevated BP is normalized with antihypertensive treatment.13 Once hypertension occurs, 
rarefaction develops or worsens over a relatively short time interval.14
The combination of hypertension and renal toxicity during angiogenesis inhibition is 
often referred to as a preeclampsia-like syndrome. Preeclampsia, a condition occurring 
after 20 weeks of pregnancy, is characterized by hypertension, proteinuria, elevated 
circulating ET-1 levels as well as glomerular endotheliosis. Indeed, we demonstrated 
that angiogenesis inhibition with sunitinib in rats induces similar clinical and renal 
histopathological characteristics (Chapter 4). Interestingly, both conditions also share 
common underlying pathophysiological mechanisms. Preeclampsia is associated with 
increased placental production of sFlt-1, a soluble VEGF-binding receptor with anti-
angiogenic properties. Furthermore, injection of recombinant adenovirus encoding the 
murine sFlt-1 gene product in pregnant rats induced a rise in BP and proteinuria, as well 
as glomerular endotheliosis, intraepithelial protein depositions and foot-process efface-
ment, changes which are all fully identical to the abnormalities found in our rats exposed 
to sunitinib.15 Increased oxidative stress is also likely to play a role in the development 
of preeclampsia, as demonstrated by decreased symptoms of preeclampsia in sFlt-1-
injected rats administered TEMPOL during pregnancy.16 Likewise, in our rats exposed to 
sunitinib TEMPOL diminished proteinuria and urinary ET-1 excretion although it had no 
effect on the elevated BP.
Hypertension has been suggested as a biomarker of therapeutic efficacy in patients with 
mRCC treated with sunitinib. In a large retrospective analysis it has recently been shown 
that patients with mRCC who develop hypertension when treated with sunitinib have 
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an improved overall and progression free survival compared to patients who remained 
free of hypertension.17 However, in this study, patients were categorical divided into 
those developing hypertension or not, using the hypertension definition of a systolic 
BP ≥ 140 mmHg and/or a diastolic BP ≥ 90 mmHg. It is well known that also within the 
so-called normotensive range a higher BP is associated with an increased cardiovascu-
lar risk, indicating that the cutoff value of 140/90 mmHg is arbitrary. If a patient has a 
baseline BP of 138 mmHg systolic, an only 2 mmHg increase in BP will classify him or 
her as being hypertensive, whereas a patient with a baseline systolic BP of 110 mmHg 
experiencing a 28 mmHg increase would not. In our patient study we demonstrated that 
after 4 weeks of sunitinib treatment BP had increased (mean rise of 13.5 ±2.1 mmHg) in 
all patients, independently of the baseline BP, but that not all patients met the criteria 
of hypertension at that time. According to this reasoning the patient’s absolute or rela-
tive BP increase rather than the presence or absence of hypertension would be a more 
sensitive biomarker. It further underscores the necessity for repeated standardized BP 
measurements in patients treated with angiogenesis inhibition.
Cardiac toxicity
Although in patients sunitinib treatment has been reported to be associated with the 
development of congestive heart failure, in swine administered sunitinib for 1 week, 
no effects on left ventricular systolic and diastolic function or on stroke volume were 
observed (Chapter 5).18 This discrepancy in observations might be due to the difference 
in exposure time to sunitinib and to the fact that the swine were young and healthy, 
whereas in patients pre-existent coronary artery disease remained as the only statisti-
cally significant predictor of congestive heart failure. The BP elevation induced by suni-
tinib was due to an increase in peripheral vascular resistance. We investigated whether 
this vasoconstrictor effect was also present in the pulmonary and coronary vasculature. 
If so, the sunitinib-induced deterioration of cardiac function could be partially explained 
by an increase in right ventricular afterload through pulmonary vasoconstriction and/
or a decrease in myocardial perfusion resulting from coronary vasoconstriction. No such 
effects were observed. Although myocardial biopsy specimens of patients developing 
cardiac dysfunction during treatment with sunitinib, showed cardiac mitochondrial 
structural changes suggesting impaired cardiac mitochondrial function, we found no 
evidence of such impaired function that could underlie the sunitinib-induced cardiac 
toxicity in rats. Instead, the cardiac toxicity might be due to ‘off-target’ effects of sunitinib 
such as inhibition of the ribosomal S6 kinase (RSK), which signals survival in the heart. 
Indeed, inhibitor-binding studies have shown that inhibition of RSKs by sunitinib occurs 
at clinically relevant concentrations.19,20
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sunitinib-induced thyroid dysfunction
Sunitinib-induced thyroid dysfunction is manifested mainly as hypothyroidism and is 
due to a combination of capillary regression within the thyroid and enhanced peripheral 
thyroid hormone metabolism as a consequence of induction of type 3 deiodinase activ-
ity that inactivates T3 and T4 (Chapter 8). The capillary regression appears to be both 
functional, due to ET-1-mediated vasoconstriction, as well as structural, directly related 
to sunitinib-induced angiogenesis inhibition (Chapter 8). As a consequence, delivery of 
iodide to the thyroid is reduced as reflected by impaired uptake of radiolabeled iodine 
during sunitinib treatment reported by others.21 Furthermore, capillary regression might 
indirectly induce thyroid tissue injury, eventually leading to thyroid tissue destruction. 
Since hypothyroidism frequently occurs in patients treated with sunitinib, regular moni-
toring of thyroid function during this treatment is recommended.
With respect to the previously mentioned resemblance of sunitinib-induced hyperten-
sion and renal toxicity with preeclampsia, it is also interesting to note that preeclampsia 
is associated with a higher risk of subclinical hypothyroidism during pregnancy and 
with a higher risk of developing hypothyroidism many years after the occurrence of 
preeclampsia.22 Thus, also with regard to the sunitinib-induced thyroid toxicity there 
appears to be a resemblance with preeclampsia.
PeRsPeCTIVes
Although increasing evidence demonstrates that the development of hypertension 
during treatment with sunitinib is associated with an improved survival, this does not 
imply that antihypertensive treatment in these patients should be withheld. Indeed, the 
improved survival related to antiangiogenic therapy and the knowledge that hyperten-
sion may accelerate and is frequently accompanied by renal damage dictate in our view 
aggressive antihypertensive treatment when this condition develops. Since activation of 
the endothelin system plays an important role in both the sunitinib-induced hyperten-
sion as well as in renal toxicity, endothelin receptor blockers seem logical candidates to 
combat these adverse effects. Endothelin receptor blockers are effective in patients with 
hypertension but are associated with several side effects. For instance, the selective ETA 
receptor blocker darusentan markedly reduced BP (17/10±15/9 mmHg with the lowest 
dose) in patients with resistant hypertension, but was associated with a high incidence 
of peripheral edema and fluid retention.23 These side effects limit the use of darusentan 
and this agent can currently not be recommended for the treatment of angiogenesis-
inhibition induced hypertension. With the knowledge that calcium channel blockers are 
166 Chapter 9
effective, safe and well-tolerated vasodilating antihypertensive agents, and of which 
the effectiveness in sunitinib-induced hypertension has been demonstrated in our ex-
perimental studies, these drugs might be preferred. In case of concomitant proteinuria, 
angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II type 1 receptor block-
ers (ARBs) might be added, since these agents stimulate podocyte nephrin expression 
and therefore may exert a beneficial effect on the integrity of the glomerular filtration 
barrier. Since plasma renin activity is decreased in response to sunitinib treatment, ACEi 
and ARBs might be less effective in lowering BP in patients treated with these agents. 
Further experimental studies have to be performed to investigate whether administra-
tion of anti- renin-angiotensin system (anti-RAS) agents can prevent the development of 
renal damage in response to sunitinib administration, because, notwithstanding effec-
tive BP reduction, renal damage could not be prevented by the calcium-channel blocker 
amlodipine in our studies (Chapter 6). It should be noted that anti-RAS agents have 
pro- as well as anti-angiogenic effects and theoretically might affect the anticancer po-
tential of angiogenesis inhibitors.24,25 With respect to future clinical research, it might be 
worthwhile to explore whether genetic or other factors may predict the development of 
sunitinib-induced hypertension in view of the growing evidence that the development 
of hypertension is associated with improved survival.
Clinical and experimental studies described in this thesis have demonstrated that acti-
vation of endothelin plays a critical role in the development of hypertension and renal 
toxicity during sunitinib exposure, however, the mechanism behind this activation is 
unknown. As an initial step we investigated the effect of sunitinib on ET-1 production 
by HUVECs. In these cells sunitinib did not increase the ET-1 production. To exclude a 
cell-type specific finding, future experiments are needed to investigate whether suni-
tinib can increase ET-1 production in other endothelial cell cultures or in HUVECs under 
different experimental conditions. If so, the molecular mechanisms underlying the 
sunitinib-induced activation of the endothelin system can be further explored.
Notwithstanding the major role for ET-1 in the sunitinib-induced hypertension and 
renal toxicity, the potential involvement of other mechanisms needs to be considered. 
Since both clinical and experimental data on NO-bioavailability during angiogenesis 
inhibition are conflicting, the enhanced NO-mediated vasodilator tone observed in 
sunitinib-administered swine, needs to be confirmed in our rat model. Furthermore, as 
suggested previously, this enhanced NO-mediated vasodilator tone may be a protective 
mechanism to counteract the adverse effects of ET-1. If so, it can be expected that the 
adverse effects of sunitinib are more pronounced in conditions where the vasodilator 
NO system is attenuated or switched off. To further investigate this hypothesis, studies in 
our rat model in which the NO-system is clamped by the combined administration of the 
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eNOS inhibitor L-NAME and the exogenous NO-donor sodium-nitroprusside, need to be 
performed. Additionally, the effects of sunitinib administration on BP and renal function 
can be explored in eNOS knock-out mice.
The observation that sunitinib impairs renal function and that this renal dysfunction 
appears in part to be independent from the sunitinib-induced rise in BP raises the ques-
tion to what extent renal function impairment contributes to the rise in BP. Although 
we did not observe sodium retention during sunitinib (no higher increase in body 
weight compared to controls) as a potential mechanism for the increase in BP in our 
experimental studies this does not exclude the possibility that it might occur in situa-
tions where sodium intake is increased. To further explore the role of sodium retention 
in the sunitinib-induced rise in BP, studies in rats on a low (normal) and high salt diet 
have to be performed.
In the Langendorff heart model we demonstrated that responses to the endothelin-
dependent vasodilator bradykinin, the endothelium-independent vasodilator sodium-
nitroprusside as well as to the vasoconstrictor angiotensin II were diminished in rats 
exposed to sunitinib (Chapter 3). These observations imply a generalized sunitinib-
induced impaired vascular smooth muscle function of which the underlying mechanism 
remains to be clarified.
Structural rarefaction might be involved, although the exercise studies in swine are not 
supportive for such a mechanism. Furthermore, a direct effect of sunitinib on vascular 
smooth muscle function or impaired vascular smooth muscle function due to prolonged 
activation of the endothelin system might also be considered. However, the observation 
that the diminished responses to the vasodilator and vasoconstrictor substances did not 
normalize during co-administration of the endothelin receptor antagonist macitentan 
makes the latter possibility less likely (Chapter 4).
Similarly to what has been reported for the development of hypertension, the occur-
rence of hypothyroidism during treatment with sunitinib is associated with a longer pro-
gression free survival.26 Whether patients developing sunitinib-induced hypothyroidism 
should be treated with thyroid hormone replacement therapy is still under debate. 
Firstly, although TSH levels increase during prolonged treatment with sunitinib in almost 
all patients, it remains difficult to determine if all such patients develop clinically overt 
hypothyroidism as differentiation between clinical symptoms related to hypothyroid-
ism or to malignancy is difficult. This is supported by the observation that 50% of the 
patients who developed sunitinib-induced hypothyroidism and were treated with levo-
thyroxine did not report symptomatic improvement.27 Secondly, accelerated growth of 
solid tumors has been observed after thyroid hormone replacement.28 Furthermore, a 
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hypothyroid state may benefit the management of various cancers as exemplified by the 
observation that patients with mRCC and a history of hypothyroidism seem to do better 
on anticancer therapy than those without such history.29 On the other hand, T3 is also 
known to stimulate cell differentiation and to inhibit cell growth and therefore thyroid 
hormone replacement in patients with sunitinib-induced hypothyroidism might have 
beneficial effects.26 Since until now thyroid hormone replacement has not shown to 
influence survival in patients treated with sunitinib, this therapy should not be withheld 
in patients developing TSH levels above 10 mU/L and clinical symptoms or developing 
overt hypothyroidism.26
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Angiogenese, de vorming van nieuwe bloedvaten, speelt een belangrijke rol bij de groei 
van tumoren. Vasculair endotheliale groeifactor (VEGF) en bijbehorende receptoren spe-
len een sleutelrol bij de regulatie van dit proces. Remming van VEGF-signaaloverdracht 
via het blokkeren van de tyrosine kinases van deze receptoren is inmiddels een belang-
rijke behandelingsmodaliteit van verschillende vormen van kanker. Zo wordt sunitinib, 
een orale VEGF receptor tyrosine kinase remmer, als eerstelijns middel gebruikt in 
de behandeling van het gemetastaseerde niercelcarcinoom en imatinib-resistente 
gastrointestinale tumoren. Helaas gaat deze behandeling gepaard met bijwerkingen 
waaronder hypertensie, renale en cardiale toxiciteit, en schildklierdisfunctie bij een 
groot aantal van de behandelde patiënten. De onderzoeken beschreven in dit proef-
schrift hebben mechanismen die zijn betrokken bij het ontstaan van deze bijwerkingen 
ontrafeld en vormen daarmee een aanknopingspunt voor de ontwikkeling van nieuwe 
behandelingsstrategieën van deze bijwerkingen, waardoor de potentiële effectiviteit 
van anti-angiogenese behandeling verder geoptimaliseerd kan worden.
sunitinib-geïnduceerde cardiovasculaire toxiciteit en nefrotoxiciteit
Hypertensie
Sunitinib-geïnduceerde hypertensie treedt bij ongeveer 47% van de patiënten op 
(Hoofdstuk 1). Binding van VEGF aan de VEGF receptoren stimuleert het endotheliale 
stikstofmono-oxidesynthase (eNOS) waardoor de biologische beschikbaarheid van de 
vaatverwijder stikstofmono-oxide (NO) toeneemt. Verondersteld wordt daarom dat 
blokkade van de VEGF signaaloverdracht leidt tot een afname in NO-beschikbaarheid, 
hetgeen resulteert in vasoconstrictie en een bloeddrukstijging. Daarnaast kan een af-
name van NO de balans tussen de vaatverwijder NO en de vaatvernauwer endotheline-1 
(ET-1) verstoren met als resultaat een toename van ET-1-geïnduceerde vasoconstrictie en 
een verdere bloeddrukstijging (Hoofdstuk 1). ET-1 induceert niet alleen vasoconstrictie, 
maar veroorzaakt, via activatie van het NADPH-oxidase en een verhoogde productie van 
zuurstofradicalen (“reactive oxygen species” ROS), een toename van oxidatieve stress. 
Bij hypertensie is de oxidatieve stress vaak toegenomen, hetgeen wordt bevestigd door 
studies die hebben laten zien dat TEMPOL, een superoxide-dismutasemimeticum met 
anti-oxidatieve werking, de bloeddruk in verschillende hypertensieve diermodellen 
verlaagt.
De effecten van sunitinib op de bloeddruk in patiënten, ratten en varkens en de 
onderliggende rol van ET-1, NO-beschikbaarheid en oxidatieve stress zijn in de studies 
beschreven in dit proefschrift onderzocht.
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In patiënten was al na 4 weken behandeling met sunitinib de bloeddruk met 15 mmHg 
gestegen, terwijl de hartslag afnam. Daarnaast werd de fysiologische bloeddrukdaling 
die tijdens de nacht optreedt (‘dipping’ ≥ 10%) niet meer waargenomen. Genoemde 
hemodynamische veranderingen verdwenen na het staken van sunitinib. Laboratorium-
onderzoek liet een stijging zien van de plasma ET-1-spiegel tijdens behandeling met 
sunitinib, terwijl de plasma reninespiegel daalde en de plasma catecholaminespiegels 
onveranderd bleven. Deze bevindingen wijzen erop dat activatie van het endotheline 
systeem, maar niet van het renine-angiotensine systeem of een toegenomen sympa-
thicustonus, een rol speelt bij het ontstaan van hypertensie tijdens behandeling met 
sunitinib (Hoofdstuk 3).
In ratten leidde toediening van sunitinib tot een reversibele bloeddrukstijging, een af-
name in hartslag, het verdwijnen van het circadiane bloeddrukritme en een stijging van 
de plasma ET-1-spiegel. Gelijktijdige behandeling met de duale ETA/ETB receptorblokker 
macitentan kon de bloeddrukstijging grotendeels voorkomen, wijzend op een cruciale 
rol van het endotheline-systeem bij het ontstaan van sunitinib-geïnduceerde hyper-
tensie. De uitscheiding van NO-metabolieten in de urine, een maat voor globale NO-
beschikbaarheid, nam af onder invloed van sunitinib en herstelde niet na het stoppen 
van dit middel. Gelijktijdige toediening van de anti-oxidant TEMPOL had een minimaal 
effect op de sunitinib-geïnduceerde bloeddrukstijging, erop wijzend dat oxidatieve 
stress geen belangrijke rol speelt in de pathogenese van sunitinib-geïnduceerde hyper-
tensie (Hoofdstuk 3, 4).
In varkens leidde toediening van sunitinib al binnen 4 uur na de eerste dosis tot een 
bloeddrukstijging van 10±5 mmHg. Deze stijging bereikte een maximum van 14±5 
mmHg na dagelijkse toediening van sunitinib gedurende 1 week en ging gepaard 
met een daling van de hartslag. De bloeddrukstijging werd veroorzaakt door een 
toename van de perifere vaatweerstand. Toediening van de duale ETA/ETB receptorblok-
ker tezosentan in varkens die vooraf waren blootgesteld aan sunitinib leidde tot een 
sterkere daling van de systemische vaatweerstand en bloeddruk dan bij de controle 
dieren, hetgeen wijst op een toegenomen ET-1- gemedieerde vasoconstrictie tijdens 
sunitinib. Toediening van de L-arginine analoog LNNA, een eNOS-remmer, leidde tot een 
sterkere bloeddrukstijging in de met sunitinib-behandelde dieren dan in de controle 
dieren, wijzend op een toegenomen NO-gemedieerde vaatverwijdende tonus tijdens 
sunitinib. Wij veronderstellen dat deze toegenomen NO-gemedieerde vaattonus een 
tegenspeler is van de ET-1 gemedieerde vasoconstrictie. Toediening van een cocktail 
van anti-oxidanten, waaronder TEMPOL, liet geen aanwijzingen zien voor een toename 
van oxidatieve stress als oorzaak van de sunitinib-geïnduceerde vasoconstrictie. Dus 
noch een afname in NO-beschikbaarheid, noch een toename in oxidatieve stress bleken 
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in dit varkensmodel de sunitinib-geïnduceerde bloeddrukstijging te mediëren (Hoofd-
stuk 5).
Nefrotoxiciteit
Sunitinib-geïnduceerde nefrotoxiciteit manifesteert zich vooral als proteïnurie. Aange-
zien in de allereerste klinische studies met sunitinib niet routinematig werd gescreend 
op proteïnurie is de precieze incidentie van deze bijwerking onbekend. VEGF speelt een 
belangrijke rol in de functie en overleving van podocyten in de glomerulus via regulatie 
van de expressie van nefrine, een eiwit dat de podocytenapoptosis tegengaat. VEGF is 
daarom belangrijk voor het behoud van de glomerulaire filtratiebarrière (Hoofdstuk 
1). Remming van VEGF- signaaloverdracht zou de integriteit van deze barrière kunnen 
aantasten, leidend tot proteïnurie. Er wordt verondersteld dat ET-1, via stimulatie van 
voornamelijk de ETA receptor, bij chronische nieraandoeningen een belangrijke rol speelt 
bij het ontstaan van de histopathologische nierafwijkingen, en tevens de glomerulaire 
permeabiliteit verhoogt, onafhankelijk van de bloeddruk. Ook is er veel literatuur waarin 
wordt aangetoond dat oxidatieve stress een rol speelt bij het ontstaan van nierschade 
in het algemeen.
Het effect van sunitinib op nierfunctie en – histologie bij patiënten en ratten, alsmede 
de rol van ET-1 en oxidatieve stress hierbij, werd onderzocht in de studies beschreven 
in dit proefschrift.
In patiënten trad er geen verandering op in het serum kreatinine na 10 weken behande-
ling met sunitinib, maar de urine kreatinineklaring, een schatting van de glomerulaire 
filtratie snelheid, daalde tijdens sunitinib behandeling, terwijl de proteïnurie toenam 
(Hoofdstuk 3).
In ratten leidde toediening van sunitinib gedurende 8 dagen tot een stijging van het 
serum kreatinine, alsmede tot proteïnurie, albuminurie en een stijging van de urine ET-1 
excretie. Al deze parameters normaliseerden na staken van sunitinib, met uitzondering 
van het serum kreatinine en de urine ET-1 excretie. Licht- en electronenmicroscopisch 
onderzoek van de nier toonde forse afwijkingen, waaronder intra-epitheliale eiwitde-
posities, epitheel- en endotheelcelzwelling leidend tot obliteratie van het capillaire 
lumen, verlies van endotheliale fenestratie en afvlakking van de podocytenvoetjes. De 
combinatie van endotheelcelzwelling, verlies van fenestratie en obliteratie van het 
capillaire lumen wordt ook wel glomerulaire endotheliose genoemd. Interessant hierbij 
is dat pre-eclampsie, een aandoening die zich kan voordoen bij vrouwen vanaf de 20ste 
zwangerschapsweek, ook wordt gekenmerkt door hypertensie, proteïnurie, een stijging 
in circulerende ET-1 spiegels en glomerulaire endotheliose. Er wordt gedacht dat een 
verhoogde placentaire produktie van het vrij circulerende fms-achtige tyrosinekinase-1 
Samenvatting 175
(sFlt-1), het extracellulaire deel van de VEGF receptor (VEGFR)-1, hierbij een rol speelt. 
sFlt-1 bindt VEGF en onderbreekt zo de VEGF-VEGFR signaaloverdracht waardoor er 
een situatie ontstaat die vergelijkbaar is met die tijdens de behandeling met sunitinib. 
Daarom wordt de combinatie van hypertensie en proteïnurie die tijdens behandeling 
met sunitinib optreedt ook wel een pre-eclampsie-achtig syndroom genoemd (Hoofd-
stuk 4).
Om verder te onderzoeken wat de rol is van ET-1, de bloeddruk en oxidatieve stress 
bij het ontstaan van sunitinib-geïnduceerde nefrotoxiciteit, werden de ratten tijdens 
toediening van sunitinib gelijktijdig behandeld met de duale ETA/ETB receptor antago-
nist macitentan, amlodipine of de ROS-scavenger TEMPOL. Macitentan en amlodipine 
in de gebruikte doseringen verlaagden de sunitinib-geïnduceerde bloeddrukstijging 
even effectief. Macitentan verminderde ook de proteïnurie en urine ET-1 excretie, maar 
had geen effect op het serum kreatinine. Amlodipine daarentegen, had geen effect op 
de sunitinib-geïnduceerde proteïnurie en toegenomen urine ET-1 excretie, hoewel het 
even effectief als macitentan de bloeddrukstijging verminderde (Hoofdstuk 6). Toedie-
ning van de antioxidant TEMPOL verminderde ook de proteïnurie en urine ET-1 excretie, 
maar had slechts een marginaal effect op de bloeddruk. Noch macitentan, noch amlo-
dipine, noch TEMPOL verminderde de sunitinib-geïnduceerde histologische nierafwij-
kingen, hoewel tijdens behandeling met macitentan de glomerulaire intra-epitheliale 
eiwitdeposities afnamen (Hoofdstuk 4). Op grond van deze bevindingen kan worden 
geconcludeerd dat sunitinib-geïnduceerde nefrotoxiciteit gemedieerd wordt door ET-1, 
maar onafhankelijk is van de bloeddrukstijging. Oxidatieve stress blijkt vrijwel geen rol 
te spelen bij de sunitinib-geïnduceerde bloeddrukstijging, maar speelt wel een rol bij 
het ontstaan van sunitinib-geïnduceerde nefrotoxiciteit.
Cardiale toxiciteit
Bij 28% van de patiënten die wordt behandeld met sunitinib is een verminderde hart-
functie waargenomen. Daarnaast zijn angina pectoris en een stijging in biomarkers 
van cardiale schade gerapporteerd (Hoofdstuk 1). Hartspierbiopten van patiënten die 
een verminderde hartfunctie ontwikkelden tijdens behandeling met sunitinib, tonen 
structurele veranderingen in de mitochondria van de cardiomyocyten. Daarom is er 
gesuggereerd dat een verminderde ATP-productie, secundair aan mitochondriale dis-
functie, ten grondslag zou kunnen liggen aan de verminderde linkerventrikelfunctie die 
bij sommige patiënten ten tijde van behandeling met sunitinib wordt waargenomen. 
Tevens is bekend dat oxidatieve stress vaak verhoogd is bij hypertensie en dat dit een 
pathogenetische rol speelt in de ontwikkeling en progressie van hart- en vaatziekten. 
Een toegenomen oxidatieve stress zou dus ook een rol kunnen spelen in het ontstaan 
van de sunitinib-geassocieerde cardiovasculaire bijwerkingen. Hoewel de effecten van 
sunitinib op de systemische circulatie enigszins bekend zijn, zijn er geen studies gerap-
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porteerd die het effect van sunitinib op de coronaire en pulmonale circulatie hebben 
bestudeerd.
De effecten van sunitinib op de cardiale mitochondriale functie en de coronaire micro-
vasculaire functie in ratten, alsmede het effect op de coronaire en pulmonale circulatie 
en op de cardiale functie in varkens, en de mogelijke rol van ET-1, NO-beschikbaarheid 
en oxidatieve stress werden verder onderzocht in de studies beschreven in dit proef-
schrift.
Ex vivo onderzoek van mitochondria van cardiomyocyten afkomstig van de rat toonde 
dat sunitinib geen invloed had op de ATP-productie, suggerend dat verminderde cardi-
ale mitochondriale ATP-productie geen rol speelt in de sunitinib-geïnduceerde afname 
in linkerventrikelfunctie (Hoofdstuk 3). Coronaire microvasculaire functie studies in het 
Langendorff hartmodel van ratten behandeld met sunitinib, toonden dat de coronaire 
flow niet alleen verminderde in respons op de endotheel-afhankelijke vaatverwijder 
bradykinine, maar ook in respons op de endotheel-onafhankelijke vaatverwijder natri-
um-nitroprusside en de vaatvenauwer angiotensine II. Deze resultaten wijzen erop dat 
sunitinib gegeneraliseerde gladde spierceldisfunctie induceert, hetgeen ook, tenminste 
ten dele, de verminderde respons op bradykinine kan verklaren (Hoofdstuk 3). Het 
mechanisme achter deze gegeneraliseerde microvasculaire gladde spierceldisfunctie 
moet nog worden opgehelderd.
In varkens had toediening van sunitinib geen effect op de pulmonale circulatie of 
coronaire bloeddoorstroming. Acute toediening van de duale ETA/ETB receptorblokker 
tezosentan maakte de systemische hemodynamische effecten van sunitinib ongedaan. 
Dit ondersteunt onze eerdere observatie in ratten dat een toename in ET-1-gemedieerde 
vasoconstrictoire tonus ten grondslag ligt aan de sunitinib-geïnduceerde bloeddruk-
stijging (Hoofdstuk 3, 4). Er werden geen aanwijzingen gevonden voor een afname in 
NO-gemedieerde vasodilatatoire tonus of een toename in oxidatieve stress die een rol 
zouden kunnen spelen in de systemische sunitinib-geïnduceerde vasoconstrictie. Hoe-
wel beschreven is dat sunitinib in patiënten een afname in linkerventrikelejectiefractie 
kan veroorzaken, was dit niet aantoonbaar in de varkens (Hoofdstuk 5). Hierbij dient 
wel te worden opgemerkt dat de tijd van blootstelling aan sunitinib kort was. Mogelijk 
dat een langere blootstellingsduur ook in onze varkens leidt tot een afname in linker-
ventrikelfunctie, hoewel, zeker bij langdurige blootstelling aan sunitinib, het lastig is om 
te differentiëren tussen bloeddrukafhankelijke en -onafhankelijke effecten.
sunitinib-geïnduceerde schildkliertoxiciteit
Schildklierdisfunctie, met name hypothyreoïdie, wordt in retrospectieve studies be-
schreven bij 53-85% en in prospectieve studies bij 36-46% van de patiënten behandeld 
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met sunitinib (Hoofdstuk 2). Aangezien met name het capillaire bed van de schildklier 
gevoelig is voor VEGF-remming, is gesuggereerd dat capillaire regressie een rol speelt 
bij het ontstaan van sunitinib-geassocieerde schildklierdisfunctie (‘capillaire regressie 
hypothese’). Tevens is beschreven dat bij patiënten met een voorgeschiedenis van 
hypothyreoïdie die al werden behandeld met levothyroxine (LT4), een dosisverhoging 
van LT4 was geïndiceerd tijdens behandeling met sunitinib. Dit wijst erop dat sunitinib 
interfereert met het thyroxine (T4) en triiodothyronine (T3) metabolisme (‘metabolic 
hypothesis’) (Hoofdstuk 2).
Het effect van sunitinib op de schildklierfunctie en de mogelijke mechanismen die 
hierbij betrokken zouden kunnen zijn, inclusief de schildkliervasculatuur en het schild-
klierhormoonmetabolisme werd verder onderzocht in de studies beschreven in dit 
proefschrift.
Retrospectieve analyse in 108 patiënten liet een stijging in TSH-spiegels (TSH > 5.0 
mU/l) zien bij 42% van de patiënten, die in 5 patiënten vooraf werd gegaan door een 
onderdrukking van het TSH. Prospectieve analyse in 15 patiënten toonde een 4-vou-
dige stijging van de TSH-spiegels, binnen 10 weken na het starten van de behandeling, 
terwijl de FT4 en T3 spiegels onveranderd bleven. Desalniettemin trad er wel een daling 
op in de T3/rT3-ratio, wijzend op een versneld schildklierhormoonmetabolisme. De 
schildklierperoxidase-antistoftiter veranderde niet (Hoofdstuk 8).
In ratten was toediening van sunitinib geassocieerd met een toename van dejodase 
type 3 activiteit, dat T3 en T4 omzet in de minder actieve metabolieten T2 en rT3, en een 
afname in dejodase type 1 activiteit, dat T4 en rT3 omzet in T3 en T2. De schildklierhor-
moonspiegels daalden overeenkomstig. Beide dejodaseactiviteiten normaliseerden na 
staken van sunitinib. Histologische beoordeling van schildklierweefsel toonde uitge-
sproken capillaire regressie in schildklierweefsel afkomstig van ratten behandeld met 
sunitinib. Na het stoppen van sunitinib toediening normaliseerde niet alleen het aantal 
capillairen, maar onstond er zelfs een capillaire overshoot. Ratten die naast sunitinib 
ook de duale ETA/ETB receptor antagonist macitentan kregen toegediend, een middel 
dat vasodilatatie induceert in situaties waar het endotheline-systeem is geactiveerd, 
toonden een minder uitgesproken capillaire regressie in het schildklierweefsel dan de 
ratten die alleen sunitinib kregen toegediend (Hoofdstuk 8). Dit wijst erop dat sunitinib 
in de schildklier niet alleen structurele, maar ook functionele rarefactie veroorzaakt. 
Concluderend laten onze resultaten zien dat sunitinib-geïnduceerde hypothyreoïdie 
wordt veroorzaakt door een combinatie van veranderingen in dejodaseactiviteit, lei-
dend tot verandering in het T4/T3 metabolisme, en uitgesproken capillaire regressie in 
de schildklier.
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AbbReVIATIons
ABPM Ambulatory Blood Pressure Measurement
ACE-I Angiotensin Converting Enzyme Inhibitor
ADP Adenosine DiPhosphate
Ang II Angiotensin II
ARB Angiotensin Receptor Blocker
ATP AdenosineTriPhosphate
BK Bradykinin
BNP B-type Natriuretic Peptide
BP Blood Pressure
BVO2 Body oxygen consumption
BW Body Weight
CBF Coronary Blood Flow
CF Coronary Flow
CO Cardiac Output
CVR Coronary Vascular Resistance
D1 type 1 Deiodinase
DBP Diastolic Blood Pressure
eNOS endothelial Nitric Oxide Synthase
ET-1 Endothelin-1
FT4 Free Thyroxine
GIST GastroIntestinal Stromal Tumor
HIF-1 Hypoxia Inducible Factor 1
HR Heart Rate
HUVEC Human Umbilical Vein Endothelial Cell
HW Heart Weight
KW Kidney Weight
LAP Left Atrial Pressure
L-NNA Nω-nitro-L-arginine
LT4 Levothyroxine
LVdP/dt change in Left Ventricular Pressure
LVEF Left Ventricular Ejection Fraction
LVSP Left Ventricular Systolic Pressure
MAP Mean Arterial Pressure
mRCC metastatic Renal Cell Carcinoma
NADPH-oxidase Nicotinamide Adenine Dinucleotide Phosphate-oxidase
NO Nitric Oxide
PAP Pulmonary Artery Pressure
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PVR Pulmonary Vascular Resistance
rT3 reverse T3
ROS Reactive Oxygen Species
RTKI Receptor Tyrosine Kinase Inhibitor
SBP Systolic Blood Pressure
sFlt-1 soluble Fms-Like Tyrosine kinase 1
SHR Spontaneous Hypertensive Rat
SNP Sodium NitroPrusside
SVR Systemic Vascular Resistance
T3 Triiodothyronine
T4 Thyroxine
TBARS ThioBarbituric Acid Reactive Substances
TEMPOL 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl
TFT Thyroid Function Test
TH Thyroid Hormone
TPO-Ab Thyroid PerOxidase antibodies
TSH Thyroid Stimulating Hormone
VEGF Vascular Endothelial Growth Factor
VEGFR Vascular Endothelial Growth Factor Receptor
vWf von Willebrand factor
WKY Wistar Kyoto rat
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Mijn copromotor, dr. A.H. van den Meiracker, beste Ton, het is allemaal begonnen tijdens 
mijn opleiding tot vasculair geneeskundige met mijn vraag aan jou: ‘Ton, graag zou ik 
vasculair onderzoek willen doen. Heb jij iets voor mij?’ ‘Nee, ik heb geen onderzoeksvoor-
stel klaar liggen’, antwoordde jij. ‘Maar, Stefan Sleijfer, oncoloog in de Daniel den Hoed 
Kliniek, vroeg mij onlangs of ik weet hoe het komt dat patiënten die worden behandeld 
met een angiogeneseremmer hypertensie ontwikkelen. Misschien kun je daar iets mee.’ 
Deze vraag vormde de basis van het onderzoek dat uiteindelijk heeft geresulteerd in het 
huidige proefschrift. De afgelopen jaren heb ik met veel plezier met jou samengewerkt. 
Jouw analytisch vermogen, manier van verwoorden en vertalen van preklinische resul-
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gevoerd over de opzet van de studies, de resultaten, de inhoud van de artikelen alsmede 
het commentaar van de reviewers. Het verbaasde jou dat in mijn gedachten de reviewer 
altijd een mannelijk persoon was…
Prof.dr. T.J. Visser en prof.dr. D.J. Duncker wil ik bedanken voor hun bereidheid zitting te 
nemen in de kleine commissie. Prof. T.J. Visser, beste Theo, ik wil je tevens bedanken voor 
de zeer prettige samenwerking in de afgelopen jaren. Dit heeft uiteindelijk geresulteerd 
in een prachtig manuscript. Je was niet alleen geïnteresseerd in de voortgang van mijn 
wetenschappelijk onderzoek, zowel op het gebied van de schildklier als daarbuiten, 
maar toonde ook altijd interesse voor mijn privé-leven, zoals de ontwikkeling van Tho-
mas. Dat heb ik zeer gewaardeerd. Prof.dr. D.J. Duncker, bedankt voor de gelegenheid 
die je hebt gegeven om het cardiovasculaire deel van mijn onderzoek uit te breiden naar 
het varkensmodel.
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